PARP7 inhibitors and their uses

Abstract

Poly(adenosine diphosphate-ribose) polymerase-7 (PARP7) inhibitors, comprising a compound of formula (I) or a pharma- ceutically acceptable salt, deuterated compound, solvate, ester, acid, metabolite or prodrug thereof, and their use in the selective inhibition of PARP7 activity or in the treatment or prevention of a disease, disorder or condition controlled or affected by PARP7 activity, or associated with PARP7 activity or overexpression thereof. [C1] TIFF2024534208000830.tif36156

Description

[Technical Field]

[0001] The present invention relates to the field of medicine, in particular to pyridazinone derivatives and their preparations, as well as methods and uses thereof for treating and / or preventing diseases. [Background technology]

[0002] PARPs (poly ADP-ribose polymerases), a family of 17 enzymes that utilize nicotinamide adenine dinucleotide (NAD+) as a substrate to transfer ADP-ribose (ADPR) to target proteins, are multifunctional protein post-translational modifying enzymes present in most eukaryotic cells. They are activated by recognizing structurally damaged DNA segments and are considered DNA damage receptors involved in various cellular processes, such as DNA repair and genome stability.

[0003] The PARP family is divided into two subclasses: poly-PARP and mono-PARP. Poly-PARP sequentially adds multiple ADPR (ADP-ribose) molecules to proteins, resulting in ADPR chains that can reach hundreds of units. In contrast, mono-PARP modifies proteins by binding only one ADPR molecule. Therefore, poly-PARP and mono-PARP have different ADP-ribosylated protein substrates and play different roles in regulating cell signaling and protein function, making them two different types of therapeutic targets.

[0004] PARP7 (TIPARP), a mono-PARP, is a key factor in regulating innate immunity, transcription factor activity, and cellular stress responses. Several studies have demonstrated that PARP7 plays an important role in innate immune signaling pathways, particularly as a negative regulator of type I interferon antiviral responses, and that knockdown of PARP7 enhances nucleic acid sensor agonist- or virus-induced interferon beta (IFN-β) expression in various cell types. PARP7 acts as a repressor of aryl hydrocarbon receptor (AHR) activity, and its expression is upregulated in response to cellular stress activated via the AHR after viral infection or exposure to cigarette smoke. Furthermore, PARP7 is also regulated by liver X receptor (LXR) and hypoxia-inducible factor 1 (HIF-1).

[0005] PARP7 is not highly expressed in normal cells but is overactive in various tumors. Upon cancer cell or viral infection, intracellular free nucleic acid fragments phosphorylate the cytoplasmic interferon regulatory factor IRF-3, triggering innate immune detection via the TBK1-mediated type I IFN pathway. Then, the cytoplasmic interferon regulatory factor IRF-3 translocates to the nucleus, binds to transcriptional coactivators, promotes the transcription of IFN-α and IFN-β, and recruits immune cells such as dendritic cells, macrophages, and lymphocytes to recognize and kill cancer cells. However, when highly expressed, PARP7 acts as a brake in cancer cells, preventing the phosphorylation of IRF-3 and subsequently the production of type I IFN, thereby avoiding recognition and tracking by immune cells. Inhibition of PARP7 effectively suppresses cancer cell growth, restores interferon signaling, and effectively activates innate and adaptive immunity.

[0006] PARP7 negatively regulates aryl hydrocarbon receptor (AHR) and type I interferon (IFN-I) signaling, both of which are associated with intestinal homeostasis and immunity. Because the absence of PARP7 expression increases AHR and IFN-I signaling pathways, the absence of PARP7 expression reduced the expression of inflammatory genes, including IL-6, CXCL1, and lipocalin-2, in a mouse model of dextran sulfate sodium (DSS)-induced colitis. Experimental results suggest that PARP7 may be involved in the recruitment of immune cells to inflammatory sites. Accordingly, inhibition of PARP7 reduced the severity of DSS-induced colitis in mice and suppressed the production of inflammatory cytokines in tissues from patients with inflammatory bowel disease.

[0007] Only a relatively small number of PARP7 inhibitors have been reported, and the most advanced are still in early clinical development. RBN-2397, a trifluoropyridazinone compound developed by Ribon Therapeutics in the United States, inhibits the enzymatic activity of PARP7, inhibiting the growth and proliferation of a wide range of cancer cells and resulting in tumor regression in mouse xenograft and syngeneic tumor models (Gozgit JM et al., Cancer Cell 2021, 39, 1-13). However, RBN-2397 has poor in vivo pharmacokinetic properties, including low in vivo plasma exposure, a short plasma half-life, and poor oral bioavailability. Therefore, it is desirable to develop PARP7 inhibitors with improved in vivo pharmacokinetic properties, better antitumor activity and therapeutic efficacy, reduced clinical side effects, and applicable to a wider range of tumor indications. Summary of the Invention [Problem to be solved by the invention]

[0008] An object of the present invention is to provide a compound capable of selectively inhibiting the enzymatic activity of PARP7. [Means for solving the problem]

[0009] In one aspect, a compound of formula (I) or a pharmaceutically acceptable salt, deuterated compound, solvate, ester, acid, metabolite or prodrug thereof

[0010] [ka] (In the formula,

[0011] [ka] represents a double bond or a single bond, provided that at most one double bond is attached to any atom; X is halogen, C 1~6 Haloalkyl and C 2~6 alkanoyl, or together with Y and the carbon atom to which they are attached form a fused benzene ring or heterocycle; Y is selected from the group consisting of NH and O, or together with X and the carbon atom to which it is attached form a fused benzene ring or heterocycle; A is a nitrogen-oxo group selected from the group consisting of -NO-, =NO-, -ON- and -ON=, and the N atom, when its valence is unsaturated, is hydrogen, C 1~6 Alkyl, C 2~6 Alkanoyl or C 1~6 optionally substituted with sulfonyl; L is -(CH2) n -,

[0012] [ka] wherein n is 1, 2, or 3; R5 and R5' are each independently selected from the group consisting of hydrogen, C 1~3 R5 and R5' together with the carbon atom to which they are attached are selected from the group consisting of alkyl, halogen, deuterium, and hydroxyl; 3~6 Forming a cycloalkyl; R1 and R2 are each independently hydrogen, C 1~6 Alkyl, C1~6 Hydroxyalkyl, C 1~6 Haloalkyl, C 3~6 Cycloalkyl, C 3~6 Hydroxycycloalkyl or C 3~6 halocycloalkyl, or R and R together with the carbon atom to which they are attached are selected from the group consisting of C 5~8 Forming a cycloalkyl; M is a group represented by the formulas (M-1), (M-2), (M-3), (M-4) and (M-5):

[0013] [ka] (In the formula, D 1 , D 2 , D 3 , D 4 , D 5 , D 6 , D 7 , D 8 , D 9 and D 10 are each independently selected from the group consisting of N and CH, provided that at least one N is included as a ring atom of the M moiety; R3 is independently hydrogen, halogen, hydroxyl, C 1~4 Alkyl, C 1~6 Haloalkyl and C 1~6 hydroxyalkyl; Each m is independently selected from the group consisting of 0, 1, or 2. a moiety selected from the group consisting of: G is a 5- to 6-membered aromatic heterocyclic group optionally substituted with one or two R groups, each R being independently selected from hydroxyl, cyano, C 1~6 Alkyl, C 1~6 Hydroxyalkyl, C 1~6 Haloalkyl, halogen, C 3~6 Cycloalkyl, C 2~6 Alkenyl, C 2~6alkynyl, -NR6R6', -C(O)NR6R6', -NR6C(O)R7, -C(O)OR6, -OR6, -S(O)2NR6R6', -NR6S(O)2R7, -S(O)2R7, -C(O)R6, and phenyl optionally substituted with halogen, or two R4 groups together with the carbon atom to which they are attached are selected from the group consisting of C(O) optionally substituted with hydroxyl, methyl, halogen, or oxo. 5~8 R6, R6' and R7 each independently represent hydrogen, C 1~6 Alkyl, C 1~6 Haloalkyl, C 3~6 Cycloalkyl and C 1~6 hydroxyalkyl) In a preferred embodiment, the heterocycle is a 5- to 8-membered monocyclic ring containing an N atom, preferably piperidine, pyrrolidine, piperazine, or tetrahydropyridine.

[0014] In some embodiments, M is selected from the group consisting of formulas (M-1a), (M-2a), (M-3a), (M-4a), and (M-5a):

[0015] [ka] (In the formula, D 1 is selected from the group consisting of N or CH; each m is independently selected from the group consisting of 0, 1, or 2; and each R is independently selected from the group consisting of hydrogen, hydroxyl, halogen, or C 1~4 alkyl) is a moiety selected from the group consisting of:

[0016] In some embodiments, G is selected from the group consisting of formulas (G-1), (G-2), (G-3), (G-4), (G-5), (G-6), and (G-7):

[0017] [ka] wherein each Q is independently selected from the group consisting of N or CH; more preferably, Q is N and R4 is as defined above. is a moiety selected from the group consisting of:

[0018] Preferably, the R groups are any substituent and each independently is selected from the group consisting of cyano, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 1~4 Haloalkyl, halogen, C 3~6 Cycloalkyl, C 2~4 Alkenyl, C 2~4 alkynyl, —NR6R6′, —C(O)NR6R6′, —C(O)OR6, —OR6, —C(O)R6, and phenyl optionally substituted with halogen, wherein R6 and R6′ are each independently selected from the group consisting of hydrogen and C 1~4 alkyl.

[0019] In preferred embodiments, X is selected from the group consisting of bromine, trifluoromethyl, and acetyl, or X together with Y and the carbon atom to which they are attached form a fused benzene ring or a fused piperidine ring; and Y is selected from NH, or X together with the carbon atom to which they are attached form a fused benzene ring or a fused piperidine ring.

[0020] In a further preferred embodiment, D of formula (M-1) or formula (M-1a) 1 is N, when L is -(CH2) n -,

[0021] [ka] selected from the group consisting of: D 1 is CH, when L is -(CH2) n -,

[0022] [ka] wherein n, R5, and R5' are defined as above.

[0023] In some embodiments, when A is -NO-, L is

[0024] [ka] and when A is =NO-, L is

[0025] [ka] and when A is -ON-, L is

[0026] [ka] and when A is -ON=, L is

[0027] [ka] is.

[0028] In a preferred aspect of the present invention, there is provided a PARP7 inhibitor comprising a compound of formula (I) or a pharmaceutically acceptable salt, deuterated compound, solvate, ester, acid, metabolite or prodrug thereof, wherein X is C 1~6 Haloalkyl and C 2~6 alkanoyl, and X is more preferably C 1~6 haloalkyl, especially trifluoromethyl; Y is NH; A is a nitrogen-oxo group selected from the group consisting of =NO-, -ON- and -ON=, more preferably -ON-; L is

[0029] [ka] More preferably

[0030] [ka] wherein R5 and R5' are each independently selected from the group consisting of hydrogen or halogen, more preferably hydrogen; M is selected from the group consisting of formula (M-1a) and (M-5a) (wherein D 1 is selected from the group consisting of N or CH, more preferably CH; m is independently 1; and each R3 is independently hydrogen, halogen, or C 1~3 and R4 is selected from the group consisting of alkyl, more preferably hydrogen; G is a moiety selected from the group consisting of formula (G-1), (G-3) and (G-4), more preferably formula (G-1) 1~6 Haloalkyl, halogen, C 3~6 Cycloalkyl and phenyl optionally substituted with halogen, more preferably C 1~6 haloalkyl, especially trifluoromethyl); R and R are each independently hydrogen, C 1~6 Alkyl and C 3~6 cycloalkyl, or R1 and R2 together with the carbon atom to which they are attached are selected from the group consisting of C 5~8 More preferably, R and R are each independently hydrogen and C 1~6 alkyl.

[0031] In a further preferred aspect, the present invention provides a PARP7 inhibitor comprising a compound of formula (I) or a pharmaceutically acceptable salt, deuterated compound, solvate, ester, acid, metabolite or prodrug thereof, wherein:

[0032] [ka] represents a double bond or a single bond, provided that at most one double bond is attached to any atom; X is halogen and C 1~6haloalkyl, or together with Y and the carbon atom to which they are attached form a fused benzene ring or heterocycle; Y is NH or together with X and the carbon atom to which they are attached form a fused benzene ring or heterocyclic ring; A is a nitrogen-oxo group selected from the group consisting of -NO-, =NO-, -ON- and -ON=, and when the N atom is not saturated, it may be hydrogen, C 1~6 Alkyl, C 2~6 Alkanoyl or C 1~6 optionally substituted with sulfonyl; L is -(CH2) n -,

[0033] [ka] wherein n is 1, 2, or 3; R5 and R5' are each independently hydrogen or C 1~3 alkyl, or R5 and R5' together with the carbon atom to which they are attached are selected from the group consisting of C 3~6 Forming a cycloalkyl; R1 and R2 are each independently hydrogen, C 1~6 Alkyl, C 1~6 Hydroxyalkyl, C 1~6 Haloalkyl, C 3~6 Cycloalkyl, C 3~6 Hydroxycycloalkyl or C 3~6 halocycloalkyl, or R and R together with the carbon atom to which they are attached are selected from the group consisting of C 5~8 Forming a cycloalkyl; M is a compound represented by the formula (M-1), (M-2), (M-3) and (M-4):

[0034] [ka] (In the formula, D 1 , D 2 , D 3 , D4 , D 5 , D 6 , D 7 , D 8 and D 9 are each independently selected from the group consisting of N and CH, provided that at least one N is included as a ring atom of the M moiety; R3 independently represents a halogen atom, a hydroxyl group, or a C 1~4 Alkyl and C 1~6 haloalkyl; Each m is independently selected from the group consisting of 0, 1, or 2. a moiety selected from the group consisting of: G is a 5- to 6-membered aromatic heterocyclic group optionally substituted with one or two R groups, each R being independently hydroxyl, cyano, C 1~6 Alkyl, C 1~6 Hydroxyalkyl and C 1~6 haloalkyl, or two R groups together with the carbon atom to which they are attached are selected from the group consisting of C optionally substituted with hydroxyl or methyl. 5~8 Forms a cycloalkyl.

[0035] More preferably, M is selected from the group consisting of formulas (M-1a), (M-2a), (M-3a) and (M-4a):

[0036] [ka] (In the formula, D 1 is selected from the group consisting of N or CH; each m is independently selected from the group consisting of 0, 1, or 2; each R is independently selected from the group consisting of hydroxyl, halogen, or C 1~4 alkyl) is a moiety selected from the group consisting of:

[0037] Even more preferably, G is a group represented by the formula (G-1) and (G-2):

[0038] [ka] wherein Q is selected from the group consisting of N or CH. is a moiety selected from the group consisting of:

[0039] Particularly preferably, D of formula (M-1) or formula (M-1a) 1 is N, when L is -(CH2) n -,

[0040] [ka] selected from the group consisting of: D 1 is CH, when L is -(CH2) n -,

[0041] [ka] is selected from the group consisting of:

[0042] Also particularly preferably, when A is -NO-, L is

[0043] [ka] and when A is =NO-, L is

[0044] [ka] and when A is -ON-, L is

[0045] [ka] and when A is -ON=, L is

[0046] [ka] is.

[0047] The present invention also preferably provides a compound of formula (II) or a pharmaceutically acceptable salt, deuterated compound, solvate, ester, acid, metabolite or prodrug thereof:

[0048] [ka] (In the formula,

[0049] [ka] represents a double bond or a single bond, provided that at most one double bond is attached to any atom; X is a halogen and C 1~6 haloalkyl, or together with Y and the carbon atom to which they are attached form a fused benzene or piperidine ring; Y is selected from NH or together with X and the carbon atom to which they are attached form a fused benzene or piperidine ring; A is a nitrogen-oxo group selected from the group consisting of -NO-, =NO-, -ON- and -ON=, and the N atom, when its valence is unsaturated, is hydrogen, C 1~6 Alkyl, C 2~6 Alkanoyl or C 1~6 optionally substituted with sulfonyl; L is -(CH2) n -,

[0050] [ka] wherein n is 1, 2, or 3; R5 and R5' are each independently hydrogen or C 1~3 alkyl, or R5 and R5' together with the carbon atom to which they are attached are selected from the group consisting of C 3~6 Forming a cycloalkyl; D is selected from the group consisting of N or CH; Q is selected from the group consisting of N or CH; R1 and R2 are each independently hydrogen, C 1~6 Alkyl, C 3~6 cycloalkyl, or R and R together with the carbon atom to which they are attached are selected from the group consisting of C 5~8 Forming a cycloalkyl; R3 is hydrogen or C 1~3 selected from the group consisting of alkyl; R4 is hydroxyl, cyano, C 1~6 Alkyl, C 1~6 Hydroxyalkyl and C 1~6 haloalkyl) The present invention provides a PARP7 inhibitor comprising:

[0051] In another aspect of the invention, there is provided a pharmaceutical composition comprising a compound of the invention or a pharmaceutically acceptable salt, deuterated compound, solvate, ester, acid, metabolite, or prodrug thereof, a pharmaceutically acceptable carrier or excipient, and optionally other therapeutic agents.

[0052] Other aspects of the present invention also relate to methods or uses of the compounds of the present invention or pharmaceutically acceptable salts, deuterated compounds, solvates, esters, acids, metabolites or prodrugs thereof for selectively inhibiting the activity of PARP7, or to the use of the compounds of the present invention or pharmaceutically acceptable salts, deuterated compounds, solvates, esters, acids, metabolites or prodrugs thereof in the preparation of a medicament for selectively inhibiting the activity of PARP7.

[0053] Further aspects of the invention relate to methods or uses of compounds of the invention or pharmaceutically acceptable salts, deuterated compounds, solvates, esters, acids, metabolites or prodrugs thereof for treating or preventing diseases, disorders or conditions regulated or affected by or associated with PARP7 activity, or the use of compounds of the invention or pharmaceutically acceptable salts, deuterated compounds, solvates, esters, acids, metabolites or prodrugs thereof in the preparation of a medicament for treating or preventing diseases, disorders or conditions regulated or affected by PARP7 activity or associated with PARP7 activity or overexpression.

[0054] Preferably, the disease, disorder or condition regulated or influenced by PARP7 activity or associated with PARP7 activity or overexpression is a hyperproliferative disease, in particular a cancerous disease, an autoimmune disease or an inflammatory disease.

[0055] In a more preferred embodiment, the disease, disorder, or condition is selected from the group consisting of cancers, including, but not limited to, squamous cell lung cancer, lung adenocarcinoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, breast cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, colorectal cancer, melanoma, ovarian cancer, esophageal squamous cell carcinoma, gastric cancer, liver cancer, oral cancer, urothelial cancer, prostate cancer, bladder cancer, renal cell carcinoma, gastrointestinal stromal tumor, cervical cancer, endometrial cancer, rhabdomyosarcoma, fibrosarcoma, neuroendocrine tumor, mesothelioma, brain cancer, or malignant glioma.

[0056] In other preferred embodiments, the disease, disorder, or condition is selected from the group consisting of autoimmune or inflammatory diseases, including, but not limited to, ulcerative colitis, Crohn's disease, multiple sclerosis, autoimmune liver disease, type I diabetes, bronchial asthma, systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis, polymyositis, or dermatomyositis. DETAILED DESCRIPTION OF THE INVENTION

[0057] definition Unless otherwise defined, all technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs. As used herein, the singular also encompasses the plural unless the context clearly dictates otherwise. All publications, patent applications, patents, or other references mentioned herein are incorporated herein by reference. In case of conflict, the present specification, including definitions, will control. Furthermore, the materials, methods, and embodiments are illustrative only and are not intended to limit the scope of the invention.

[0058] Unless otherwise indicated, the present invention employs conventional methods of mass spectrometry, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA technology, and pharmacology, which are within the skill of those of ordinary skill in the art. Unless specific definitions are provided, the nomenclature and laboratory procedures and techniques related to analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are known to those of ordinary skill in the art. In general, the techniques and steps described above may be performed by conventional methods well known in the art and described in the various general and more specific references cited and discussed herein.

[0059] The term "alkyl" refers to an aliphatic hydrocarbon group, which may be a branched or straight-chain alkyl group. Depending on the structure, the alkyl group may be a monovalent or divalent group (i.e., alkylene). For purposes of the present invention, an alkyl group is preferably an alkyl group having 1 to 8 carbon atoms, more preferably a "lower alkyl" group having 1 to 6 carbon atoms, and even more preferably an alkyl group having 1 to 4 carbon atoms. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, and the like. References herein to "alkyl" should be understood to include all possible configurations and arrangements of such alkyl groups; for example, references herein to "propyl" include n-propyl and iso-propyl, "butyl" include n-butyl, isobutyl, and tert-butyl, "pentyl" include n-pentyl, iso-pentyl, neo-pentyl, tert-pentyl, pentan-3-yl, and the like.

[0060] The term "alkoxy" refers to -O-alkyl, where alkyl is as defined herein. Exemplary alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, and the like.

[0061] The term "alkoxyalkyl" means an alkyl group, as defined herein, substituted with an alkoxy group, as defined herein.

[0062] The term "cycloalkyl" refers to a monocyclic or polycyclic group containing only carbon and hydrogen. Cycloalkyl groups include groups having 3 to 12 ring carbon atoms. Depending on the structure, cycloalkyl groups can be monovalent or divalent (e.g., cycloalkylene). In the present invention, cycloalkyl groups are preferably cycloalkyl groups having 3 to 8 carbon atoms, more preferably "lower cycloalkyl groups" having 3 to 6 carbon atoms. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and adamantyl.

[0063] The term "alkyl(cycloalkyl)" or "cycloalkylalkyl" means an alkyl group, as defined herein, substituted with a cycloalkyl group, as defined herein. Examples of cycloalkylalkyl groups include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, and the like.

[0064] The term "aromatic" refers to a planar ring having a peripheral π-electron system and containing 4n+2 π-electrons (n ​​is an integer). An aromatic ring can contain 5, 6, 7, 8, 9, or 10 or more atoms. An aromatic group can be optionally substituted. The term "aromatic" includes carbocyclic aryl groups (e.g., phenyl) and heterocyclic aryl (or "heteroaryl" or "heteroaromatic") groups (e.g., pyridine). The term includes monocyclic or heterocyclic polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups.

[0065] The term "aryl," as used herein, refers to an aromatic ring in which each of the atoms constituting the ring is a carbon atom. The aryl ring may contain 5, 6, 7, 8, 9, or 10 or more atoms. The aryl group may be optionally substituted. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, phenanthryl, anthracenyl, fluorenyl, and indenyl. Depending on the structure, the aryl group may be a monovalent group or a divalent group (i.e., an arylidene).

[0066] The term "aryloxy" refers to -O-aryl, where aryl is as defined herein.

[0067] The term "heteroaryl" means that an aryl group contains one or more ring heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. An N-containing "heteroaryl" moiety means that at least one of the skeletal atoms of the ring of the aromatic group is a nitrogen atom. Depending on the structure, heteroaryl groups can be monovalent or divalent groups (i.e., heteroarylene groups). Examples of heteroaryl groups include, but are not limited to, pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furanyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolyl, isoquinolyl, indolyl, benzimidazolyl, benzofuranyl, indazolyl, indazolyl, phthalazinyl, pyridazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothienyl, benzothiazolyl, benzoxazolyl, quinazolinyl, naphthyridinyl, furazopyridinyl, and the like.

[0068] The term "alkyl(aryl)" or "arylalkyl" means an alkyl group, as defined herein, substituted with an aryl group, as defined herein. Examples of alkyl(aryl) groups include benzyl, phenylethyl, and the like.

[0069] The term "alkyl(heteroaryl)" or "heteroarylalkyl" means an alkyl group, as defined herein, substituted with a heteroaryl group, as defined herein.

[0070] The term "heteroalkyl," as used herein, refers to an alkyl group, as defined herein, in which one or more of the main chain atoms is a heteroatom, such as oxygen, nitrogen, sulfur, silicon, phosphorus, or a combination thereof. The heteroatom (or atoms) can be located at any position within the heteroalkyl group or at the position at which the heteroalkyl group is attached to the remainder of the molecule.

[0071] The term "heterocycloalkyl," as used herein, refers to a non-aromatic ring in which one or more of the atoms comprising the ring are heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. Heterocycloalkyl rings can be monocyclic or polycyclic rings containing 3, 4, 5, 6, 7, 8, 9, or more atoms. Heterocycloalkyl rings can be optionally substituted. Examples of heterocycloalkyls include, but are not limited to, lactams, lactones, cyclic imines, cyclic thioimines, cyclic carbamates, tetrahydrothiopyrans, 4H-pyrans, tetrahydropyrans, piperidines, 1,3-dioxines, 1,3-dioxanes, 1,4-dioxanes, 1,4-dioxanes, piperazines, 1,3-oxathianes, 1,4-oxathiines, 1,4-oxathianes, tetrahydro-1,4-thiazines, 2H-1,2-oxazines, maleimides, succinimides, barbituric acids, thiobarbituric acids, and dioxypiperazines. , ethylene carbazone, dihydrouracil, morpholine, trioxane, hexahydro-1,3,5-triazine, tetrahydrothiophene, tetrahydrofuran, pyrrolidine, pyrrolidine, imidazolidine, pyrrolidone, pyrazoline, pyrazolidine, imidazolidine, imidazolidine, 1,3-dioxahexene, 1,3-dioxolane, 1,3-dithiolane, 1,3-dithiolane, isoxazoline, isoxazolidine, oxazoline, oxazolidine, oxazolidinone, thiazoline, thiazolidine, and 1,3-oxathiolane. Depending on the structure, heterocycloalkyl groups can be monovalent or divalent groups (i.e., heterocycloalkylene groups).

[0072] The terms "alkyl(heterocycloalkyl)" or "heterocycloalkylalkyl" mean an alkyl group, as defined herein, substituted with a heterocycloalkyl group, as defined herein.

[0073] The terms "alkoxy(heterocycloalkyl)" or "heterocycloalkylalkoxy" mean an alkoxy group, as defined herein, substituted with a heterocycloalkyl group, as defined herein.

[0074] The term "halogen" means fluorine, chlorine, bromine and iodine.

[0075] The terms "haloalkyl," "haloalkoxy," and "haloheteroalkyl" include alkyl, alkoxy, or heteroalkyl structures in which at least one hydrogen is replaced by a halogen atom. In some embodiments, when two or more hydrogen atoms are replaced by halogen atoms, the halogen atoms are the same or different from one another.

[0076] The term "hydroxyl" refers to an --OH group.

[0077] The term "cyano" refers to the group --CN.

[0078] The term "ester group" means a chemical moiety having the formula -COOR, where R is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (linked by ring carbons), and heterocycles (linked by ring carbons).

[0079] The term "amino" refers to the group --NH.sub.2.

[0080] The term "carbamoyl" refers to the group -CO-NH2.

[0081] The term "alkylcarbamoyl" refers to a -CO-NH-R group, where R is an alkyl group as defined herein.

[0082] The term "amido" or "acylamino" refers to --NR--CO--R', where R and R' are each independently hydrogen or alkyl.

[0083] The term "alkylamino" refers to an amino substituent further substituted with one or two alkyl groups, specifically an -NRR' group, where R and R' are each independently selected from the group consisting of hydrogen or lower alkyl groups, with the proviso that -NRR' is not -NH. "Alkylamino" includes a group of compounds in which the nitrogen of -NH is bound to at least one alkyl group. Examples of alkylamino groups include, but are not limited to, methylamino, ethylamino, and the like. "Dialkylamino" includes a moiety in which the nitrogen of -NH is bound to at least two other alkyl groups. Examples of dialkylamino groups include, but are not limited to, dimethylamino, diethylamino, and the like.

[0084] The terms "arylamino" and "diarylamino" refer to amino substituents further substituted with one or two aryl groups, respectively, specifically the group --NRR', where R and R' are each independently selected from the group consisting of hydrogen, lower alkyl, or aryl, and N is bonded to at least one or two aryl groups.

[0085] The term "cycloalkylamino" means an amino substituent which is further substituted with one or two cycloalkyl groups, as defined herein.

[0086] The term "heteroalkylamino" refers to an amino substituent which is further substituted with one or two heteroalkyl groups, as defined herein.

[0087] The term "arylalkylamino" refers herein to the group --NRR' where R is a lower arylalkyl group and R' is hydrogen, lower alkyl, aryl, or lower arylalkyl.

[0088] The term "heteroarylamino" means an amino substituent which is further substituted with one or two heteroaryl groups, as defined herein.

[0089] The term "heterocycloalkylamino" means an amino group, as defined herein, substituted with a heterocycloalkyl group, as defined herein.

[0090] The term "alkylaminoalkyl" means an alkyl group, as defined herein, substituted with an alkylamino group, as defined herein.

[0091] The term "aminoalkyl" refers to an alkyl substituent which is further substituted with one or more amino groups.

[0092] The term "aminoalkoxy" refers to an alkoxy substituent which is further substituted with one or more amino groups.

[0093] The terms "hydroxyalkyl" or "hydroxylalkyl" refer to an alkyl substituent that is further substituted with one or more hydroxyl groups.

[0094] The term "cyanoalkyl" refers to an alkyl substituent that is further substituted with one or more cyano groups.

[0095] The term "alkanoyl" refers to a monovalent radical of atoms remaining after a hydroxyl group is removed from an organic or inorganic oxygen-containing acid and has the general formula RM(O)-, where M is usually C.

[0096] The term "carbonyl" refers to an organic functional group consisting of two atoms, a carbon atom and an oxygen atom, connected by a double bond (C=O).

[0097] The terms "alkanoyl" or "alkylcarbonyl" refer to a carbonyl group further substituted with an alkyl group. Exemplary alkanoyl groups include, but are not limited to, acetyl, propanoyl, butanoyl, pentanoyl, hexanoyl, and the like.

[0098] The term "arylcarbonyl" means a carbonyl group, as defined herein, substituted with an aryl group, as defined herein.

[0099] The term "alkoxycarbonyl" refers to a carbonyl group further substituted with an alkoxy group.

[0100] The term "heterocycloalkylcarbonyl" refers to a carbonyl group that is further substituted with a heterocycloalkyl group.

[0101] The terms "alkylaminocarbonyl," "cycloalkylaminocarbonyl," "arylaminocarbonyl," "arylalkylaminocarbonyl," and "heteroarylaminocarbonyl" mean a carbonyl group, as defined herein, substituted with an alkylamino group, cycloalkylamino group, arylamino group, arylalkylamino group, or heteroarylamino group, as defined herein.

[0102] The terms "alkylcarbonylalkyl" or "alkanoylalkyl" refer to an alkyl group that is further substituted with an alkylcarbonyl group.

[0103] The terms "alkylcarbonylalkoxy" or "alkanoylalkoxy" refer to an alkoxy group that is further substituted with an alkylcarbonyl group.

[0104] The term "heterocycloalkylcarbonylalkyl" refers to an alkyl group that is further substituted with a heterocycloalkylcarbonyl group.

[0105] The term "sulfhydryl" refers to an -SH group. The term "alkylthio" means a mercapto group, as defined herein, substituted with an alkyl group, as defined herein.

[0106] The term "sulfone" or "sulfonyl" refers to the sulfonic acid functionality after loss of the hydroxyl group, specifically the -S(=O)2- group.

[0107] The term "sulfinyl" refers to -S(=O)-.

[0108] The term "aminosulfonyl" refers to the group -S(=O)2-NH2.

[0109] The term "alkylsulfinyl" refers to alkyl-S(=O)-.

[0110] The term "alkylsulfone" or "alkylsulfonyl" refers to -S(=O)2-R, where R is alkyl.

[0111] The term "alkylaminosulfone" means a sulfone group, as defined herein, substituted with an alkylamino group, as defined herein.

[0112] The terms "alkylsulfonylamino" and "cycloalkylsulfonylamino" mean an amino group, as defined herein, substituted with an alkylsulfonyl or cycloalkylsulfonyl group, as defined herein, respectively, i.e., -NH-S(=O)-R, where R is alkyl and cycloalkyl, respectively.

[0113] The terms "cycloalkylsulfone" and "cycloalkylsulfonyl" refer to -S(=O)2-R, where R is cycloalkyl.

[0114] The term "quaternary ammonium group" refers to a -N + RR'R'' (wherein R, R', and R'' are each independently selected from the group consisting of alkyl groups having 1 to 8 carbon atoms).

[0115] The term "optionally" means that one or more of the events described below may or may not occur, and includes both cases where the event occurs and cases where the event does not occur. The term "optionally substituted" or "substituted" means that the referenced group may be substituted with one or more additional groups, each individually and independently selected from the group consisting of alkyl groups, cycloalkyl groups, aryl groups, heteroaryl groups, heterocycloalkyl groups, hydroxyl, alkoxy, cyano, halogen, amido, nitro, haloalkyl, amino, methylsulfonyl, alkylcarbonyl, alkoxycarbonyl, heteroarylalkyl, heterocycloalkylalkyl, aminocarbonyl, amino-protecting groups, etc. Among them, amino-protecting groups are preferably selected from the group consisting of pivaloyl, tert-butoxycarbonyl, benzyloxycarbonyl, 9-fluorenylmethoxycarbonyl, benzyl, p-methoxybenzyl, allyloxycarbonyl, trifluoroacetyl, etc.

[0116] The term "pharmaceutically acceptable salts" as used herein refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects. These pharmaceutically acceptable salts can be prepared in situ during the final isolation and purification of the compounds, or can be prepared by reacting only the free acid or free base form of the purified compound with a suitable base or acid, respectively.

[0117] "Solvate" or "solvate compound" refers to a solvent addition form containing stoichiometric or non-stoichiometric solvent. Some compounds tend to trap a certain molar proportion of solvent molecules in the crystalline solid state, resulting in the formation of a solvate. When the solvent is water, the solvate formed is a hydrate; when the solvent is alcohol, the solvate formed is an alcoholate. A hydrate is formed by combining one or more water molecules with a molecule of the substance, and the water retains its molecular state as HO.

[0118] A "metabolite" of a compound disclosed herein is a derivative of that compound formed when the compound is metabolized. The term "active metabolite" refers to a biologically active derivative of a compound formed when the compound is metabolized. The term "metabolized," as used herein, refers to the entire process by which a particular substance is modified by an organism, including, but not limited to, hydrolysis and enzyme-catalyzed reactions, such as oxidation. Thus, enzymes can bring about specific structural transformations in compounds. For example, cytochrome P450 catalyzes various oxidation and reduction reactions, and diphosphoglucuronosyltransferase catalyzes the conversion of activated glucuronic acid molecules to aromatic alcohols, aliphatic alcohols, carboxylic acids, amines, and free sulfhydryl groups. Further information regarding metabolism can be obtained from *The Pharmacological Basis of Therapeutics*, 9th Edition, McGraw-Hill (1996). Metabolites of a compound disclosed herein can be identified by administering the compound to a host and analyzing tissue samples from the host, or by incubating the compound with hepatocytes in vitro and analyzing the resulting compound. Both methods are known in the art. In some embodiments, a metabolite of a compound is formed by an oxidative process and corresponds to the corresponding hydroxyl-containing compound. In some embodiments, a compound is metabolized to a pharmaceutically active metabolite.

[0119] The term "modulate," as used herein, refers to interacting directly or indirectly with a target to alter the activity of the target, such as, by way of example only, enhancing the activity of the target, inhibiting the activity of the target, limiting the activity of the target, or prolonging the activity of the target.

[0120] The term "prodrug" or "precursor drug" refers to a derivative that may not be pharmacologically active, but which may be metabolized in vivo to form a pharmacologically active compound of the invention, optionally after being given orally or parenterally. Non-limiting examples of prodrugs include esters, carbonates, sesquiterpenes, phosphate esters, nitroesters, sulfates, sulfoxides, amides, carbamates, nitrogen-containing compounds, phosphoramidites, glycosides, ethers, acetals, and ketone acetals.

[0121] An "effective amount" refers to an amount of a drug or agent that elicits a biological or medical response in a tissue, system, animal, human, etc., that is the subject of study by a researcher or physician. Furthermore, the term "therapeutically effective amount" refers to any amount that results in improved treatment, cure, prevention, or alleviation of a disease, disorder, or side effect, or a reduction in the incidence of a disease or disorder, compared to a corresponding subject that does not receive that amount. This term also includes an amount that is effective in improving normal physiological function.

[0122] The term "treatment," as used herein, refers to the alleviation of at least one symptom of a disease, disorder, or condition. This term includes administering and / or applying one or more of the compounds described herein to a subject to provide management or treatment of the condition. For purposes of this disclosure, "treatment" may, but need not, provide a cure; rather, "treatment" can be a form of condition management. When using the compounds described herein to treat harmful proliferating cells, including cancer, "treatment" includes the partial or complete destruction of the harmful proliferating cells while minimizing the impact on the destruction of normal cells. The desired treatment mechanism for harmful, rapidly proliferating cells, including cancer cells, is apoptosis at the cellular level.

[0123] The term "prevention," as used herein, includes co-prevention or alleviation of the onset of clinically significant disease progression or the onset of a pre-clinically significant disease stage in at-risk individuals. Includes prophylactic treatment of individuals at risk for developing a disease.

[0124] The term "subject" or "patient" includes organisms, such as humans and non-human animals, that suffer from a condition or pathology associated with reduced or insufficient programmed cell death (apoptosis) or that can benefit from the administration of a compound of the invention. Preferred humans include human patients suffering from or susceptible to a disease or related condition described herein. The term "non-human animal" includes vertebrates, such as mammals, e.g., non-human primates, sheep, cows, rodents, such as dogs, cats, and mice, and non-mammals, such as chickens, amphibians, and reptiles.

[0125] As used herein, GI 50 refers to the concentration of a drug required to cause 50% cell growth inhibition, i.e., the concentration of a drug at which the drug inhibits or controls the growth of 50% of cells (e.g., cancer cells).

[0126] As used herein, IC 50 refers to the amount, concentration, or dose of a particular test compound that achieves 50% inhibition of the maximal effect in an assay that measures that effect.

[0127] As used herein, EC 50 refers to the dose, concentration or amount of an assay compound that produces a dose-dependent response of 50% of the maximal expression of a particular response induced, stimulated or enhanced by a particular assay compound.

[0128] PARP7 inhibitors of the present invention The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, deuterated compound, solvate, ester, acid, metabolite or prodrug thereof:

[0129] [ka] (In the formula,

[0130] [ka] represents a double bond or a single bond, provided that at most one double bond is attached to any atom; X is halogen, C 1~6 Haloalkyl and C 2~6 alkanoyl, or together with Y and the carbon atom to which they are attached form a fused benzene ring or heterocycle; Y is selected from the group consisting of NH and O, or together with X and the carbon atom to which it is attached form a fused benzene ring or heterocycle; A is a nitrogen-oxo group selected from the group consisting of -NO-, =NO-, -ON- and -ON=, and the N atom, when its valence is unsaturated, is hydrogen, C 1~6 Alkyl, C 2~6 Alkanoyl or C 1~6 optionally substituted with sulfonyl; L is -(CH2) n -,

[0131] [ka] wherein n is 1, 2, or 3; R5 and R5' are each independently selected from the group consisting of hydrogen, C 1~3 R5 and R5' together with the carbon atom to which they are attached are selected from the group consisting of alkyl, halogen, deuterium, and hydroxyl; 3~6 Forming a cycloalkyl; R1 and R2 are each independently hydrogen, C 1~6 Alkyl, C 1~6 Hydroxyalkyl, C 1~6 Haloalkyl, C 3~6 Cycloalkyl, C 3~6 Hydroxycycloalkyl or C 3~6 halocycloalkyl, or R and R together with the carbon atom to which they are attached are selected from the group consisting of C 5~8 Forming a cycloalkyl; M is a group represented by the formulas (M-1), (M-2), (M-3), (M-4) and (M-5):

[0132] [ka] (In the formula, D 1 , D 2 , D 3 , D 4 , D 5 , D 6 , D 7 , D 8 , D 9 and D 10 are each independently selected from the group consisting of N and CH, provided that at least one N is included as a ring atom of the M moiety; R3 is independently hydrogen, halogen, hydroxyl, C 1~4 Alkyl, C 1~6 Haloalkyl and C 1~6 hydroxyalkyl; Each m is independently selected from the group consisting of 0, 1, or 2. a moiety selected from the group consisting of: G is a 5- to 6-membered aromatic heterocyclic group optionally substituted with one or two R groups, each R being independently selected from hydroxyl, cyano, C 1~6 Alkyl, C 1~6 Hydroxyalkyl, C 1~6 Haloalkyl, halogen, C 3~6 Cycloalkyl, C 2~6 Alkenyl, C 2~6 alkynyl, -NR6R6', -C(O)NR6R6', -NR6C(O)R7, -C(O)OR6, -OR6, -S(O)2NR6R6', -NR6S(O)2R7, -S(O)2R7, -C(O)R6, and phenyl optionally substituted with halogen, or two R4 groups together with the carbon atom to which they are attached are selected from the group consisting of C(O) optionally substituted with hydroxyl, methyl, halogen, or oxo. 5~8 R6, R6' and R7 each independently represent hydrogen, C 1~6 Alkyl, C 1~6 Haloalkyl, C3~6 Cycloalkyl and C 1~6 hydroxyalkyl) In a preferred embodiment, the heterocycle is a 5- to 8-membered monocyclic ring containing an N atom, preferably piperidine, pyrrolidine, piperazine or tetrahydropyridine.

[0133] In some embodiments, M is selected from the group consisting of formulas (M-1a), (M-2a), (M-3a), (M-4a), and (M-5a):

[0134] [ka] (In the formula, D 1 is selected from the group consisting of N or CH; each m is independently selected from the group consisting of 0, 1, or 2; and each R is independently selected from the group consisting of hydrogen, hydroxyl, halogen, or C 1~4 alkyl) is a moiety selected from the group consisting of:

[0135] In some embodiments, G is selected from the group consisting of formulas (G-1), (G-2), (G-3), (G-4), (G-5), (G-6), and (G-7):

[0136] [ka] wherein each Q is independently selected from the group consisting of N or CH; more preferably, Q is N and R4 is as defined above. is a moiety selected from the group consisting of:

[0137] In the description herein, the substitution position of any substituent R4 is not limited, and it can be attached at any unsaturated carbon of the heteroaryl moiety represented by G. For example, when the heteroaryl moiety represented by G forms a fused bicyclic ring (e.g., the above formulas G-3, G-4), the description herein does not limit the position of the R4 substituent to the monocyclic ring to which it is attached, but rather the R4 substitution can occur at any unsaturated carbon of either ring of the fused bicyclic ring.

[0138] Preferably, the R groups are any substituent and each independently is selected from the group consisting of cyano, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 1~4 Haloalkyl, halogen, C 3~6 Cycloalkyl, C 2~4 Alkenyl, C 2~4 alkynyl, —NR6R6′, —C(O)NR6R6′, —C(O)OR6, —OR6, —C(O)R6, and phenyl optionally substituted with halogen, wherein R6 and R6′ are each independently selected from the group consisting of hydrogen and C 1~4 alkyl.

[0139] In preferred embodiments, X is selected from the group consisting of bromine, trifluoromethyl, and acetyl, or X together with Y and the carbon atom to which they are attached form a fused benzene ring or a fused piperidine ring; and Y is selected from NH, or X together with the carbon atom to which they are attached form a fused benzene ring or a fused piperidine ring.

[0140] In a further preferred embodiment, D of formula (M-1) or formula (M-1a) 1 is N, when L is -(CH2) n -,

[0141] [ka] selected from the group consisting of: D 1 is CH, when L is -(CH2) n-,

[0142] [ka] wherein n, R5, and R5' are defined as above.

[0143] In some embodiments, when A is -NO-, L is

[0144] [ka] and when A is =NO-, L is

[0145] [ka] and when A is -ON-, L is

[0146] [ka] and when A is -ON=, L is

[0147] [ka] is.

[0148] In a preferred aspect of the present invention, there is provided a PARP7 inhibitor comprising a compound of formula (I) or a pharmaceutically acceptable salt, deuterated compound, solvate, ester, acid, metabolite or prodrug thereof, wherein X is C 1~6 Haloalkyl and C 2~6 alkanoyl, and X is more preferably C 1~6 haloalkyl, especially trifluoromethyl; Y is NH; A is a nitrogen-oxo group selected from the group consisting of =NO-, -ON- and -ON=, more preferably -ON-; L is

[0149] [ka] More preferably

[0150] [ka] wherein R5 and R5' are each independently selected from the group consisting of hydrogen or halogen, more preferably hydrogen; M is selected from the group consisting of formula (M-1a) and (M-5a) (wherein D 1 is selected from the group consisting of N or CH, more preferably CH; m is independently 1; and each R3 is independently hydrogen, halogen, or C 1~3 and R4 is selected from the group consisting of alkyl, more preferably hydrogen; G is a moiety selected from the group consisting of formula (G-1), (G-3) and (G-4), more preferably formula (G-1) 1~6 Haloalkyl, halogen, C 3~6 Cycloalkyl and phenyl optionally substituted with halogen, more preferably C 1~6 haloalkyl, especially trifluoromethyl); R and R are each independently hydrogen, C 1~6 Alkyl and C 3~6 cycloalkyl, or R1 and R2 together with the carbon atom to which they are attached are selected from the group consisting of C 5~8 More preferably, R and R are each independently hydrogen and C 1~6 alkyl.

[0151] In a further preferred aspect, the present invention provides a PARP7 inhibitor comprising a compound of formula (I) or a pharmaceutically acceptable salt, deuterated compound, solvate, ester, acid, metabolite or prodrug thereof, wherein:

[0152] [ka] represents a double bond or a single bond, provided that at most one double bond is attached to any atom; X is halogen and C 1~6 haloalkyl, or together with Y and the carbon atom to which they are attached form a fused benzene ring or heterocycle; Y is NH or together with X and the carbon atom to which they are attached form a fused benzene ring or heterocyclic ring; A is a nitrogen-oxo group selected from the group consisting of -NO-, =NO-, -ON- and -ON=, and the N atom, when its valence is unsaturated, is hydrogen, C 1~6 Alkyl, C 2~6 Alkanoyl or C 1~6 optionally substituted with sulfonyl; L is -(CH2) n -,

[0153] [ka] wherein n is 1, 2, or 3; R5 and R5' are each independently hydrogen or C 1~3 alkyl, or R5 and R5' together with the carbon atom to which they are attached are selected from the group consisting of C 3~6 Forming a cycloalkyl; R1 and R2 are each independently hydrogen, C 1~6 Alkyl, C 1~6 Hydroxyalkyl, C 1~6 Haloalkyl, C 3~6 Cycloalkyl, C 3~6 Hydroxycycloalkyl or C 3~6 halocycloalkyl, or R and R together with the carbon atom to which they are attached are selected from the group consisting of C 5~8 Forming a cycloalkyl; M is a compound represented by the formula (M-1), (M-2), (M-3) and (M-4):

[0154] [ka] (In the formula, D 1 , D 2 , D 3 , D 4 , D 5 , D 6 , D 7 , D 8 and D 9 are each independently selected from the group consisting of N and CH, provided that at least one N is included as a ring atom of the M moiety; R3 independently represents a halogen atom, a hydroxyl group, or a C 1~4 Alkyl and C 1~6 haloalkyl; Each m is independently selected from the group consisting of 0, 1, or 2. a moiety selected from the group consisting of: G is a 5- to 6-membered aromatic heterocyclic group optionally substituted with one or two R groups, each R being independently hydroxyl, cyano, C 1~6 Alkyl, C 1~6 Hydroxyalkyl and C 1~6 haloalkyl, or two R groups together with the carbon atom to which they are attached are selected from the group consisting of C optionally substituted with hydroxyl or methyl. 5~8 Forms a cycloalkyl.

[0155] More preferably, M is selected from the group consisting of formulas (M-1a), (M-2a), (M-3a) and (M-4a):

[0156] [ka] (In the formula, D 1 is selected from the group consisting of N or CH; each m is independently selected from the group consisting of 0, 1, or 2; each R is independently selected from the group consisting of hydroxyl, halogen, or C 1~4 alkyl) is a moiety selected from the group consisting of:

[0157] Even more preferably, G is a group represented by the formula (G-1) and (G-2):

[0158] [ka] wherein Q is selected from the group consisting of N or CH. is a moiety selected from the group consisting of:

[0159] Particularly preferably, D of formula (M-1) or formula (M-1a) 1 is N, when L is -(CH2) n -,

[0160] [ka] selected from the group consisting of: D 1 is CH, when L is -(CH2) n -,

[0161] [ka] is selected from the group consisting of:

[0162] Also particularly preferably, when A is -NO-, L is

[0163] [ka] and when A is =NO-, L is

[0164] [ka] and when A is -ON-, L is

[0165] [ka] and when A is -ON=, L is

[0166] [ka] is.

[0167] The present invention also preferably provides a compound of formula (II) or a pharmaceutically acceptable salt, deuterated compound, solvate, ester, acid, metabolite or prodrug thereof:

[0168] [ka] (In the formula,

[0169] [ka] represents a double bond or a single bond, provided that at most one double bond is attached to any atom; X is a halogen and C 1~6 haloalkyl, or together with Y and the carbon atom to which they are attached form a fused benzene or piperidine ring; Y is selected from NH or together with X and the carbon atom to which they are attached form a fused benzene or piperidine ring; A is a nitrogen-oxo group selected from the group consisting of -NO-, =NO-, -ON- and -ON=, and the N atom, when its valence is unsaturated, is hydrogen, C 1~6 Alkyl, C 2~6 Alkanoyl or C 1~6 optionally substituted with sulfonyl; L is -(CH2) n -,

[0170] [ka] wherein n is 1, 2, or 3; R5 and R5' are each independently hydrogen or C 1~3 alkyl, or R5 and R5' together with the carbon atom to which they are attached are selected from the group consisting of C 3~6Forming a cycloalkyl; D is selected from the group consisting of N or CH; Q is selected from the group consisting of N or CH; R1 and R2 are each independently hydrogen, C 1~6 Alkyl, C 3~6 cycloalkyl, or R and R together with the carbon atom to which they are attached are selected from the group consisting of C 5~8 Forming a cycloalkyl; R3 is hydrogen or C 1~3 selected from the group consisting of alkyl; R4 is hydroxyl, cyano, C 1~6 Alkyl, C 1~6 Hydroxyalkyl and C 1~6 haloalkyl) The present invention provides a PARP7 inhibitor comprising:

[0171] More preferably, the present invention relates to the compounds shown in the table below or a pharmaceutically acceptable salt, deuterated compound, solvate, ester, acid, metabolite or prodrug thereof.

[0172] [Table 1] [Table 2] [Table 3] [Table 4]

[0173] Novel PARP7 inhibitors are described herein. Pharmaceutically acceptable salts, deuterated compounds, solvates, esters, acids, metabolites, or prodrugs of the compounds are also described herein.

[0174] The compounds of the present invention may exist in free form, for example in the form of a free base or free acid or zwitterion, or in the form of a salt, which may be any salt, whether organic or inorganic, and in particular any physiologically acceptable organic or inorganic salt commonly used in pharmacology.

[0175] Preferred salts for the purposes of the present invention are physiologically acceptable salts of the compounds of the present invention, but also include salts which are not themselves suitable for pharmacological uses but which can be used, for example, to isolate or purify the compounds of the present invention.

[0176] The term "pharmaceutically acceptable salts" refers to relatively non-toxic, inorganic or organic acid addition salts of compounds of the present invention. See, for example, S. M. Berge et al., "Pharmaceutical Salts, J. Pharm. Sci. 1977, 66, 1-19."

[0177] Pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts of inorganic acids, carboxylic acids, and sulfonic acids, such as the salts of the following acids: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, pyrosulfuric acid, phosphoric acid, and nitric acid; or organic acids, such as formic acid, acetic acid, acetoacetic acid, pyruvic acid, trifluoroacetic acid, propionic acid, butyric acid, caproic acid, heptanoic acid, undecylenic acid, lauric acid, benzoic acid, salicylic acid, 2-(4-hydroxybenzoyl)-benzoic acid, camphoric acid, cinnamic acid, cyclopentanepropionic acid, digluconic acid, 3-hydroxy-2-naphthalenecarboxylic acid, nicotinic acid, paraffinic acid, pectinic acid, persulfuric acid, 3-phenylpropionic acid, Examples of suitable salts include salts of picric acid, tert-valeric acid, 2-hydroxyethanesulfonic acid, itaconic acid, sulfamic acid, trifluoromethanesulfonic acid, dodecylsulfonic acid, ethylsulfonic acid, phenylsulfonic acid, p-toluenesulfonic acid, methylsulfonic acid, 2-naphthalenesulfonic acid, naphthalenedisulfonic acid, camphorsulfonic acid, citric acid, tartaric acid, stearic acid, lactic acid, oxalic acid, malonic acid, succinic acid, malic acid, adipic acid, alginic acid, maleic acid, fumaric acid, D-gluconic acid, mandelic acid, ascorbic acid, glucoheptanoic acid, glycerophosphoric acid, aspartic acid, sulfosalicylic acid, hemisulfuric acid, and thiocyanic acid.

[0178] Pharmaceutically acceptable salts of the compounds of the present invention include salts of commonly used bases, for example, preferably alkali metal salts (e.g., sodium salts and potassium salts), alkaline earth metal salts (e.g., calcium salts and magnesium salts), and ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms. Examples of the organic amines include, for example, preferably, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine, N-methylpiperidine, N-methylglucosamine, dimethylglucosamine, ethylglucosamine, 1,6-hexanediamine, aminoglucose, sarcosine, serotonin, tris(hydroxymethyl)aminomethane, aminopropylene glycol, Sovak base, and 1-amino-2,3,4-butanetriol.

[0179] The present invention includes all possible salts of the compounds of the present invention, whether they be single salts or any mixture of said salts in any proportion.

[0180] The present invention includes all possible deuterated compounds of the present invention, where the deuterium atom may optionally be substituted on a carbon or nitrogen atom.

[0181] Solvates is the term used for the purposes of the present invention for those forms of the compounds of the present invention which form a complex with solvent molecules by coordination in the solid or liquid state. Hydrates are specific solvate forms in which coordination with water occurs. Hydrates are preferred solvates within the scope of the present invention.

[0182] Furthermore, the present invention includes prodrugs of the compounds of the present invention. The term "prodrug" includes compounds that may themselves be biologically active or inactive, but that are converted (e.g., by metabolism or hydrolysis) into the compounds of the present invention during their residence in the body.

[0183] Furthermore, the present invention includes all possible crystalline forms or polymorphs of the compounds of the present invention, either as individual polymorphs or as mixtures of two or more polymorphs in any proportion.

[0184] In this specification, in some cases, for convenience, the structural formula of a compound represents a specific isomer, but the present invention includes all isomers such as geometric isomers, optical isomers based on asymmetric carbon atoms, stereoisomers, tautomers, etc.

[0185] The chiral compounds encompassed by the present invention may be in any configuration or mixed racemic form. When the compounds used according to the present invention contain two or more chiral centers, they may exist in diastereomeric forms. The diastereomeric compounds can be separated by methods known to those skilled in the art (e.g., chromatography or crystallization), and the individual enantiomers can be separated as described above. The present invention encompasses the application of the diastereomeric compounds used according to the present invention and mixtures thereof. The compounds used according to the present invention may be in different tautomeric forms or different geometric isomers, and the present invention encompasses the application of the individual tautomeric and / or geometric isomers of the compounds used according to the present invention, as well as mixtures thereof. The compounds used according to the present invention can exist in amphoteric forms. The present invention encompasses the application of the individual amphoteric forms of the compounds used according to the present invention and mixtures thereof.

[0186] Screening and characterization of pharmaceutically acceptable salts, polymorphs, and / or solvates can be achieved using a variety of techniques, including but not limited to, thermal analysis, X-ray diffraction, spectroscopy, microscopy, and elemental analysis. Spectroscopic techniques that may be used include, but are not limited to, Raman, FTIR, UVIS, and NMR (liquid-state and solid-state). Microscopy techniques include, but are not limited to, IR microscopy and Raman microscopy.

[0187] Thus, the present invention includes all possible salts, polymorphs, metabolites, hydrates, deuterated compounds, solvates or prodrugs (e.g., esters) of the compounds of the present invention, either as an individual salt, polymorph, metabolite, hydrate, deuterated compound, solvate or prodrug, or as a mixture of two or more salts, polymorphs, metabolites, hydrates, deuterated compounds, solvates, prodrugs in any proportion.

[0188] Medical uses of the present invention The compounds of formula (I) or formula (II) of the present invention, or pharmaceutically acceptable salts, deuterated compounds, solvates, esters, acids, metabolites or prodrugs thereof, can selectively inhibit the enzymatic activity of PARP7 and can therefore be used to treat or prevent diseases, disorders or conditions that are regulated or affected by PARP7 activity or that involve PARP7 activity or overexpression.

[0189] In a preferred embodiment, the disease, disorder or condition regulated or affected by PARP7 activity or associated with PARP7 activity or overexpression is a hyperproliferative disease, particularly a cancerous disease, including, but not limited to, squamous cell lung cancer, lung adenocarcinoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, breast cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, colorectal cancer, melanoma, ovarian cancer, esophageal squamous cell carcinoma, gastric cancer, liver cancer, oral cancer, urothelial cancer, prostate cancer, bladder cancer, renal cell carcinoma, gastrointestinal stromal tumor, cervical cancer, endometrial cancer, rhabdomyosarcoma, fibrosarcoma, neuroendocrine tumor, mesothelioma, brain cancer or malignant glioma.

[0190] In other preferred aspects, the disease, disorder or condition regulated or affected by PARP7 activity or associated with PARP7 activity or overexpression is an autoimmune or inflammatory disease, including, but not limited to, ulcerative colitis, Crohn's disease, multiple sclerosis, autoimmune liver disease, type I diabetes, bronchial asthma, systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis, polymyositis or dermatomyositis.

[0191] The compounds of the invention may act systemically and / or locally and for this purpose may be administered in a suitable manner, for example by oral, parenteral, pulmonary, nasal, sublingual, lingual, intranasal, rectal, cutaneous, transdermal, conjunctival or aural routes, or in the form of an implant or scaffold.

[0192] Preferably, in an embodiment of the present invention, a drug containing a compound of the present invention may be administered to a patient by at least one of injection, oral, inhalation, rectal and transdermal administration.

[0193] Regardless of the route of administration selected, the PARP7 inhibitors of the present invention and / or pharmaceutical compositions of the present invention are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.

[0194] When treating a patient according to the present invention, the amount of drug administered will depend on numerous factors, including the specific dosing regimen, the type and severity of the disease or condition, and the identity (e.g., body weight) of the individual or host being treated. However, depending on the specific circumstances, including the specific drug being used, the route of administration, the condition being treated, and the individual or host being treated, the dose to be administered can be routinely determined by methods known in the art. Typically, for doses for therapeutic use in adults, the administered dose will typically range from 0.02 to 5000 mg / day, e.g., about 1 to 1500 mg / day. This desired dose can conveniently be expressed as a single dose or as divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, e.g., two, three, four, or more divided doses per day. While the above dose ranges are given, those skilled in the art will understand that the specific effective amount can be appropriately adjusted depending on the patient's condition and in conjunction with the physician's diagnosis.

[0195] Actual dosage levels and time-course of administration of the compounds of the present invention may be varied to provide an amount of the active ingredient that is effective to achieve a desired therapeutic response in a particular patient and which is non-toxic to said patient.

[0196] Pharmaceutical Composition Another aspect of the present invention relates to a pharmaceutical composition comprising a compound of Formula (I) or Formula (II) of the present invention, or a pharmaceutically acceptable salt, deuterated compound, solvate, ester, acid, metabolite or prodrug thereof, a pharmaceutically acceptable diluent, carrier or excipient, and optionally one or more other therapeutic agents.

[0197] The compounds of the present invention can be administered in the form of separate pharmaceutical preparations or in combination with one or more other therapeutic agents, provided that the combination does not cause unacceptable side effects. Pharmaceutical compositions include administration of a single pharmaceutical dosage formulation containing a compound of the present invention and one or more other therapeutic agents, as well as administration of a compound of the present invention and various other therapeutic agents in their own separate pharmaceutical dosage formulations. For example, a compound of formula (I) or formula (II) can be administered to a patient together with other therapeutic agents in the form of a single oral dosage composition, such as a tablet or capsule, or each agent can be administered in its own separate dosage formulation.

[0198] When used as separate dosage formulations, the compound of the invention and the one or more other therapeutic agents may be administered substantially simultaneously (e.g., simultaneously) or at different staggered times (e.g., sequentially).

[0199] In particular, the compounds of the present invention may be used in fixed or separate combinations with other anti-tumor agents, such as alkylating agents, antimetabolites, plant-derived anti-tumor agents, hormonal therapy agents, topoisomerase inhibitors, camptothecin derivatives, kinase inhibitors, targeting agents, antibodies, interferons and / or biological response modifiers, anti-angiogenic compounds and other anti-tumor agents.

[0200] The compounds of the invention may also be used in cancer treatment in conjunction with radiation therapy and / or surgical intervention.

[0201] Preparation of compounds The compounds of the present invention can be synthesized using standard synthetic techniques known to those skilled in the art, or by combining methods known to those skilled in the art with the methods described herein. Furthermore, solvents, temperatures, and other reaction conditions shown herein can be varied according to the skill of the art. For further guidance, the following synthetic methods can also be used.

[0202] The above reactions may be used sequentially to provide compounds described herein, or may be used to synthesize fragments that are then incorporated by methods described herein and / or known in the art.

[0203] The starting materials for synthesizing the compounds described herein can be synthesized or obtained from commercially available sources. The compounds described herein and other related compounds with different substituents can be synthesized using techniques and raw materials known to those skilled in the art. The general method for preparing the compounds disclosed herein can be derived from reactions known in the art, and the reactions can be modified by reagents and conditions deemed appropriate by those skilled in the art to introduce various moieties of the molecules provided herein.

[0204] If desired, the reaction products can be isolated and purified using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and other methods. The products can be characterized using conventional methods, including physical constants and graphical data.

[0205] Non-limiting embodiments of synthetic schemes for preparing compounds of Formula (I) or Formula (II) are set forth below. [Example]

[0206] The following specific, non-limiting embodiments are to be construed as merely illustrative, and not limiting of the invention in any way. Further elaboration is not necessary, but it is believed that one skilled in the art can, based on the description herein, utilize the present disclosure to its fullest extent.

[0207] The structure of the compound was determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). The solvent used for NMR measurements was deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated chloroform (CDCl3) or deuterated methanol (CD3OD).

[0208] In embodiments, unless otherwise specified, the solution is an aqueous solution.

[0209] In the embodiment, the reaction temperature is room temperature, for example, 20°C to 30°C, unless otherwise specified.

[0210] In the embodiment, the reaction process was monitored by thin layer chromatography (TLC) and LCMS. The developer used in the reaction, the column chromatography eluent used for compound purification, and the developer system for thin layer chromatography included A: dichloromethane / methanol system, B: n-hexane / ethyl acetate system, and C: petroleum ether / ethyl acetate system. The volume ratio of the solvents was adjusted depending on the polarity of the compounds, and can also be adjusted by adding small amounts of basic or acidic reagents, such as triethylamine and acetic acid.

[0211] Example 1 (S)-5-((1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one

[0212] [ka]

[0213] 1.1) Synthesis of intermediates Step A: Synthesis of 4,5-dibromo-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one

[0214] [ka] To a solution of 4,5-dibromopyridazin-3(2H)-one (10.00 g, 39.39 mmol, 1.0 equiv) in DMF (84 mL) was added NaH (60%, 1.89 g, 47.27 mmol, 1.2 equiv) in an ice-water bath under nitrogen at 0 °C in small portions. The resulting mixture was stirred at 0 °C for 1 h, followed by the dropwise addition of 2-(trimethylsilyl)ethoxymethyl chloride (7.22 g, 43.33 mmol, 1.1 equiv) at 0 °C. The reaction mixture was stirred at 25 °C for an additional 3 h. The mixture was carefully quenched by the addition of water (400 mL), and the mixture was extracted with EtOAc (3 × 400 mL). The organic layers were combined, washed with brine (400 mL), dried over Na SO , and concentrated in vacuo. The crude product was purified by silica gel chromatography (petroleum ether / EtOAc=20 / 1; V / V) to give 4,5-dibromo-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (7.45 g, yield 49.2%) as a yellow oil.

[0215]

number

[0216] Step B: Synthesis of 4-bromo-5-chloro-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one

[0217] [ka] To a solution of 4,5-dibromo-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (7.45 g, 19.39 mmol, 1.0 equiv) in NMP (15 mL) was added LiCl (814 mg, 19.39 mmol, 1.0 equiv). The mixture was stirred at 95° C. for 4 hours. The mixture was cooled to room temperature and diluted with water (100 mL). The mixture was extracted with EtOAc (3×80 mL). The organic layers were combined, washed with brine (80 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc=20 / 1; V / V) to give 4-bromo-5-chloro-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (5.45 g, 82.7% yield) as a yellow oil.

[0218]

number

[0219] Step C: Synthesis of 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (Intermediate A)

[0220] [ka] To a solution of 4-bromo-5-chloro-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (3.25 g, 9.57 mmol, 1.0 equiv) in DMF (10 mL) was added CuI (1.28 g, 6.70 mmol, 0.7 equiv), followed by the dropwise addition of methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (5.52 g, 28.71 mmol, 3.0 equiv). The resulting mixture was stirred at 95 °C for 3 h. The mixture was cooled to room temperature and quenched by the addition of water (80 mL). The mixture was extracted with EtOAc (3 × 80 mL). The organic layers were combined, washed with brine (80 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=10 / 1; V / V) to give 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (2.80 g, 89.0%) as a colorless oil.

[0221]

number

[0222] Step D: Synthesis of (S)-5-((1-hydroxypropan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (Intermediate B)

[0223] [ka] To a solution of 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (2.80 g, 8.51 mmol, 1.0 equiv) in EtOH (21 mL) were added TEA (860 mg, 8.51 mmol, 1.0 equiv) and L-alaninol (2.56 g, 34.04 mmol, 4.0 equiv), and the resulting mixture was stirred at 60° C. for 3 h. The mixture was cooled to room temperature and diluted with water (50 mL). The mixture was extracted with EtOAc (3×50 mL). The organic layers were combined, washed with brine (50 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=1 / 1; V / V) to give (S)-5-((1-hydroxypropan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (450 mg, 14.4%) as a yellow oil.

[0224]

number

[0225] Step E: Synthesis of tert-butyl 4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazine-1-carboxylate

[0226] [ka] To a solution of 2-chloro-5-(trifluoromethyl)pyrimidine (4.00 g, 21.92 mmol, 1.05 equiv.) and tert-butyl piperazine-1-carboxylate (3.89 g, 20.87 mmol, 1.0 equiv.) in NMP (40 mL) was added K2CO3 (3.46 g, 25.04 mmol, 1.2 equiv.). The mixture was heated to 80 °C and stirred for 5 h. The mixture was cooled to room temperature and diluted with water (150 mL). The precipitated solid was collected by filtration. The product was redissolved in EtOAc (150 mL) and dried over Na2SO4. The solvent was removed in vacuo to give tert-butyl 4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazine-1-carboxylate (6.4 g, 87.9% yield) as a white solid.

[0227]

number

[0228] Step F: Synthesis of 2-(piperazin-1-yl)-5-(trifluoromethyl)pyrimidine (Intermediate C)

[0229] [ka] To a solution of tert-butyl 4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazine-1-carboxylate (3.00 g, 9.03 mmol, 1.0 equiv) in DCM (10 mL) was added HCl / dioxane (4 M, 10 mL). The resulting mixture was stirred at 25 °C for 1 h. DIPEA was added dropwise to the mixture to adjust the pH to 7-8. The mixture was concentrated in vacuo to give 2-(piperazin-1-yl)-5-(trifluoromethyl)pyrimidine (2.90 g, 100% yield) as a white solid.

[0230]

number

[0231] Step G: Synthesis of tert-butyl 2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxycarbamate

[0232] [ka] To a solution of 2-(piperazin-1-yl)-5-(trifluoromethyl)pyrimidine (2.90 g, 12.49 mmol, 1.0 equiv) in DMF (50 mL) was added DIPEA (8.07 g, 62.45 mmol, 5.0 equiv) and HATU (5.70 g, 14.99 mmol, 1.2 equiv), followed by the dropwise addition of 2-(((tert-butoxycarbonyl)amino)oxy)acetic acid (2.62 g, 13.74 mmol, 1.1 equiv). The resulting mixture was stirred at 25 °C for 2 h. The reaction mixture was quenched with water (200 mL) and extracted with EtOAc (3 x 150 mL). The organic layers were combined, washed with brine (150 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=1 / 1; V / V) to obtain tert-butyl 2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxycarbamate (4.50 g, yield 88.9%) as a yellow oil.

[0233]

number

[0234] Step H: Synthesis of 2-(aminooxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)hexahydropyrazin-1-yl)ethanone hydrochloride (Intermediate D)

[0235] [ka] To a solution of tert-butyl 2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxycarbamate (2.25 g, 5.55 mmol, 1.0 equiv) in DCM (60 mL) was added HCl / dioxane (4 M HCl gas in dioxane; 12 mL). The resulting mixture was stirred at 25° C. for 2 h. The reaction mixture was concentrated in vacuo to give 2-(aminooxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)hexahydropyrazin-1-yl)ethanone hydrochloride (1.73 g, 91.2% yield) as a yellow solid.

[0236]

number

[0237] 1.2) Synthesis of Compound 1 Step A: Synthesis of (S)-tert-butyl (1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)carbamate (Intermediate E)

[0238] [ka] To a mixture of 2-(aminooxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)hexahydropyrazin-1-yl)ethanone hydrochloride (342 mg, 1.00 mmol, 1.0 equiv) in MeOH (10 mL) was added DIPEA (388 mg, 3.00 mmol, 3.0 equiv) and Boc-L-alaninal (208 mg, 1.20 mmol, 1.2 equiv). The mixture was stirred at 55° C. for 3 h. The mixture was cooled to room temperature, and acetic acid (240 mg, 4.00 mmol, 4.0 equiv) and sodium cyanoborohydride (629 mg, 10.00 mmol, 10.0 equiv) were added to the mixture. The mixture was stirred at 55° C. for an additional 16 h. The mixture was cooled to room temperature, quenched with saturated aqueous NaHCO3 (100 mL), and extracted with EtOAc (2 x 80 mL). The organic layers were combined, dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc / petroleum ether = 2 / 1; V / V) to give (S)-tert-butyl (1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)carbamate (330 mg, 71.3%) as a white solid.

[0239]

number

[0240] Step B: Synthesis of (S)-2-(((2-aminopropyl)amino)oxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone

[0241] [ka] To a solution of (S)-tert-butyl (1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)carbamate (148 mg, 0.32 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (1.5 mL). The mixture was stirred at 25 °C for 1 h. Excess TFA was neutralized with saturated aqueous NaHCO (40 mL), and the mixture was extracted with DCM (2 × 50 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo to give (S)-2-(((2-aminopropyl)amino)oxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone (116 mg, 99.0%) as a pale yellow solid.

[0242]

number

[0243] Step C: Synthesis of (S)-5-((1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one

[0244] [ka] To a solution of (S)-2-(((2-aminopropyl)amino)oxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone (116 mg, 0.32 mmol, 1.0 equiv) in EtOH (6 mL) was added TEA (162 mg, 1.60 mmol, 5.0 equiv) and 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (316 mg, 0.96 mmol, 3.0 equiv). The mixture was heated to 60° C. and stirred for 3 h. The mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc / petroleum ether=2 / 1; V / V) to give (S)-5-((1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (37 mg, 17.7%) as a pale yellow solid.

[0245]

number

[0246] Step D: Synthesis of (S)-5-((1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one

[0247] [ka] To a solution of (S)-5-((1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (26 mg, 0.04 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (0.4 mL). The mixture was stirred at 25 °C for 0.5 h. The mixture was neutralized with saturated aqueous NaHCO (30 mL) and extracted with DCM (3 × 50 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (3 mL) and potassium carbonate (20 mg, 0.15 mmol, 3.6 equiv) was added. The mixture was stirred for an additional 1 h at 25° C. The mixture was filtered, and the filtrate was purified by preparative HPLC to give (S)-5-((1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (3.62 mg, 15.7%) as a pale yellow solid.

[0248]

number

[0249] Example 2 (S)-5-((1-(methyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one

[0250] [ka]

[0251] Step A: Synthesis of (S)-tert-butyl (1-(methyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)carbamate

[0252] [ka] To a solution of (S)-tert-butyl (1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)carbamate (240 mg, 0.52 mmol, 1.0 equiv) in MeOH (10 mL) was added formaldehyde (37% in water, 421 mg, 5.19 mmol, 10.0 equiv). The mixture was stirred at 23 °C for 3 h. Acetic acid (125 mg, 2.08 mmol, 4.0 equiv) and sodium cyanoborohydride (326 mg, 5.19 mmol, 10.0 equiv) were added to the reaction mixture. The mixture was stirred at 23 °C for an additional 16 h. The mixture was diluted with water (80 mL) and neutralized with saturated aqueous NaHCO (10 mL). The mixture was extracted with EtOAc (3 × 80 mL). The combined organic layers were washed with brine (80 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc = 2 / 1; V / V) to afford (S)-tert-butyl (1-(methyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)carbamate (200 mg, yield 76.0%) as a colorless oil.

[0253]

number

[0254] Step B: Synthesis of (S)-2-(((2-aminopropyl)(methyl)amino)oxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone

[0255] [ka] To a solution of (S)-tert-butyl (1-(methyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)carbamate (170 mg, 0.36 mmol, 1.0 equiv) in DCM (4 mL) was added TFA (2 mL). The mixture was stirred at 23 °C for 1 h. Excess TFA was neutralized with saturated aqueous NaHCO (50 mL), and the mixture was extracted with DCM (3 × 80 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo to give (S)-2-(((2-aminopropyl)(methyl)amino)oxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone (120 mg, 78.6%) as a white solid.

[0256]

number

[0257] Step C: Synthesis of (S)-5-((1-(methyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one

[0258] [ka] To a solution of (S)-2-(((2-aminopropyl)(methyl)amino)oxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone (120 mg, 0.32 mmol, 1.0 equiv) in EtOH (10 mL) was added TEA (162 mg, 1.60 mmol, 5.0 equiv), followed by 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (210 mg, 0.64 mmol, 2.0 equiv). The mixture was heated to 60° C. and stirred for 3 h. The mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc=2 / 1; V / V) to give (S)-5-((1-(methyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (50 mg, 15.0%) as a yellow oil.

[0259]

number

[0260] Step D: Synthesis of (S)-5-((1-(methyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one

[0261] [ka] To a solution of (S)-5-((1-(methyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (25 mg, 0.037 mmol, 1.0 equiv) in DCM (2 mL) was added TFA (0.2 mL). The mixture was stirred at 21 °C for 2 h. The mixture was neutralized with saturated NaHCO (30 mL) and extracted with DCM (3 × 50 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (2 mL) and potassium carbonate (19 mg, 0.14 mmol, 3.6 equiv) was added. The mixture was stirred for an additional 1 h at 21° C. The mixture was filtered, and the filtrate was purified by preparative HPLC to give (S)-5-((1-(methyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (4.8 mg, 22.9% yield) as a white solid.

[0262]

number

[0263] Example 3 (S)-5-((1-(ethyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one

[0264] [ka]

[0265] Step A: Synthesis of (S)-tert-butyl (1-(ethyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)carbamate

[0266] [ka] To a solution of (S)-tert-butyl (1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)carbamate (250 mg, 0.54 mmol, 1.0 equiv) in MeOH (10 mL) was added acetaldehyde (238 mg, 5.41 mmol, 10.0 equiv). The mixture was stirred at 23 °C for 3 h. To the mixture was then added acetic acid (32 mg, 0.54 mmol, 1.0 equiv) and sodium cyanoborohydride (340 mg, 5.41 mmol, 10.0 equiv). The mixture was stirred at 23 °C for an additional 16 h. The mixture was diluted with water (80 mL) and neutralized with saturated aqueous NaHCO (5 mL). The mixture was extracted with EtOAc (3 × 80 mL). The combined organic layers were washed with brine (80 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / Et0Ac=2 / 1; V / V) to afford (S)-tert-butyl (1-(ethyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)carbamate (180 mg, yield 63.8%) as a yellow oil.

[0267]

number

[0268] Step B: Synthesis of (S)-2-(((2-aminopropyl)(ethyl)amino)oxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone

[0269] [ka] To a solution of (S)-tert-butyl (1-(ethyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)carbamate (160 mg, 0.33 mmol, 1.0 equiv) in DCM (4 mL) was added TFA (2 mL). The mixture was stirred at 23 °C for 1 h. Excess TFA was neutralized with saturated aqueous NaHCO (40 mL), and the mixture was extracted with DCM (3 × 50 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo to give (S)-2-(((2-aminopropyl)(ethyl)amino)oxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone (160 mg, 95.5%) as a white solid.

[0270]

number

[0271] Step C: Synthesis of (S)-5-((1-(ethyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one

[0272] [ka] To a solution of (S)-2-(((2-aminopropyl)(ethyl)amino)oxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone (160 mg, 0.41 mmol, 1.0 equiv) in EtOH (2 mL) was added TEA (207 mg, 2.05 mmol, 5.0 equiv) and 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (270 mg, 0.82 mmol, 2.0 equiv). The mixture was heated to 60° C. and stirred for 3 h. The mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc=1 / 1; V / V) to give (S)-5-((1-(ethyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (110 mg, 33.4%) as a yellow oil.

[0273]

number

[0274] Step D: Synthesis of (S)-5-((1-(ethyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one

[0275] [ka] To a solution of (S)-5-((1-(ethyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (105 mg, 0.15 mmol, 1.0 equiv) in DCM (2 mL) was added TFA (0.2 mL). The mixture was stirred at 21 °C for 2 h. The mixture was neutralized with saturated aqueous NaHCO (50 mL) and extracted with DCM (2 × 80 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (2 mL) and potassium carbonate (77 mg, 0.55 mmol, 3.6 equiv) was added. The mixture was stirred for an additional 1 h at 21° C. The mixture was filtered, and the filtrate was purified by preparative HPLC to give (S)-5-((1-(ethyl(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)amino)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (23.29 mg, 27.4% yield) as a white solid.

[0276]

number

[0277] Example 4 (S)-2-(4-(2-((methyl(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propyl)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile

[0278] [ka]

[0279] 4.1) Synthesis of intermediate G Step A: Synthesis of tert-butyl 4-(5-cyanopyrimidin-2-yl)piperazine-1-carboxylate

[0280] [ka] To a solution of 2-chloropyrimidine-5-carbonitrile (3.0 g, 21.50 mmol, 1.0 equiv) and tert-butyl piperazine-1-carboxylate (4.00 g, 21.50 mmol, 1.0 equiv) in NMP (30 mL) was added K2CO3 (5.94 g, 43.00 mmol, 2.0 equiv). The mixture was heated to 80 °C and stirred for 1.0 h. The mixture was cooled to room temperature and diluted with water (40 mL). The mixture was extracted with EtOAc (3 × 50 mL). The organic layers were combined, washed with brine (50 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=5 / 1; V / V) to obtain tert-butyl 4-(5-cyanopyrimidin-2-yl)piperazine-1-carboxylate (4.0 g, yield 64.3%) as a yellow solid.

[0281]

number

[0282] Step B: Synthesis of 2-(piperazin-1-yl)pyrimidine-5-carbonitrile hydrochloride (intermediate G)

[0283] [ka] To a solution of tert-butyl 4-(5-cyanopyrimidin-2-yl)piperazine-1-carboxylate (1.0 g, 3.46 mmol, 1.0 equiv) in DCM (5 mL) was added HCl / dioxane (4 M, 15 mL). The resulting mixture was stirred at 15° C. for 1 hour. The mixture was concentrated in vacuo to give 2-(piperazin-1-yl)pyrimidine-5-carbonitrile hydrochloride (720 mg, 92.3% yield) as a white solid.

[0284]

number

[0285] 4.2) Synthesis of Compound 4 Step A: Synthesis of tert-butyl (2-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-2-oxoethoxy)carbamate

[0286] [ka] To a solution of 2-(piperazin-1-yl)pyrimidine-5-carbonitrile hydrochloride (7.1 g, 37.57 mmol, 1.0 equiv) in THF (100 mL) was added DIEA (7.2 g, 56.25 mmol, 1.5 equiv) and HATU (21 g, 56.25 mmol, 1.5 equiv), followed by the dropwise addition of 2-(((tert-butoxycarbonyl)amino)oxy)acetic acid (7.1 g, 37.57 mmol, 1.1 equiv). The resulting mixture was stirred at 25 °C for 2 h. The reaction mixture was quenched with water (200 mL) and extracted with EtOAc (3 x 150 mL). The organic layers were combined, washed with brine (150 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=1 / 1; V / V) to give tert-butyl (2-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-2-oxoethoxy)carbamate (8.3 g, yield 61%) as a white solid.

[0287]

number

[0288] Step B: Synthesis of 2-(4-(2-(aminooxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile hydrochloride

[0289] [ka] To a solution of tert-butyl (2-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-2-oxoethoxy)carbamate (500 mg, 1.38 mmol, 1.0 equivalent) in DCM (5 mL) was added HCl / dioxane (4 M, 3 mL). The resulting mixture was stirred at 25° C. for 2 hours. The reaction mixture was concentrated in vacuo. The residue was purified by silica gel chromatography (DCM / MeOH=92 / 8, V / V) to give 2-(4-(2-(aminooxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile hydrochloride (200 mg, 72% yield) as a white solid.

[0290]

number

[0291] Step C: Synthesis of tert-butyl (S)-(1-((2-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-2-oxoethoxy)amino)propan-2-yl)carbamate

[0292] [ka] To a solution of 2-(4-(2-(aminooxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile hydrochloride (200 mg, 0.764 mmol, 1.0 equiv) in MeOH (4 mL) was added tert-butyl (S)-(1-oxopropan-2-yl)carbamate (200 mg, 1.15 mmol, 1.5 equiv). The mixture was stirred at 55° C. for 2 h. Acetic acid (182 mg, 3.1 mmol, 4.0 equiv) and sodium cyanoborohydride (380 mg, 7.6 mmol, 10.0 equiv) were added to the reaction mixture. The mixture was stirred at 55° C. for an additional 16 h. The mixture was quenched with saturated aqueous NH4Cl and extracted with EtOAc (3×30 mL). The organic layers were combined, washed with brine (40 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc = 1 / 1, V / V) to give tert-butyl (S)-(1-((2-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-2-oxoethoxy)amino)propan-2-yl)carbamate (200 mg, yield 62.0%) as a white solid.

[0293]

number

[0294] Step D: Synthesis of tert-butyl (S)-(1-((2-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-2-oxoethoxy)(methyl)amino)propan-2-yl)carbamate

[0295] [ka] To a solution of tert-butyl (S)-(1-((2-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-2-oxoethoxy)amino)propan-2-yl)carbamate (850 mg, 2.03 mmol, 1.0 equiv) in MeOH (12 mL) was added formaldehyde (290 mg, 2.44 mmol, 1.2 equiv). The mixture was stirred at 35° C. for 2 h. Acetic acid (125 mg, 2.08 mmol, 4.0 equiv) and sodium cyanoborohydride (1.2 g, 20.3 mmol, 10.0 equiv) were added to the reaction mixture. The mixture was stirred at 35° C. for an additional 16 h. The mixture was diluted with water (35 mL) and extracted with EtOAc (3×30 mL). The combined organic layers were washed with brine (40 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc = 1 / 2, V / V) to afford tert-butyl (S)-(1-((2-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-2-oxoethoxy)(methyl)amino)propan-2-yl)carbamate (650 mg, yield 74.0%) as a pale yellow solid.

[0296]

number

[0297] Step E: Synthesis of (S)-2-(4-(2-(((2-aminopropyl)(methyl)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile

[0298] [ka] To a solution of tert-butyl (S)-(1-((2-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-2-oxoethoxy)(methyl)amino)propan-2-yl)carbamate (900 mg, 2.08 mmol, 1.0 equiv) in DCM (9 mL) was added TFA (4 mL). The mixture was stirred at 23 °C for 1 h. Excess TFA was neutralized with saturated NaHCO (50 mL), and the mixture was extracted with DCM (3 × 80 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo to give (S)-2-(4-(2-(((2-aminopropyl)(methyl)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile (500 mg, 72%) as a white solid.

[0299]

number

[0300] Step F: Synthesis of (S)-2-(4-(2-((methyl(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propyl)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile

[0301] [ka] To a solution of (S)-2-(4-(2-(((2-aminopropyl)(methyl)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile (340 mg, 1.02 mmol, 1.0 equiv) in EtOH (10 mL) was added TEA (247 mg, 2.44 mmol, 2.0 equiv) and 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (400 mg, 1.22 mmol, 1.20 equiv). The mixture was heated at 60° C. and stirred for 1 h. The mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc = 1 / 1, V / V) to give (S)-2-(4-(2-((methyl(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propyl)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile (70 mg, 11.0%) as a colorless oil.

[0302]

number

[0303] Step G: Synthesis of (S)-2-(4-(2-((methyl(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propyl)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile

[0304] [ka] To a solution of (S)-2-(4-(2-((methyl(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propyl)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile (70 mg, 0.112 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (0.3 mL). The mixture was stirred at 21 °C for 2 h. The mixture was neutralized with saturated NaHCO (30 mL) and extracted with DCM (3 × 50 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was dissolved in MeOH (3 mL) and potassium carbonate (60 mg, 0.4 mmol, 3 equiv) was added to the reaction mixture. The mixture was stirred at 21 °C for an additional 1 h. The mixture was concentrated under vacuum, and the residue was purified by column chromatography (petroleum ether / EtOAc=1 / 100, V / V) to give (S)-2-(4-(2-((methyl(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propyl)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile (20 mg, yield 36.3%) as a white solid.

[0305]

number

[0306] Example 5 Synthesis of (S,E)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime

[0307] [ka]

[0308] Step A: Synthesis of Boc-L-alaninal

[0309] [ka] To a solution of Boc-L-alaninol (5.26 g, 30.00 mmol, 1.0 equiv) in DCM (120 mL) was added Dess-Martin periodinane (17.81 g, 42.00 mmol, 1.4 equiv) in an ice-water bath at 0 °C. The mixture was stirred at 20 °C for 1 h. The mixture was slowly quenched by adding water (756 mg, 42.00 mmol, 1.4 equiv) followed by the addition of EtOAc / petroleum ether (1 / 15; v / v, 150 mL). The mixture was filtered, and the filtrate was concentrated. The residue was redissolved in EtOAc / petroleum ether (1 / 15; v / v, 150 mL) and washed with a mixture of saturated aqueous NaHCO3 and 10% aqueous sodium thiosulfate (1:1; v / v, 3 × 120 mL). The aqueous layer was back-extracted with EtOAc / petroleum ether (1 / 10; V / V, 5 × 150 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo to give Boc-L-alaninal (3.02 g, 17.44 mmol, 58.1% yield) as a pale yellow solid.

[0310]

number

[0311] Step B: Synthesis of (S,E)-tert-butyl (1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)propan-2-yl)carbamate

[0312] [ka] To a solution of 2-(aminooxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone hydrochloride (400 mg, 1.17 mmol, 1.0 equiv) in MeOH (20 mL) was added DIPEA (454 mg, 3.51 mmol, 3.0 equiv) and Boc-L-alaninal (284 mg, 1.64 mmol, 1.4 equiv). The mixture was stirred at 55 °C for 3 h. Acetic acid (71 mg, 1.17 mmol, 1.0 equiv) and sodium cyanoborohydride (111 mg, 1.76 mmol, 1.5 equiv) were added to the reaction mixture. The mixture was stirred at 55 °C for an additional 0.5 h. The mixture was diluted with saturated aqueous NaHCO (50 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with brine (80 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by column chromatography (Et0Ac / petroleum ether = 3 / 4; V / V) to afford (S,E)-tert-butyl (1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)propan-2-yl)carbamate (350 mg, yield 64.3%) as a white solid.

[0313]

number

[0314] Step C: Synthesis of (S,E)-2-aminopropanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime

[0315] [ka] To a solution of (S,E)-tert-butyl (1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)propan-2-yl)carbamate (300 mg, 0.65 mmol, 1.0 equiv) in DCM (6 mL) was added TFA (2 mL). The mixture was stirred at 23 °C for 1 h. Excess TFA was neutralized with saturated aqueous NaHCO (50 mL), and the mixture was extracted with DCM (3 × 80 mL). The organic layers were combined, dried over Na2SO4, and concentrated in vacuo to give (S,E)-2-aminopropanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (200 mg, 57.9% yield) as a white solid.

[0316]

number

[0317] Step D: Synthesis of (S,E)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime

[0318] [ka] To a solution of (S,E)-2-aminopropanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (200 mg, 0.56 mmol, 1.0 equiv) in EtOH (10 mL) was added TEA (281 mg, 2.76 mmol, 5.0 equiv), followed by 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (365 mg, 1.11 mmol, 2.0 equiv). The mixture was heated to 60° C. and stirred for 3 h. The mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / petroleum ether=3 / 5; V / V) to give (S,E)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (160 mg, yield 40.0%) as a yellow oil.

[0319]

number

[0320] Step E: Synthesis of (S,E)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime

[0321] [ka] To a solution of (S,E)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (150 mg, 0.23 mmol, 1.0 equiv) in DCM (10 mL) was added TFA (1 mL). The mixture was stirred at 21 °C for 1 h. The mixture was neutralized with saturated aqueous NaHCO (50 mL) and extracted with DCM (2 × 80 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (5 mL) and potassium carbonate (114 mg, 0.83 mmol, 3.6 equiv) was added. The mixture was stirred for an additional 1 hour at 21° C. The mixture was filtered, and the filtrate was purified by preparative HPLC to give (S,E)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (43.89 mg, 36.6% yield) as a white solid.

[0322]

number

[0323] Example 6 (S,E)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)butanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime

[0324] [ka]

[0325] Step A: Synthesis of (S)-tert-butyl(1-oxobutan-2-yl)carbamate

[0326] [ka] To a solution of (S)-tert-butyl (1-hydroxybutan-2-yl)carbamate (600 mg, 3.17 mmol, 1.0 equiv) in dichloromethane (20 mL) was added Dess-Martin periodinane (1.88 g, 4.44 mmol, 1.4 equiv) at 0 °C. The mixture was stirred at 15 °C for 1 h. The mixture was diluted with water (12 mL) and EtOAc / petroleum ether (1 / 15; V / V, 18 mL). The mixture was filtered, and the filtrate was concentrated. The residue was redissolved in EtOAc / petroleum ether (1 / 15; V / V, 18 mL) and washed with a mixture of saturated aqueous NaHCO3 and 10% aqueous sodium thiosulfate (1 / 1; V / V, 3 × 15 mL). The aqueous layer was back-extracted with EtOAc / petroleum ether (1 / 10, 3 × 18 mL). The organic layers were combined, dried over Na.sub.2SO.sub.4, and concentrated in vacuo to give (S)-tert-butyl (1-oxobutan-2-yl)carbamate (355 mg, 53.8% yield) as a yellow solid.

[0327]

number

[0328] Step B: Synthesis of (S,E)-tert-butyl (1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)butan-2-yl)carbamate

[0329] [ka] To a solution of (S)-tert-butyl(1-oxobutan-2-yl)carbamate (150 mg, 0.81 mmol, 1.0 equiv) in THF (10 mL) was added 2-(aminooxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone hydrochloride (329 mg, 0.96 mmol, 1.2 equiv), tetraethoxytitanium (457 mg, 2.01 mmol, 2.5 equiv), and DIPEA (311 mg, 2.41 mmol, 3.0 equiv). The resulting mixture was stirred at 80 °C for 2 h. The mixture was cooled to room temperature, quenched with water (50 mL), and extracted with EtOAc (3 × 80 mL). The organic layers were combined, washed with brine (100 mL), dried over anhydrous NaSO, and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / petroleum ether=1 / 2; V / V) to give (S,E)-tert-butyl (1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)butan-2-yl)carbamate (260 mg, yield 68.4%) as a white solid.

[0330]

number

[0331] Step C: Synthesis of (S,E)-2-aminobutanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime

[0332] [ka] To a solution of (S,E)-tert-butyl (1-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)butan-2-yl)carbamate (220 mg, 0.46 mmol, 1.0 equiv) in DCM (6 mL) was added TFA (2 mL). The resulting mixture was stirred at 15 °C for 1 h. The reaction mixture was quenched with saturated aqueous NaHCO3 (20 mL) and extracted with DCM (2 x 50 mL). The organic layers were combined, washed with brine (20 mL), dried over NaSO, and concentrated in vacuo to give (S,E)-2-aminobutanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (170 mg, 60.7% yield) as a yellow solid.

[0333]

number

[0334] Step D: Synthesis of (S,E)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)butanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime

[0335] [ka] To a solution of (S,E)-2-aminobutanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (170 mg, 0.45 mmol, 1.0 equiv) in EtOH (10 mL) was added 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (224 mg, 0.68 mmol, 1.5 equiv) and TEA (230 mg, 2.27 mmol, 5.0 equiv). The mixture was stirred at 60 °C for 4 h. The mixture was cooled to room temperature, diluted with water (100 mL), and extracted with ethyl acetate (2 × 100 mL). The organic layer was washed with brine (100 mL), dried over Na SO , and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / petroleum ether=1 / 2; V / V) to give (S,E)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)butanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (110 mg, 34.1%) as a yellow oil.

[0336]

number

[0337] Step E: (S,E)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)butanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime

[0338] [ka] To a solution of (S,E)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)butanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (100 mg, 0.15 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (1 mL). The mixture was stirred at 15 °C for 1 h. The mixture was neutralized with saturated aqueous NaHCO (50 mL) and extracted with DCM (3 × 80 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (4 mL) and potassium carbonate (77 mg, 0.55 mmol, 3.6 equiv) was added. The mixture was stirred for an additional 1 hour at 15° C. The mixture was filtered, and the filtrate was purified by preparative HPLC to give (S,E)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)butanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (14.66 mg, 18.1% yield) as a white solid.

[0339]

number

[0340] Example 7 (S,E)-2-(4-(2-(((2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile

[0341] [ka]

[0342] Step A: Synthesis of methyl 2-(((tert-butoxycarbonyl)amino)oxy)acetate

[0343] [ka] To a solution of 2-(((tert-butoxycarbonyl)amino)oxy)acetic acid (6.00 g, 31.38 mmol, 1.0 equiv.) and K2CO3 (5.21 g, 37.66 mmol, 1.2 equiv.) in DMF (50 mL) was added iodomethane (4.45 g, 31.38 mmol, 1.0 equiv.). The mixture was stirred at 15 °C for 1 h. The reaction was quenched with water (100 mL) and extracted with EtOAc (3 × 60 mL). The organic layers were combined, washed with brine (40 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc = 2 / 1; V / V) to give methyl 2-(((tert-butoxycarbonyl)amino)oxy)acetate (5.08 g, 78.9%) as a colorless oil.

[0344]

number

[0345] Step B: Synthesis of methyl 2-(aminooxy)acetate hydrochloride

[0346] [ka] To a solution of methyl 2-(((tert-butoxycarbonyl)amino)oxy)acetate (2.85 g, 13.89 mmol, 1.0 equiv) in DCM (10 mL) was added HCl / dioxane (4 M, 50 mL). The mixture was stirred at 15° C. for 1 h. The mixture was concentrated under reduced pressure to give methyl 2-(aminooxy)acetate hydrochloride (1.96 g, 99.9%) as a white solid.

[0347]

number

[0348] Step C: Synthesis of methyl (S,E)-6,10,10-trimethyl-8-oxo-3,9-dioxa-4,7-diazaundec-4-enoate

[0349] [ka] To a mixture of methyl 2-(aminooxy)acetate hydrochloride (1.96 g, 13.85 mmol, 1.2 equiv.) in THF (120 mL) was added DIPEA (5.7 mL, 34.62 mmol, 3.0 equiv.), (S)-tert-butyl(1-oxopropan-2-yl)carbamate (2.00 g, 11.54 mmol, 1.0 equiv.), and tetraethoxytitanium (2.63 g, 11.54 mmol, 1.0 equiv.). The mixture was stirred at 80 °C for 2 h. The reaction was then quenched with water (100 mL) and extracted with EtOAc (3 × 100 mL). The organic layers were combined, washed with brine (100 mL), dried over anhydrous NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=2 / 1) to give methyl (S,E)-6,10,10-trimethyl-8-oxo-3,9-dioxa-4,7-diazaundec-4-enoate (1.69 g, 56.3%) as a white solid.

[0350]

number

[0351] Step D: Synthesis of ((((6S,7E)-2,2,6-trimethyl-4-oxo-5-aza-3-oxaheptan-7-ylidene)amino)oxy)acetic acid (Intermediate F)

[0352] [ka] To a solution of methyl (S,E)-6,10,10-trimethyl-8-oxo-3,9-dioxa-4,7-diazaundec-4-enoate (900 mg, 3.46 mmol, 1.0 equiv) in MeOH (30 mL) and HO (5 mL) was added LiOH (124 mg, 5.19 mmol, 1.5 equiv). The mixture was stirred at 40 °C for 2 h. The mixture was cooled to room temperature and diluted with water (40 mL). The mixture was acidified to pH 3 with 1 M aqueous HCl and extracted with DCM (3 × 50 mL). The organic layers were combined, washed with brine (80 mL), dried over Na2SO4, and concentrated under reduced pressure to give ((((6S,7E)-2,2,6-trimethyl-4-oxo-5-aza-3-oxaheptan-7-ylidene)amino)oxy)acetic acid (851 mg, 99.9%) as a yellow oil.

[0353]

number

[0354] Step E: Synthesis of (S,E)-tert-butyl (1-((2-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-2-oxoethoxy)imino)propan-2-yl)carbamate

[0355] [ka] To a solution of ((((6S,7E)-2,2,6-trimethyl-4-oxo-5-aza-3-oxaheptan-7-ylidene)amino)oxy)acetic acid (135 mg, 0.55 mmol, 1.0 equiv) and 2-(piperazin-1-yl)pyrimidine-5-carbonitrile hydrochloride (136 mg, 0.60 mmol, 1.1 equiv) in DMF (8 mL) was added DIPEA (0.54 mL, 3.30 mmol, 6.0 equiv), HATU (250 mg, 0.66 mmol, 1.2 equiv) at room temperature. The mixture was stirred at 25 °C for 2 h. The reaction was quenched with water (40 mL) and extracted with EtOAc (3 × 40 mL). The organic layers were combined, washed with brine (50 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=1 / 1) to give (S,E)-tert-butyl (1-((2-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-2-oxoethoxy)imino)propan-2-yl)carbamate (180 mg, 78.7%) as a yellow oil.

[0356]

number

[0357] Step F: Synthesis of (S,E)-2-(4-(2-(((2-aminopropylidene)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile

[0358] [ka] To a solution of (S,E)-tert-butyl (1-((2-(4-(5-cyanopyrimidin-2-yl)piperazin-1-yl)-2-oxoethoxy)imino)propan-2-yl)carbamate (210 mg, 0.52 mmol, 1.0 equiv) in DCM (8 mL) was added TFA (2 mL). The resulting solution was stirred at 15 °C for 0.5 h. The mixture was quenched with saturated NaHCO (40 mL) and extracted with DCM (3 × 50 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo to give (S,E)-2-(4-(2-(((2-aminopropylidene)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile (150 mg, 95.0%) as a yellow oil.

[0359]

number

[0360] Step G: Synthesis of (S,E)-2-(4-(2-(((2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile

[0361] [ka] To a solution of (S,E)-2-(4-(2-(((2-aminopropylidene)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile (64 mg, 0.20 mmol, 1.0 equiv) and 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (73 mg, 0.22 mmol, 1.1 equiv) in EtOH (3 mL) was added TEA (41 mg, 0.40 mmol, 2.0 equiv). The mixture was heated to 60° C. and stirred for 2 h. The reaction was then quenched with water (20 mL) and extracted with EtOAc (3×30 mL). The organic layers were combined, washed with brine (30 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=1 / 3) to give (S,E)-2-(4-(2-(((2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile (56 mg, 45.5%) as a yellow oil.

[0362]

number

[0363] Step H: Synthesis of (S,E)-2-(4-(2-(((2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile

[0364] [ka] To a solution of (S,E)-2-(4-(2-(((2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile (56 mg, 0.09 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (1 mL). The resulting solution was stirred at 15 °C for 0.5 h. The mixture was concentrated in vacuo. The residue was redissolved in MeOH (1 mL) and KCO (10 mg, 0.07 mmol) was added. The mixture was stirred at 15 °C for 0.5 h. The mixture was filtered and the filtrate was purified by preparative HPLC to afford (S,E)-2-(4-(2-(((2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)pyrimidine-5-carbonitrile (18.42 mg, 41.8%) as a white solid.

[0365]

number

[0366] Example 8 (S,E)-5-((3-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)butan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one

[0367] [ka]

[0368] Step A: Synthesis of (S)-tert-butyl(3-oxobutan-2-yl)carbamate

[0369] [ka] To a solution of (S)-tert-butyl (1-(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate (581 mg, 2.50 mmol, 1.0 equiv.) in THF (12 mL) was slowly added MeMgBr (1 M, 7.5 mL, 7.50 mmol, 3.0 equiv.) at 0 °C in an ice-water bath under a N atmosphere. The mixture was stirred at 0 °C for 1 h. The mixture was slowly quenched with saturated aqueous NH Cl (30 mL) and extracted with EtOAc (2 × 50 mL). The organic layers were combined, dried over Na SO , and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc / petroleum ether = 1 / 4; V / V) to give (S)-tert-butyl (3-oxobutan-2-yl)carbamate (400 mg, 85.4% yield) as a pale yellow solid.

[0370]

number

[0371] Step B: Synthesis of (S,E)-tert-butyl (3-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)butan-2-yl)carbamate

[0372] [ka] To a suspension of 2-(aminooxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)hexahydropyrazin-1-yl)ethanone hydrochloride (205 mg, 0.60 mmol, 1.0 equiv) in THF (8 mL) was added DIPEA (233 mg, 1.80 mmol, 3.0 equiv), (S)-tert-butyl(3-oxobutan-2-yl)carbamate (135 mg, 0.72 mmol, 1.2 equiv), and tetraethoxytitanium (342 mg, 1.50 mmol, 2.5 equiv). The mixture was stirred at 80 °C for 2 h. The mixture was cooled to room temperature, quenched with saturated aqueous NaHCO (50 mL), and extracted with DCM (3 × 80 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (MeOH / DCM=1 / 33; V / V) to obtain (S,E)-tert-butyl (3-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)butan-2-yl)carbamate (240 mg, yield 84.3%) as a pale yellow oil.

[0373]

number

[0374] Step C: Synthesis of (S,E)-2-(((3-aminobutan-2-ylidene)amino)oxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone

[0375] [ka] To a solution of (S,E)-tert-butyl (3-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)butan-2-yl)carbamate (250 mg, 0.53 mmol, 1.0 equiv) in DCM (4 mL) was added TFA (1 mL). The mixture was stirred at 10 °C for 0.5 h. Excess TFA was neutralized with saturated aqueous NaHCO (40 mL), and the mixture was extracted with DCM (3 × 60 mL). The organic layers were combined, dried over Na2SO4, and concentrated in vacuo to give (S,E)-2-(((3-aminobutan-2-ylidene)amino)oxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone (197 mg, 99.9% yield) as a pale yellow oil.

[0376]

number

[0377] Step D: Synthesis of (S,E)-5-((3-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)butan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one

[0378] [ka] To a solution of (S,E)-2-(((3-aminobutan-2-ylidene)amino)oxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone (197 mg, 0.53 mmol, 1.0 equiv) in EtOH (8 mL) was added TEA (213 mg, 2.11 mmol, 4.0 equiv), followed by 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (346 mg, 1.05 mmol, 2.0 equiv). The mixture was heated to 60° C. and stirred for 3 h. The mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by silica gel chromatography (MeOH / DCM=1 / 33; V / V) to give (S,E)-5-((3-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)butan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (190 mg, yield 30.9%) as a pale yellow oil.

[0379]

number

[0380] Step E: Synthesis of (S,E)-5-((3-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)butan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one

[0381] [ka] To a solution of (S,E)-5-((3-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)butan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (187 mg, 0.16 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (1 mL). The mixture was stirred at 10 °C for 0.5 h. The mixture was neutralized with saturated aqueous NaHCO (30 mL) and extracted with DCM (3 × 50 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (3 mL) and KCO (30 mg, 0.22 mmol) was added. The mixture was stirred for an additional 1 h at 10° C. The mixture was filtered, and the filtrate was purified by preparative HPLC (FA) to give (S,E)-5-((3-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)butan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (36.39 mg, 41.8% yield) as a yellow solid.

[0382]

number

[0383] Example 9 (S,E)-5-((2-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)cyclopentyl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one

[0384] [ka]

[0385] Step A: Synthesis of tert-butyl ((1S,2S)-2-hydroxycyclopentyl)carbamate

[0386] [ka] To a solution of (1S,2S)-2-aminocyclopentanol hydrochloride (2.00 g, 14.53 mmol, 1.0 equiv) in MeOH (40 mL) were added TEA (5.88 g, 58.12 mmol, 4.0 equiv) and BocO (327 mg, 21.80 mmol, 1.5 equiv). The mixture was stirred at 25 °C for 18 h. The reaction was quenched with water (40 mL) and extracted with DCM (3 × 50 mL). The organic layers were combined, washed with brine (200 mL), dried over anhydrous NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc = 1 / 1; V / V) to give tert-butyl ((1S,2S)-2-hydroxycyclopentyl)carbamate (2.80 g, 95.7%) as a white solid.

[0387]

number

[0388] Step B: Synthesis of (S)-tert-butyl(2-oxocyclopentyl)carbamate

[0389] [ka] To a solution of tert-butyl ((1S,2S)-2-hydroxycyclopentyl)carbamate (1.00 g, 4.97 mmol, 1.0 equiv) in DCM (25 mL) was added Dess-Martin periodinane (4.22 g, 9.94 mmol, 2.0 equiv). The mixture was stirred at 15 °C for 2 h. The reaction was quenched with saturated aqueous NaHCO (100 mL) and extracted with DCM (3 × 50 mL). The organic layers were combined, washed with brine (200 mL), dried over anhydrous NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc = 1 / 1; V / V) to give (S)-tert-butyl (2-oxocyclopentyl)carbamate (980 mg, 99.0%) as a colorless oil.

[0390]

number

[0391] Step C: Synthesis of (S,E)-tert-butyl (2-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)cyclopentyl)carbamate

[0392] [ka] To a mixture of 2-(aminooxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone hydrochloride (229 mg, 0.67 mmol, 1.0 equiv) in THF (15 mL) was added DIPEA (260 mg, 2.01 mmol, 3.0 equiv), (S)-tert-butyl(2-oxocyclopentyl)carbamate (159 mg, 0.80 mmol, 1.2 equiv), and tetraethoxytitanium (383 mg, 1.68 mmol, 2.5 equiv). The mixture was stirred at 80 °C for 2 h. The mixture was cooled to room temperature, quenched with saturated aqueous NaHCO (20 mL), and extracted with DCM (3 × 50 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (DCM / MeOH=20 / 1; V / V) to obtain (S,E)-tert-butyl (2-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)cyclopentyl)carbamate (290 mg, 89.0%) as a pale yellow oil.

[0393]

number

[0394] Step D: Synthesis of (S,E)-2-(((2-aminocyclopentylidene)amino)oxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone

[0395] [ka] To a solution of (S,E)-tert-butyl (2-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)cyclopentyl)carbamate (290 mg, 0.60 mmol, 1.0 equiv) in DCM (9 mL) was added TFA (3 mL). The mixture was stirred at 15 °C for 0.5 h. The mixture was quenched with saturated aqueous NaHCO (30 mL) and extracted with DCM (3 × 50 mL). The organic layers were combined, dried over NaSO, and concentrated under reduced pressure to give (S,E)-2-(((2-aminocyclopentylidene)amino)oxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone (135 mg, 45.3%) as a white solid.

[0396]

number

[0397] Step E: Synthesis of (S,E)-5-((2-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)cyclopentyl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one

[0398] [ka] To a solution of (S,E)-2-(((2-aminocyclopentylidene)amino)oxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone (151 mg, 0.39 mmol, 1.0 equiv) and 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (256 mg, 0.78 mmol, 2.0 equiv) in EtOH (5 mL) was added TEA (158 mg, 1.56 mmol, 4.0 equiv). The mixture was heated to 60 °C and stirred for 3 h. The reaction was cooled to room temperature, quenched with water (20 mL), and extracted with EtOAc (3 × 20 mL). The organic layers were combined, washed with brine (40 mL), dried over Na SO , and concentrated under reduced pressure. The residue was purified by column chromatography (DCM / MeOH=20 / 1; V / V) to give (S,E)-5-((2-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)cyclopentyl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (145 mg, 55.0%) as a yellow oil.

[0399]

number

[0400] Step F: Synthesis of (S,E)-5-((2-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)cyclopentyl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one

[0401] [ka] To a solution of (S,E)-5-((2-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)cyclopentyl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (149 mg, 0.22 mmol, 1.0 equiv) in DCM (6 mL) was added TFA (2 mL). The mixture was stirred at 15 °C for 0.5 h. The mixture was concentrated in vacuo. The residue was redissolved in MeOH (2 mL) and KCO (21 mg, 0.15 mmol) was added. The mixture was stirred at 15 °C for an additional 1 h. The mixture was filtered and the filtrate was purified by preparative HPLC to afford (S,E)-5-((2-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)cyclopentyl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (50.87 mg, 42.9%) as a white solid.

[0402]

number

[0403] Example 10 (S,E)-2-Cyclopropyl-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)acetaldehyde O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime

[0404] [ka]

[0405] Step A: Synthesis of (S)-methyl 2-amino-2-cyclopropyl acetate hydrochloride

[0406] [ka] To a solution of (S)-2-amino-2-cyclopropylacetic acid (806 mg, 7.00 mmol, 1.0 equiv) in MeOH (9 mL) was added SOCl (3.1 mL, 42.01 mmol, 6.0 equiv) slowly in an ice-water bath at 0 °C. The mixture was stirred at 10 °C for 16 h. The mixture was concentrated in vacuo to give crude (S)-methyl 2-amino-2-cyclopropylacetate hydrochloride (1.16 g, 99.1%) as a pale yellow solid.

[0407]

number

[0408] Step B: Synthesis of (S)-methyl 2-((tert-butoxycarbonyl)amino)-2-cyclopropyl acetate

[0409] [ka] To a solution of (S)-methyl 2-amino-2-cyclopropyl acetate hydrochloride (1.16 g, 7.00 mmol, 1.0 equiv) in DCM (20 mL) was added TEA (4.9 mL, 35.02 mmol, 5.0 equiv), followed by the addition of BocO (1.83 g, 8.40 mmol, 1.2 equiv) in an ice-water bath at 0 °C. The mixture was stirred at 10 °C for 16 h. The mixture was quenched with saturated aqueous NH4Cl (80 mL) and extracted with EtOAc (2 × 80 mL). The organic layers were combined, washed with saturated aqueous NH4Cl (80 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc / petroleum ether=1 / 9; V / V) to give (S)-methyl 2-((tert-butoxycarbonyl)amino)-2-cyclopropyl acetate (1.56 g, 96.9%) as a pale yellow oil.

[0410]

number

[0411] Step C: Synthesis of (S)-tert-butyl(1-cyclopropyl-2-oxoethyl)carbamate

[0412] [ka] To a mixture of (S)-methyl 2-((tert-butoxycarbonyl)amino)-2-cyclopropyl acetate (229 mg, 1.00 mmol, 1.0 equiv.) in anhydrous THF (3 mL) under a N atmosphere, DIBAL-H (1 M, 1.40 mL, 1.40 mmol, 1.4 equiv.) was added dropwise at −78°C in a dry ice-EtOH bath. The mixture was stirred at −78°C for 0.5 h. The mixture was quenched with saturated aqueous NH4Cl (50 mL) and extracted with a mixture of petroleum ether and EtOAc (1 / 1; V / V, 3 × 50 mL). The organic layers were combined, washed with saturated aqueous NH4Cl (2 x 50 mL), dried over Na2SO4, and concentrated in vacuo to give crude (S)-tert-butyl (1-cyclopropyl-2-oxoethyl)carbamate (230 mg, 57.7% yield) as a yellow oil.

[0413]

number

[0414] Step D: Synthesis of (S,E)-tert-butyl(1-cyclopropyl-2-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)ethyl)carbamate

[0415] [ka] To a mixture of 2-(aminooxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)hexahydropyrazin-1-yl)ethanone hydrochloride (150 mg, 0.44 mmol, 1.0 equiv) in THF (7 mL) was added DIPEA (175 mg, 1.32 mmol, 3.0 equiv), (S)-tert-butyl(1-cyclopropyl-2-oxoethyl)carbamate (175 mg, 0.44 mmol, 1.0 equiv), and tetraethoxytitanium (250 mg, 1.10 mmol, 2.5 equiv). The mixture was stirred at 80 °C for 2 h. The mixture was cooled to room temperature, quenched with saturated aqueous NaHCO (50 mL), and extracted with EtOAc (2 × 80 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc / petroleum ether=9 / 11; V / V) to give (S,E)-tert-butyl (1-cyclopropyl-2-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)ethyl)carbamate (133 mg, 62.3%) as a white solid.

[0416]

number

[0417] Step E: Synthesis of (S,E)-2-amino-2-cyclopropylacetaldehyde O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime

[0418] [ka] To a solution of (S,E)-tert-butyl (1-cyclopropyl-2-((2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethoxy)imino)ethyl)carbamate (163 mg, 0.34 mmol, 1.0 equiv) in DCM (8 mL) was added TFA (2 mL). The mixture was stirred at 15 °C for 1 h. The mixture was quenched with saturated aqueous NaHCO3 (40 mL) and extracted with DCM (3 × 35 mL). The organic layers were combined, dried over Na2SO4, and concentrated in vacuo to give (S,E)-2-amino-2-cyclopropylacetaldehyde O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (106 mg, 81.9%) as a yellow oil.

[0419]

number

[0420] Step F: Synthesis of (S,E)-2-cyclopropyl-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)acetaldehyde O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime

[0421] [ka] To a solution of (S,E)-2-amino-2-cyclopropylacetaldehyde O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (106 mg, 0.27 mmol, 1.0 equiv) and 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (178 mg, 0.54 mmol, 2.0 equiv) in EtOH (3 mL) was added TEA (55 mg, 0.54 mmol, 2.0 equiv). The mixture was heated to 60° C. and stirred for 2 h. The reaction was cooled to room temperature, quenched with water (15 mL), and extracted with EtOAc (3×20 mL). The organic layers were combined, washed with brine (40 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc = 1 / 3; V / V) to give (S,E)-2-cyclopropyl-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)acetaldehyde O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (74 mg, 39.7%) as a yellow oil.

[0422]

number

[0423] Step G: Synthesis of (S,E)-2-cyclopropyl-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)acetaldehyde O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime

[0424] [ka] To a solution of (S,E)-2-cyclopropyl-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)acetaldehyde O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (74 mg, 0.11 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (1 mL). The mixture was stirred at 15° C. for 0.5 h. The mixture was concentrated in vacuo. The residue was redissolved in MeOH (1 mL) and KCO (10 mg, 0.07 mmol) was added. The mixture was stirred at 15° C. for an additional 0.5 h. The mixture was filtered. The filtrate was purified by preparative HPLC to afford (S,E)-2-cyclopropyl-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)acetaldehyde O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (15.28 mg, 25.6%) as a white solid.

[0425]

number

[0426] Example 11 (S,E)-6-(4-(2-(((2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)nicotinonitrile

[0427] [ka]

[0428] 11.1) Synthesis of Intermediate H Step A: Synthesis of tert-butyl 4-(5-cyanopyridin-2-yl)piperazine-1-carboxylate

[0429] [ka] To a solution of 6-chloronicotinonitrile (5.00 g, 36.09 mmol, 1.0 equiv) in NMP (150 mL) was added tert-butyl piperazine-1-carboxylate (7.39 g, 39.70 mmol, 1.1 equiv) and K2CO3 (14.96 g, 108.27 mmol, 3.0 equiv). The resulting solution was stirred at 80 °C for 2 h. The reaction was cooled to room temperature. The mixture was quenched with water (150 mL) and extracted with EtOAc (3 × 150 mL). The organic layers were combined, washed with brine (500 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=2 / 1; V / V) to obtain tert-butyl 4-(5-cyanopyridin-2-yl)piperazine-1-carboxylate (8.40 g, 80.7%) as a yellow solid.

[0430]

number

[0431] Step B: Synthesis of 6-(piperazin-1-yl)nicotinonitrile hydrochloride (intermediate H)

[0432] [ka] To a solution of tert-butyl 4-(5-cyanopyridin-2-yl)piperazine-1-carboxylate (1.30 g, 4.51 mmol, 1.0 equiv) in DCM (2 mL) was added HCl / dioxane (4 M, 15 mL). The mixture was stirred at 15° C. for 1 hour. The mixture was concentrated under reduced pressure to give 6-(piperazin-1-yl)nicotinonitrile hydrochloride (0.99 g, 97.2%) as a white solid.

[0433]

number

[0434] 11.2) Synthesis of compound 11: Step A: Synthesis of (S,E)-tert-butyl (1-((2-(4-(5-cyanopyridin-2-yl)piperazin-1-yl)-2-oxoethoxy)imino)propan-2-yl)carbamate

[0435] [ka] To a solution of ((((6S,7E)-2,2,6-trimethyl-4-oxo-5-aza-3-oxaheptan-7-ylidene)amino)oxy)acetic acid (100 mg, 0.40 mmol, 1.0 equiv) and 6-(piperazin-1-yl)nicotinonitrile hydrochloride (99 mg, 0.44 mmol, 1.1 equiv) in DMF (6 mL) was added DIPEA (315 mg, 2.40 mmol, 6.0 equiv) and HATU (185 mg, 0.48 mmol, 1.2 equiv). The mixture was stirred at 25 °C for 2 h. The mixture was quenched with water (40 mL) and extracted with EtOAc (3 × 50 mL). The organic layers were combined, washed with brine (80 mL), dried over anhydrous NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (DCM / MeOH=20 / 1; V / V) to give (S,E)-tert-butyl (1-((2-(4-(5-cyanopyridin-2-yl)piperazin-1-yl)-2-oxoethoxy)imino)propan-2-yl)carbamate (120 mg, 71.0%) as a yellow oil.

[0436]

number

[0437] Step B: Synthesis of (S,E)-6-(4-(2-(((2-aminopropylidene)amino)oxy)acetyl)piperazin-1-yl)nicotinonitrile

[0438] [ka] To a solution of (S,E)-tert-butyl (1-((2-(4-(5-cyanopyridin-2-yl)piperazin-1-yl)-2-oxoethoxy)imino)propan-2-yl)carbamate (120 mg, 0.29 mmol, 1.0 equiv) in DCM (4 mL) was added TFA (1 mL). The resulting solution was stirred at 15 °C for 0.5 h. The mixture was quenched with saturated aqueous NaHCO (20 mL) and extracted with DCM (3 × 20 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo to afford (S,E)-6-(4-(2-(((2-aminopropylidene)amino)oxy)acetyl)piperazin-1-yl)nicotinonitrile (70 mg, 76.8%) as a yellow oil.

[0439]

number

[0440] Step C: Synthesis of (S,E)-6-(4-(2-(((2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)nicotinonitrile

[0441] [ka] To a solution of (S,E)-6-(4-(2-(((2-aminopropylidene)amino)oxy)acetyl)piperazin-1-yl)nicotinonitrile (70 mg, 0.22 mmol, 1.0 equiv) and 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (80 mg, 0.24 mmol, 1.1 equiv) in EtOH (3 mL) was added TEA (45 mg, 0.44 mmol, 2.0 equiv). The mixture was heated to 60° C. and stirred for 2 h. The reaction was quenched with water (20 mL) and extracted with EtOAc (3×20 mL). The organic layers were combined, washed with brine (80 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=1 / 3; V / V) to give (S,E)-6-(4-(2-(((2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)nicotinonitrile (75 mg, 56.0%) as a yellow oil.

[0442]

number

[0443] Step D: Synthesis of (S,E)-6-(4-(2-(((2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)nicotinonitrile

[0444] [ka] To a solution of (S,E)-6-(4-(2-((2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)nicotinonitrile (70 mg, 0.12 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (1 mL). The resulting solution was stirred at 15 °C for 0.5 h. The mixture was concentrated in vacuo. The residue was redissolved in MeOH (1 mL) and KCO (10 mg, 0.07 mmol) was added. The mixture was stirred at 15 °C for an additional 0.5 h. The mixture was filtered and the filtrate was purified by preparative HPLC to afford (S,E)-6-(4-(2-(((2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)nicotinonitrile (25.97 mg, 49.4%) as a white solid.

[0445]

number

[0446] Example 12 (S,E)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethyl)oxime

[0447] [ka]

[0448] 12.1) Synthesis of Intermediate I Step A: Synthesis of tert-butyl 4-(5-(trifluoromethyl)pyridin-2-yl)piperazine-1-carboxylate

[0449] [ka] To a solution of 2-chloro-5-(trifluoromethyl)pyridine (4.13 g, 22.75 mmol, 1.0 equiv.) and tert-butyl piperazine-1-carboxylate (3.26 g, 25.02 mmol, 1.1 equiv.) in NMP (30 mL) was added K2CO3 (9.43 g, 68.25 mmol, 3.0 equiv.) at room temperature. The mixture was heated to 80 °C and stirred for 1 h. The mixture was cooled to room temperature and diluted with water (500 mL). The precipitate that formed was collected by filtration. The product was redissolved in EtOAc (500 mL) and dried over Na2SO4. The solvent was removed in vacuo to give tert-butyl 4-(5-(trifluoromethyl)pyridin-2-yl)piperazine-1-carboxylate (3.50 g, 44.8% yield) as a white solid.

[0450]

number

[0451] Step B: Synthesis of 1-(5-(trifluoromethyl)pyridin-2-yl)piperazine hydrochloride (Intermediate I)

[0452] [ka] To a solution of tert-butyl 4-(5-(trifluoromethyl)pyridin-2-yl)piperazine-1-carboxylate (1.00 g, 3.02 mmol, 1.0 equiv) in DCM (10 mL) was added HCl / dioxane (4 M, 10 mL). The resulting mixture was stirred at 20° C. for 1 hour. The mixture was concentrated in vacuo to give 1-(5-(trifluoromethyl)pyridin-2-yl)piperazine hydrochloride (808 mg, 99.9% yield) as a white solid.

[0453]

number

[0454] 12.2) Synthesis of Compound 12 Step A: Synthesis of (S,E)-tert-butyl (1-((2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethoxy)imino)propan-2-yl)carbamate

[0455] [ka] To a solution of ((((6S,7E)-2,2,6-trimethyl-4-oxo-5-aza-3-oxaheptan-7-ylidene)amino)oxy)acetic acid (200 mg, 0.81 mmol, 1.0 equiv) and 1-(5-(trifluoromethyl)pyridin-2-yl)piperazine hydrochloride (239 mg, 0.89 mmol, 1.1 equiv) in DMF (10 mL) was added DIPEA (630 mg, 4.86 mmol, 6.0 equiv) and HATU (371 mg, 0.97 mmol, 1.2 equiv). The mixture was stirred at 25 °C for 2 h. The mixture was quenched with water (40 mL) and extracted with EtOAc (3 × 40 mL). The organic layers were combined, washed with brine (80 mL), dried over anhydrous NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (DCM / MeOH=20 / 1; V / V) to give (S,E)-tert-butyl (1-((2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethoxy)imino)propan-2-yl)carbamate (275 mg, 73.7%) as a yellow oil.

[0456]

number

[0457] Step B: Synthesis of (S,E)-2-aminopropanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethyl)oxime

[0458] [ka] To a solution of (S,E)-tert-butyl (1-((2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethoxy)imino)propan-2-yl)carbamate (275 mg, 0.60 mmol, 1.0 equiv) in DCM (8 mL) was added TFA (2 mL). The resulting solution was stirred at 15 °C for 0.5 h. The mixture was quenched with saturated aqueous NaHCO (20 mL) and extracted with DCM (3 × 20 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo to give (S,E)-2-aminopropanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethyl)oxime (180 mg, 83.7%) as a yellow oil.

[0459]

number

[0460] Step C: Synthesis of (S,E)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethyl)oxime

[0461] [ka] To a solution of (S,E)-2-aminopropanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethyl)oxime (79 mg, 0.22 mmol, 1.0 equiv) and 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (80 mg, 0.24 mmol, 1.1 equiv) in EtOH (3 mL) was added TEA (44 mg, 0.44 mmol, 2.0 equiv). The mixture was heated to 60° C. and stirred for 2 h. The reaction was quenched with water (20 mL) and extracted with EtOAc (3×20 mL). The organic layers were combined, washed with brine (80 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=1 / 3; V / V) to give (S,E)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethyl)oxime (72 mg, 50.3%) as a yellow oil.

[0462]

number

[0463] Step D: Synthesis of (S,E)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethyl)oxime

[0464] [ka] To a solution of (S,E)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethyl)oxime (72 mg, 0.11 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (1 mL). The resulting solution was stirred at 15 °C for 0.5 h. The mixture was concentrated in vacuo. The residue was redissolved in MeOH (1 mL) and KCO (10 mg, 0.07 mmol) was added. The mixture was stirred at 15 °C for an additional 0.5 h. The mixture was filtered, and the filtrate was purified by preparative HPLC to give (S,E)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethyl)oxime (31.76 mg, 55.3%) as a white solid.

[0465]

number

[0466] Example 13 6-((R)-3-methyl-4-(2-(((E)-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)nicotinonitrile

[0467] [ka]

[0468] Step A: Synthesis of (R)-tert-butyl 4-(5-cyanopyridin-2-yl)-2-methylpiperazine-1-carboxylate

[0469] [ka] To a solution of 6-chloronicotinonitrile (2.51 g, 18.11 mmol, 1.0 equiv.) in NMP (120 mL) was added (R)-tert-butyl 2-methylpiperazine-1-carboxylate (3.99 g, 19.92 mmol, 1.1 equiv.) and K2CO3 (7.51 g, 54.33 mmol, 3.0 equiv.). The mixture was stirred at 80 °C for 1 h. The mixture was cooled to room temperature, diluted with water (150 mL), and extracted with EtOAc (3 × 150 mL). The organic layers were combined, washed with brine (500 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=2 / 1; V / V) to obtain (R)-tert-butyl 4-(5-cyanopyridin-2-yl)-2-methylpiperazine-1-carboxylate (4.20 g, 76.7%) as a yellow solid.

[0470]

number

[0471] Step B: Synthesis of (R)-6-(3-methylpiperazin-1-yl)nicotinonitrile hydrochloride

[0472] [ka] To a solution of (R)-tert-butyl 4-(5-cyanopyridin-2-yl)-2-methylpiperazine-1-carboxylate (500 mg, 1.65 mmol, 1.0 equiv) in DCM (2 mL) was added HCl / dioxane (4 M, 10 mL). The mixture was stirred at 15° C. for 1 hour. The mixture was concentrated under reduced pressure to give (R)-6-(3-methylpiperazin-1-yl)nicotinonitrile hydrochloride (384 mg, 99.8%) as a white solid.

[0473]

number

[0474] Step C: Synthesis of tert-butyl ((S,E)-1-((2-((R)-4-(5-cyanopyridin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethoxy)imino)propan-2-yl)carbamate

[0475] [ka] To a solution of ((((6S,7E)-2,2,6-trimethyl-4-oxo-5-aza-3-oxaheptan-7-ylidene)amino)oxy)acetic acid (200 mg, 0.84 mmol, 1.0 equiv) and (R)-6-(3-methylpiperazin-1-yl)nicotinonitrile hydrochloride (227 mg, 0.92 mmol, 1.1 equiv) in DMF (12 mL) was added DIPEA (651 mg, 5.04 mmol, 6.0 equiv) and HATU (384 mg, 1.01 mmol, 1.2 equiv). The mixture was stirred at 25 °C for 2 h. The reaction was quenched with water (50 mL) and extracted with EtOAc (3 x 50 mL). The organic layers were combined, washed with brine (80 mL), dried over anhydrous NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (DCM / MeOH=20 / 1; V / V) to give tert-butyl ((S,E)-1-((2-((R)-4-(5-cyanopyridin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethoxy)imino)propan-2-yl)carbamate (280 mg, 77.3%) as a yellow oil.

[0476]

number

[0477] Step D: Synthesis of 6-((R)-4-(2-(((E)-((S)-2-aminopropylidene)amino)oxy)acetyl)-3-methylpiperazin-1-yl)nicotinonitrile

[0478] [ka] To a solution of tert-butyl ((S,E)-1-((2-((R)-4-(5-cyanopyridin-2-yl)-2-methylpiperazin-1-yl)-2-oxoethoxy)imino)propan-2-yl)carbamate (280 mg, 0.65 mmol, 1.0 equiv) in DCM (8 mL) was added TFA (2 mL). The resulting solution was stirred at 15 °C for 0.5 h. The mixture was quenched with saturated aqueous NaHCO (20 mL) and extracted with DCM (3 × 20 mL). The organic layers were combined, dried over Na2SO4, and concentrated in vacuo to give 6-((R)-4-(2-(((E)-((S)-2-aminopropylidene)amino)oxy)acetyl)-3-methylpiperazin-1-yl)nicotinonitrile (209 mg, 97.3%) as a yellow oil.

[0479]

number

[0480] Step E: Synthesis of 6-((R)-3-methyl-4-(2-(((E)-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)nicotinonitrile

[0481] [ka] To a solution of 6-((R)-4-(2-(((E)-((S)-2-aminopropylidene)amino)oxy)acetyl)-3-methylpiperazin-1-yl)nicotinonitrile (73 mg, 0.22 mmol, 1.0 equiv) and 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (80 mg, 0.24 mmol, 1.1 equiv) in EtOH (3 mL) was added TEA (45 mg, 0.44 mmol, 2.0 equiv). The mixture was heated to 60° C. and stirred for 2 h. The reaction was quenched with water (20 mL) and extracted with EtOAc (3×20 mL). The organic layers were combined, washed with brine (80 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=1 / 3; V / V) to give 6-((R)-3-methyl-4-(2-(((E)-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)nicotinonitrile (73 mg, 53.1%) as a yellow oil.

[0482]

number

[0483] Step F: Synthesis of 6-((R)-3-methyl-4-(2-(((E)-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)nicotinonitrile

[0484] [ka] To a solution of 6-((R)-3-methyl-4-(2-(((E)-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)nicotinonitrile (72 mg, 0.12 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (1 mL). The resulting solution was stirred at 15 °C for 0.5 h. The mixture was concentrated in vacuo. The residue was redissolved in MeOH (1 mL) and KCO (10 mg, 0.07 mmol) was added. The mixture was stirred at 15 °C for 0.5 h. The mixture was filtered and the filtrate was purified by preparative HPLC to afford 6-((R)-3-methyl-4-(2-(((E)-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propylidene)amino)oxy)acetyl)piperazin-1-yl)nicotinonitrile (30.73 mg, 52.0%) as a white solid.

[0485]

number

[0486] Example 14 (S,E)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethyl)oxime

[0487] [ka]

[0488] Step A: Synthesis of 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethanol

[0489] [ka] To a solution of 2-(piperidin-4-yl)ethanol (900 mg, 6.97 mmol, 1.0 equiv) in N,N-dimethylformamide (10 mL) was added 2-chloro-5-(trifluoromethyl)pyrimidine (1.29 g, 7.04 mmol, 1.01 equiv) and DIPEA (2.70 g, 20.9 mmol, 3.0 equiv). The mixture was stirred at 110° C. for 18 hours. The mixture was cooled to room temperature, diluted with water (100 mL), and extracted with ethyl acetate (2×100 mL). The organic layers were combined, washed with brine (100 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / petroleum ether=1 / 2; V / V) to obtain 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethanol (1.40 g, yield 70.8%) as a yellow solid.

[0490]

number

[0491] Step B: Synthesis of 2-(2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethoxy)isoindoline-1,3-dione

[0492] [ka] To a solution of 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethanol (150 mg, 0.55 mmol, 1.0 equiv) in THF (5 mL) was added 2-hydroxyisoindoline-1,3-dione (98 mg, 0.60 mmol, 1.1 equiv), diethyl azodicarboxylate (116 mg, 0.67 mmol, 1.22 equiv), and triphenylphosphine (172 mg, 0.65 mmol, 1.2 equiv) at 0° C. The resulting mixture was stirred at 15° C. for 1 h. The mixture was diluted with water (100 mL) and extracted with ethyl acetate (2×80 mL). The organic layers were combined, washed with brine (100 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / petroleum ether=1 / 4; V / V) to give 2-(2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethoxy)isoindoline-1,3-dione (128 mg, yield 47.5%) as a yellow solid.

[0493]

number

[0494] Step C: Synthesis of O-(2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethyl)hydroxylamine

[0495] [ka] To a solution of 2-(2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethoxy)isoindoline-1,3-dione (110 mg, 0.26 mmol, 1.0 equiv) in EtOH (5 mL) was added hydrazine hydrate (27 mg, 0.52 mmol, 2.0 equiv). The resulting mixture was stirred at 15 °C for 2 h. The mixture was filtered, and the filtrate was diluted with water (30 mL). The mixture was extracted with DCM (2 × 80 mL). The organic layers were combined, washed with brine (40 mL), dried over NaSO, and concentrated in vacuo to afford O-(2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethyl)hydroxylamine (68 mg, 90.8% yield) as a yellow solid.

[0496]

number

[0497] Step D: Synthesis of (S,E)-tert-butyl (1-((2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethoxy)imino)propan-2-yl)carbamate

[0498] [ka] To a solution of O-(2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethyl)hydroxylamine (100 mg, 0.34 mmol, 1.0 equiv) in THF (5 mL) was added (S)-tert-butyl(1-oxopropan-2-yl)carbamate (72 mg, 0.42 mmol, 1.2 equiv) and tetraethoxytitanium (79 mg, 0.34 mmol, 1.0 equiv). The resulting mixture was stirred at 80° C. for 1 h. The mixture was cooled to room temperature, diluted with water (100 mL), and extracted with ethyl acetate (2×80 mL). The organic layers were combined, washed with brine (100 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / petroleum ether=20 / 1; V / V) to give (S,E)-tert-butyl (1-((2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethoxy)imino)propan-2-yl)carbamate (120 mg, yield 75.9%) as a yellow solid.

[0499]

number

[0500] Step E: Synthesis of (S,E)-2-aminopropanal O-(2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethyl)oxime

[0501] [ka] To a solution of (S,E)-tert-butyl (1-((2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethoxy)imino)propan-2-yl)carbamate (120 mg, 0.27 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (1 mL). The resulting mixture was stirred at 15 °C for 1 h. The reaction mixture was quenched with aqueous NaHCO (20 mL) and extracted with DCM (2 × 50 mL). The organic layers were combined, washed with brine (20 mL), dried over NaSO, and concentrated in vacuo to give (S,E)-2-aminopropanal O-(2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethyl)oxime (90 mg, 96.8% yield) as a yellow solid.

[0502]

number

[0503] Step F: Synthesis of (S,E)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethyl)oxime

[0504] [ka] To a solution of (S,E)-2-aminopropanal O-(2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethyl)oxime (100 mg, 0.29 mmol, 1.0 equiv) in EtOH (5 mL) was added 5-chloro-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (143 mg, 0.43 mmol, 1.5 equiv) and TEA (147 mg, 1.45 mmol, 5.0 equiv). The mixture was stirred at 60° C. for 4 h. The mixture was cooled to room temperature, diluted with water (100 mL), and extracted with ethyl acetate (2×100 mL). The organic layers were combined, washed with brine (100 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / petroleum ether=1 / 1; V / V) to give (S,E)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethyl)oxime (40 mg, 19.5%) as a yellow oil.

[0505]

number

[0506] Step G: Synthesis of (S,E)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethyl)oxime

[0507] [ka] To a solution of (S,E)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethyl)oxime (30 mg, 0.05 mmol, 1.0 equiv) in DCM (1 mL) was added TFA (0.3 mL). The mixture was stirred at 15 °C for 1 h. The mixture was neutralized with saturated aqueous NaHCO (20 mL) and extracted with DCM (3 × 40 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (2 mL) and potassium carbonate (24 mg, 0.17 mmol, 3.6 equiv) was added. The mixture was stirred at 15 °C for an additional 1 h. The mixture was filtered, and the filtrate was purified by preparative HPLC to give (S,E)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propanal O-(2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)ethyl)oxime (3.47 mg, 14.4% yield) as a white solid.

[0508]

number

[0509] Example 15 (S,E)-2-Oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)acetaldehyde O-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propyl)oxime

[0510] [ka]

[0511] Step A: Synthesis of (S)-2-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)isoindoline-1,3-dione

[0512] [ka] To a solution of (S)-5-((1-hydroxypropan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (360 mg, 0.981 mmol, 1.0 equiv.), 2-hydroxyisoindoline-1,3-dione (192 mg, 1.177 mmol, 1.2 equiv.), and PPh3 (308 mg, 1.177 mmol, 1.2 equiv.) in THF (5 mL) was added DEAD (238 mg, 1.177 mmol, 1.2 equiv.) under N2 atmosphere at 0 °C. The mixture was stirred under N2 atmosphere at 25 °C for 1 h. The mixture was concentrated in vacuo. The residue was dissolved in a mixture of petroleum ether and EtOAc (1 / 1; V / V, 50 mL). The mixture was filtered, and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc=2 / 3; V / V) to give (S)-2-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)isoindoline-1,3-dione (350 mg, yield 70.0%) as a white solid.

[0513]

number

[0514] Step B: (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (Intermediate J)

[0515] [ka] To a solution of (S)-2-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)isoindoline-1,3-dione (350 mg, 0.683 mmol, 1.0 equiv) in EtOH (5 mL) was added hydrazine hydrate (100 mg, 1.025 mmol, 1.5 equiv) at 0° C. The resulting mixture was stirred at 25° C. for 1 h. The mixture was concentrated under vacuum. The formed precipitate was filtered and washed with MTBE (10 mL). The filtrate was concentrated in vacuo to give (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (250 mg, 95.8% yield) as a white solid.

[0516]

number

[0517] Step C: Synthesis of (S,E)-2-((2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)imino)acetic acid

[0518] [ka] To a solution of (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (100 mg, 0.261 mmol, 1.0 equiv) in MeOH (3 mL) was added 2-oxoacetic acid (20 mg, 0.274 mmol, 1.05 equiv). The mixture was stirred at 25° C. for 1 h. The mixture was diluted with water (5 mL), extracted with EtOAc (2×5 mL), dried over NaSO, and concentrated in vacuo to give (S,E)-2-((2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)imino)acetic acid (90 mg, 79% yield) as a white solid.

[0519]

number

[0520] Step D: Synthesis of (S,E)-2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)acetaldehyde O-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propyl)oxime

[0521] [ka] To a solution of (S,E)-2-((2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)imino)acetic acid (90 mg, 0.205 mmol, 1.0 equiv) in DMF (2 mL) was added DIPEA (79 mg, 0.616 mmol, 3.0 equiv) and HATU (93 mg, 0.246 mmol, 1.2 equiv), followed by the dropwise addition of 2-(piperazin-1-yl)-5-(trifluoromethyl)pyrimidine (57 mg, 0.246 mmol, 1.2 equiv). The resulting mixture was stirred at 25° C. for 1 h. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3×10 mL). The combined organic layer was washed with brine (10 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 1 / 2; V / V) to give (S,E)-2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)acetaldehyde O-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propyl)oxime (90 mg, 67% yield) as a white solid.

[0522]

number

[0523] Step E: Synthesis of (S,E)-2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)acetaldehyde O-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propyl)oxime

[0524] [ka] To a solution of (S,E)-2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)acetaldehyde O-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propyl)oxime (90 mg, 0.138 mmol, 1.0 equiv) in DCM (2 mL) was added TFA (0.3 mL). The resulting mixture was stirred at 25 °C for 1 h. The mixture was neutralized with saturated aqueous NaHCO (5 mL) and extracted with DCM (3 × 10 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (5 mL), and NaCO (36 mg, 0.345 mmol, 2.5 equiv) was added. The mixture was stirred for another 1 hour at 25° C. The reaction mixture was filtered, and the filtrate was purified by reverse-phase silica gel column chromatography (eluted with CHCN / HO=1 / 10; V / V) to give (S,E)-2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)acetaldehyde O-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propyl)oxime (14 mg, 19% yield) as a white solid.

[0525]

number

[0526] Example 16 (S,E)-5-((1-(((1-oxo-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propan-2-ylidene)amino)oxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one

[0527] [ka]

[0528] Step A: (S,E)-2-((2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)imino)propanoic acid

[0529] [ka] To a solution of (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (90 mg, 0.235 mmol, 1.0 equiv) in MeOH (3 mL) was added 2-oxopropanoic acid (22 mg, 0.247 mmol, 1.05 equiv). The mixture was stirred at 20° C. for 1 h. The mixture was diluted with water (5 mL), extracted with EtOAc (2×5 mL), dried over NaSO, and concentrated in vacuo to give (S,E)-2-((2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)imino)propanoic acid (90 mg, 85% yield) as a white solid.

[0530]

number

[0531] Step B: Synthesis of (S,E)-5-((1-(((1-oxo-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propan-2-ylidene)amino)oxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one

[0532] [ka] To a solution of (S,E)-2-((2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)imino)propanoic acid (95 mg, 0.210 mmol, 1.0 equiv) in DMF (2 mL) was added DIPEA (81 mg, 0.630 mmol, 3.0 equiv) and HATU (96 mg, 0.252 mmol, 1.2 equiv), followed by the dropwise addition of 2-(piperazin-1-yl)-5-(trifluoromethyl)pyrimidine (54 mg, 0.231 mmol, 1.2 equiv). The resulting mixture was stirred at 20° C. for 1 h. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3×10 mL). The organic layers were combined, washed with brine (10 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel column chromatography (petroleum ether / EtOAc = 1 / 1; V / V) to give (S,E)-5-((1-(((1-oxo-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propan-2-ylidene)amino)oxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (90 mg, yield 64%) as a yellow solid.

[0533]

number

[0534] Step C: Synthesis of (S,E)-5-((1-(((1-oxo-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propan-2-ylidene)amino)oxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one

[0535] [ka] To a solution of (S,E)-5-((1-(((1-oxo-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propan-2-ylidene)amino)oxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (90 mg, 0.135 mmol, 1.0 equiv) in DCM (2 mL) was added TFA (0.3 mL). The resulting mixture was stirred at 20 °C for 0.5 h. The mixture was neutralized with saturated aqueous NaHCO (5 mL) and extracted with DCM (3 × 10 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (5 mL), and KCO (46 mg, 0.3338 mmol, 2.5 equiv.) was added. The mixture was stirred at 20 °C for an additional 1 h. The reaction mixture was filtered, and the filtrate was purified by reverse-phase silica gel column chromatography (eluted with CHCN / HO = 1 / 10 to 10 / 1; V / V) to afford (S,E)-5-((1-(((1-oxo-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)propan-2-ylidene)amino)oxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (52 mg, 72% yield) as a white solid.

[0536]

number

[0537] Example 17 (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide

[0538] [ka]

[0539] 17.1) Synthesis of Intermediate S Step A: Synthesis of ethyl 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetate

[0540] [ka] To a solution of 2-chloro-5-(trifluoromethyl)pyrimidine (200 mg, 1.09 mmol, 1.0 equiv) in NMP (3 mL) were added K2CO3 (455 mg, 3.29 mmol, 3.0 equiv) and ethyl 2-(piperidin-4-yl)acetate hydrochloride (251 mg, 1.19 mmol, 1.1 equiv), and the resulting mixture was stirred at 65 °C for 2 h. The mixture was cooled to room temperature and diluted with water (5 mL). The mixture was extracted with EtOAc (3 × 10 mL). The organic layers were combined, washed with brine (10 mL), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=4 / 1; V / V) to give ethyl 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetate (300 mg, 86.8%) as a white solid.

[0541]

number

[0542] Step B: Synthesis of 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetic acid (Intermediate S)

[0543] [ka] To a solution of ethyl 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetate (300 mg, 0.946 mmol, 1.0 equiv) in a mixed solvent of THF (3 mL) and water (3 mL) was added LiOH (68 mg, 2.839 mmol, 3.0 equiv). The mixture was stirred at 25 °C for 16 h. The mixture was diluted with water (5 mL) and extracted with EtOAc (3 × 10 mL). The aqueous layer was adjusted to pH 6 with citric acid. The resulting mixture was extracted with EtOAc (3 × 15 mL), dried over NaSO, and concentrated in vacuo to give 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetic acid (220 mg, 80% yield) as a white solid.

[0544]

number

[0545] 17.2) Synthesis of Intermediate V Step A: Synthesis of (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide

[0546] [ka] To a solution of 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetic acid (69 mg, 0.238 mmol, 1.3 equiv) in DMF (2 mL) was added DIPEA (118 mg, 0.914 mmol, 5.0 equiv) and HATU (83 mg, 0.219 mmol, 1.2 equiv), followed by the dropwise addition of (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (70 mg, 0.183 mmol, 1.0 equiv). The resulting mixture was stirred at 25° C. for 2 h. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3×10 mL). The organic layers were combined, washed with brine (10 mL), dried over NaSO, and concentrated under vacuum. The residue was purified by silica gel column chromatography (petroleum ether / EtOAc = 1 / 2; V / V) to give (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide (80 mg, yield 67%) as a white solid.

[0547]

number

[0548] 17.3) Synthesis of Compound 17 Step A: Synthesis of (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide

[0549] [ka] To a solution of (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide (80 mg, 0.122 mmol, 1.0 equiv) in DCM (2 mL) was added TFA (0.3 mL). The resulting mixture was stirred at 25 °C for 0.5 h. The mixture was neutralized with saturated aqueous NaHCO (5 mL) and extracted with DCM (3 × 10 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (5 mL) and KCO (42 mg, 0.306 mmol, 2.5 equiv) was added. The mixture was stirred for another 1 hour at 25° C. The reaction mixture was filtered, and the filtrate was purified by reverse-phase silica gel column chromatography (eluted with CHCN / HO = 1 / 10 to 10 / 1; V / V) to give (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide (25.58 mg, yield 40%) as a white solid.

[0550]

number

[0551] Example 18 (E)-2-(1-oxo-1,2-dihydrophthalazin-5-yl)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime

[0552] [ka]

[0553] Step A: Synthesis of 4-bromo-3-hydroxyisobenzofuran-1(3H)-one

[0554] [ka] To a stirred solution of n-BuLi (2.5 M in hexanes, 45 mL, 112.50 mmol, 2.2 equiv.) was added a solution of 2,2,6,6-tetramethylhexahydropyridine (15.71 g, 111.19 mmol, 2.2 equiv.) in anhydrous THF (120 mL) dropwise under nitrogen at −20° C. The mixture was stirred at −20° C. for 30 minutes. After cooling to −50° C., a solution of 3-bromobenzoic acid (10.16 g, 50.54 mmol, 1.0 equiv.) in anhydrous THF (40 mL) was added dropwise, and the mixture was stirred at −50° C. for 1 hour. The mixture was then treated with DMF (15 mL, 202.17 mmol, 4.0 equiv.) at −50° C. The resulting solution was allowed to warm to room temperature and quenched with water (100 mL). The mixture was acidified to pH 4 with 2 M aqueous HCl and extracted with EtOAc (3 × 100 mL). The organic layers were combined, washed with brine (2 × 100 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by crystallization using a mixed solvent of EtOAc and petroleum ether (1 / 1; V / V, 300 mL) to give 4-bromo-3-hydroxyisobenzofuran-1(3H)-one (10.65 g, 92.0% yield) as a yellow solid.

[0555]

number

[0556] Step B: Synthesis of 5-bromophthalazin-1(2H)-one

[0557] [ka] To a solution of 4-bromo-3-hydroxyisobenzofuran-1(3H)-one (10.65 g, 46.50 mmol, 1.0 equiv) in EtOH (170 mL) was added hydrazine hydrate (13.02 g, 260.40 mmol, 5.6 equiv). The resulting solution was stirred at 80 °C for 2 h. The mixture was cooled to room temperature and quenched with water (150 mL). The mixture was extracted with EtOAc (3 × 150 mL). The organic layers were combined, washed with brine (300 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by column chromatography (DCM / MeOH = 10 / 1) to give 5-bromophthalazin-1(2H)-one (3.5 g, 33.5% yield) as a white solid.

[0558]

number

[0559] Step C: Synthesis of 5-bromo-2-((2-(trimethylsilyl)ethoxy)methyl)phthalazin-1(2H)-one

[0560] [ka] To a solution of 5-bromophthalazin-1(2H)-one (2.25 g, 4.00 mmol, 1.0 equiv) in DMF (50 mL) was added NaH (60%, 400 mg, 10.00 mmol, 2.5 equiv) at 0 °C. The mixture was stirred at 0 °C for 1.5 h. 2-(Trimethylsilyl)ethoxymethyl chloride (1.00 g, 6.00 mmol, 1.5 equiv) was added to the mixture at 0 °C. The mixture was stirred at 15 °C for an additional 2 h. The mixture was quenched with water (100 mL) and extracted with EtOAc (2 × 100 mL). The organic layers were combined, washed with brine (50 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / petroleum ether=1 / 10; V / V) to give 5-bromo-2-((2-(trimethylsilyl)ethoxy)methyl)phthalazin-1(2H)-one (2.40 g, yield 67.9%) as a yellow oil.

[0561]

number

[0562] Step D: Synthesis of 5-(prop-1-en-2-yl)-2-((2-(trimethylsilyl)ethoxy)methyl)phthalazin-1(2H)-one

[0563] [ka] To a solution of 5-bromo-2-((2-(trimethylsilyl)ethoxy)methyl)phthalazin-1(2H)-one (4.50 g, 12.66 mmol, 1.0 equiv.) in a mixed solvent of dioxane and HO (4 / 1; V / V, 45 mL), isopropenylboronic acid pinacol ester (2.34 g, 13.93 mmol, 1.1 equiv.), KCO (3.50 g, 25.33 mmol, 2.0 equiv.), and Pd(dppf)Cl (0.93 g, 1.27 mmol, 0.1 equiv.) were added at room temperature under nitrogen. The mixture was stirred at 65 °C under nitrogen for 16 h. The mixture was cooled to room temperature, diluted with water (80 mL), and extracted with ethyl acetate (2 × 100 mL). The organic layers were combined, dried over Na2SO4 and concentrated in vacuo to give 5-(prop-1-en-2-yl)-2-((2-(trimethylsilyl)ethoxy)methyl)phthalazin-1(2H)-one (3.10 g, 62.7%) as a yellow solid.

[0564]

number

[0565] Step E: Synthesis of 5-(1-hydroxypropan-2-yl)-2-((2-(trimethylsilyl)ethoxy)methyl)phthalazin-1(2H)-one

[0566] [ka] To a solution of 5-(prop-1-en-2-yl)-2-((2-(trimethylsilyl)ethoxy)methyl)phthalazin-1(2H)-one (3.10 g, 9.80 mmol, 1.0 equiv) in THF (85 mL) was added NaBH (0.59 g, 15.67 mmol, 1.6 equiv) at 0 °C. The mixture was stirred at 0 °C for 1 h. A solution of BF-OEt (1.53 g, 10.78 mmol, 1.1 equiv) in THF (5 mL) was added to the above mixture. The mixture was stirred at 15 °C for an additional 1.5 h. Water (5 mL) was added to the mixture at 0 °C, and the mixture was stirred at 15 °C for 3.5 h. A solution of oxone (9.98 g, 33.30 mmol, 3.4 equiv) in water (5 mL) was added to the mixture at 0 °C. The mixture was stirred at 15° C. for 24 hours. The mixture was diluted with water (80 mL) and extracted with ethyl acetate (2×100 mL). The organic layers were combined, washed with brine (50 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / petroleum ether=1 / 2; V / V) to give 5-(1-hydroxypropan-2-yl)-2-((2-(trimethylsilyl)ethoxy)methyl)phthalazin-1(2H)-one (1.40 g, 39.3%) as a yellow solid.

[0567]

number

[0568] Step F: Synthesis of 2-(1-oxo-2-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydrophthalazin-5-yl)propanal

[0569] [ka] To a solution of 5-(1-hydroxypropan-2-yl)-2-((2-(trimethylsilyl)ethoxy)methyl)phthalazin-1(2H)-one (700 mg, 2.09 mmol, 1.0 equiv) in DCM (15 mL) was added Dess-Martin periodinane (1.33 g, 3.14 mmol, 1.5 equiv) at room temperature. The mixture was stirred at 15 °C for 2 h. The mixture was quenched with saturated aqueous NaHCO (50 mL) and extracted with ethyl acetate (2 × 100 mL). The organic layers were combined, washed with brine (100 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / petroleum ether=2 / 1; V / V) to give 2-(1-oxo-2-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydrophthalazin-5-yl)propanal (350 mg, 50.3%) as a yellow oil.

[0570]

number

[0571] Step G: Synthesis of (E)-2-(1-oxo-2-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydrophthalazin-5-yl)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime

[0572] [ka] To a solution of 2-(aminooxy)-1-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethanone hydrochloride (100 mg, 0.33 mmol, 1.0 equiv) in MeOH (5 mL) was added 2-(1-oxo-2-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydrophthalazin-5-yl)propanal (131 mg, 0.39 mmol, 1.2 equiv) and DIPEA (128 mg, 0.98 mmol, 3.0 equiv). The mixture was stirred at 55° C. for 3 h. Acetic acid (79 mg, 1.31 mmol, 4.0 equiv) and sodium cyanoborohydride (31 mg, 0.49 mmol, 1.5 equiv) were added to the mixture. The mixture was stirred at 55° C. for an additional 0.5 h. The mixture was quenched with saturated aqueous NaHCO3 (50 mL) and extracted with ethyl acetate (2 x 100 mL). The organic layers were combined, washed with brine (50 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / petroleum ether = 2 / 1; V / V) to give (E)-2-(1-oxo-2-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydrophthalazin-5-yl)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (40 mg, 22.1%) as a yellow oil.

[0573]

number

[0574] Step H: Synthesis of (E)-2-(1-oxo-1,2-dihydrophthalazin-5-yl)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime

[0575] [ka] To a solution of (E)-2-(1-oxo-2-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydrophthalazin-5-yl)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (35 mg, 0.06 mmol, 1.0 equiv) in DCM (8 mL) was added TFA (1 mL). The mixture was stirred at 15 °C for 1 h. The mixture was neutralized with saturated aqueous NaHCO (50 mL) and extracted with DCM (3 × 80 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (3 mL) and potassium carbonate (28 mg, 0.21 mmol, 3.6 equiv) was added. The mixture was stirred at 15 °C for an additional 1 h. The mixture was filtered, and the filtrate was purified by preparative HPLC to give (£)-2-(1-oxo-1,2-dihydrophthalazin-5-yl)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyrimidin-2-yl)piperazin-1-yl)ethyl)oxime (9.48 mg, 33.8% yield) as a white solid.

[0576]

number

[0577] Example 19 (E)-2-(1-oxo-1,2-dihydrophthalazin-5-yl)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethyl)oxime

[0578] [ka]

[0579] Step A: Synthesis of tert-butyl 2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethoxycarbamate

[0580] [ka] To a solution of 1-(5-(trifluoromethyl)pyridin-2-yl)piperazine hydrochloride (808 mg, 3.02 mmol, 1.0 equiv) in DMF (20 mL) was added DIPEA (1.95 g, 15.09 mmol, 5.0 equiv) and HATU (1.38 g, 3.62 mmol, 1.2 equiv), followed by the dropwise addition of 2-(((tert-butoxycarbonyl)amino)oxy)acetic acid (635 mg, 3.32 mmol, 1.1 equiv). The resulting mixture was stirred at 15 °C for 2 h. The reaction mixture was quenched with water (100 mL) and extracted with EtOAc (2 x 100 mL). The organic layers were combined, washed with brine (50 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc / petroleum ether=1 / 3; V / V) to obtain tert-butyl 2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethoxycarbamate (1.03 g, yield 84.4%) as a yellow oil.

[0581]

number

[0582] Step B: Synthesis of 2-(aminooxy)-1-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethanone hydrochloride

[0583] [ka] A solution of tert-butyl 2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethoxycarbamate (700 mg, 1.73 mmol, 1.0 equiv) in HCl / dioxane (4 M, 10 mL) was stirred for 1 hour at 15° C. The reaction mixture was concentrated in vacuo to give 2-(aminooxy)-1-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethanone hydrochloride (590 mg, 99.9% yield) as a white solid.

[0584]

number

[0585] Step C: Synthesis of (E)-2-(1-oxo-2-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydrophthalazin-5-yl)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethyl)oxime

[0586] [ka] To a solution of 2-(aminooxy)-1-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethanone hydrochloride (100 mg, 0.29 mmol, 1.0 equiv) in THF (10 mL) was added 2-(1-oxo-2-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydrophthalazin-5-yl)propanal (118 mg, 0.35 mmol, 1.2 equiv), DIPEA (114 mg, 0.88 mmol, 3.0 equiv), and tetraethoxytitanium (74 mg, 0.32 mmol, 1.1 equiv). The mixture was stirred at 80 °C for 1 h. The mixture was diluted with water (50 mL) and extracted with ethyl acetate (2 × 100 mL). The organic layer was washed with brine (50 mL), dried over Na SO , and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / petroleum ether=2 / 3; V / V) to give (E)-2-(1-oxo-2-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydrophthalazin-5-yl)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethyl)oxime (80 mg, 44.1%) as a yellow oil.

[0587]

number

[0588] Step D: Synthesis of (E)-2-(1-oxo-1,2-dihydrophthalazin-5-yl)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethyl)oxime

[0589] [ka] To a solution of (E)-2-(1-oxo-2-((2-(trimethylsilyl)ethoxy)methyl)-1,2-dihydrophthalazin-5-yl)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethyl)oxime (60 mg, 0.097 mmol, 1.0 equiv) in DCM (5 mL) was added TFA (1.5 mL). The mixture was stirred at 15 °C for 1 h. The mixture was neutralized with saturated aqueous NaHCO (50 mL) and extracted with DCM (3 × 80 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (3 mL) and potassium carbonate (49 mg, 0.35 mmol, 3.6 equiv) was added. The mixture was stirred at 15 °C for an additional 1 h. The mixture was filtered, and the filtrate was purified by preparative HPLC to give (£)-2-(1-oxo-1,2-dihydrophthalazin-5-yl)propanal O-(2-oxo-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)ethyl)oxime (9.26 mg, 16.2% yield) as a white solid.

[0590]

number

[0591] Example 20 (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetamide

[0592] [ka]

[0593] 20.1) Synthesis of Intermediate O and Synthesis of Intermediate N Step A: Synthesis of tert-butyl 4-(2-methoxy-2-oxoethylidene)piperidine-1-carboxylate

[0594] [ka] To a solution of trimethyl phosphonoacetate (27.32 g, 150.00 mmol, 1.0 equiv) in THF (350 mL) was added NaH (60%, 6.30 g, 157.50 mmol, 1.05 equiv) in an ice-water bath under a N atmosphere at 0 °C in small portions. The mixture was stirred at 0 °C for 0.5 h. N-(tert-butoxycarbonyl)-4-piperidone (29.89 g, 150.00 mmol, 1.0 equiv) was added to the mixture. The mixture was stirred at 25 °C for 3 h. The mixture was quenched with cold saturated aqueous NH Cl (400 mL) and extracted with EtOAc (2 × 350 mL). The organic layers were combined, dried over Na SO and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc / petroleum ether=1 / 10; V / V) to obtain tert-butyl 4-(2-methoxy-2-oxoethylidene)piperidine-1-carboxylate (30.83 g, 80.5%) as a white solid.

[0595]

number

[0596] Step B: Synthesis of methyl 2-(piperidin-4-ylidene)acetate hydrochloride (intermediate O)

[0597] [ka] To a mixture of tert-butyl 4-(2-methoxy-2-oxoethylidene)piperidine-1-carboxylate (36.00 g, 47.00 mmol, 1.0 equiv) in DCM (200 mL) was added HCl / dioxane (4 M, 150 mL). The mixture was stirred at 25° C. for 1 h. The mixture was concentrated in vacuo to give methyl 2-(piperidin-4-ylidene)acetate hydrochloride (34.84 g, crude) as a white solid.

[0598]

number

[0599] Step C: Synthesis of methyl 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetate (Intermediate N)

[0600] [ka] To a mixture of methyl 2-(piperidin-4-ylidene)acetate hydrochloride (21.96 g, 114.66 mmol, 1.2 equiv.) and TEA (29.01 g, 286.65 mmol, 3.0 equiv.) in DCM (300 mL) was added 2-chloro-5-(trifluoromethyl)pyrimidine (17.44 g, 95.55 mmol, 1.0 equiv.). The reaction mixture was stirred at 25 °C for 18 h. The mixture was quenched with water (500 mL) and extracted with DCM (3 × 300 mL). The organic layers were combined, dried over Na SO , and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=10 / 1; V / V) to give methyl 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetate (22.50 g, 78.2%) as a white solid.

[0601]

number

[0602] 20.2) Synthesis of Compound 20 Step A: Synthesis of 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetic acid

[0603] [ka] To a mixture of methyl 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetate (11.38 g, 37.77 mmol, 1.0 equiv) in a mixed solvent of THF (100 mL) and HO (100 mL) was added NaOH (4.53 g, 113.31 mmol, 3.0 equiv). The mixture was stirred at 70 °C for 3 h. The reaction mixture was adjusted to pH 6 with 1 M HCl. The mixture was extracted with EtOAc (2 × 300 mL). The organic layers were combined, washed with brine (1000 mL), dried over NaSO, and concentrated in vacuo to give 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetic acid (9.67 g, 89.1%) as a yellow solid.

[0604]

number

[0605] Step B: Synthesis of 4-bromo-5-(2,2,2-trifluoroethoxy)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one

[0606] [ka] To a solution of 4,5-dibromo-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (68.80 g, 179.10 mmol, 1.0 equiv) in 2,2,2-trifluoroethanol (280 mL) was added DIPEA (46.29 g, 358.20 mmol, 2.0 equiv). The mixture was stirred at 70° C. for 18 h. The mixture was cooled to room temperature and quenched with water (800 mL). The mixture was extracted with EtOAc (3×500 mL). The organic layers were combined, washed with brine (3×1 L), dried over NaSO, and concentrated in vacuo. The crude product was purified by silica gel chromatography (petroleum ether / EtOAc = 3 / 1, V / V) to obtain 4-bromo-5-(2,2,2-trifluoroethoxy)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (82.80 g, 100%) as a yellow solid.

[0607]

number

[0608] Step C: Synthesis of 5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one

[0609] [ka] To a solution of 4-bromo-5-(2,2,2-trifluoroethoxy)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (82.80 g, 205.32 mmol, 1.0 equiv) in DMF (800 mL) was added CuI (19.55 g, 102.66 mmol, 0.5 equiv), followed by the dropwise addition of methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (157.78 g, 821.28 mmol, 4.0 equiv). The mixture was stirred at 100 °C for 3 h. The mixture was cooled to room temperature and quenched with water (1.5 L). The mixture was extracted with EtOAc (3 × 1 L). The organic layers were combined, washed with brine (2 × 2 L), dried over anhydrous NaSO, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc = 5 / 1, V / V) to give 5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (78.00 g, 96.8%) as a white solid.

[0610]

number

[0611] Step D: Synthesis of (S)-5-((1-hydroxypropan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (Intermediate B)

[0612] [ka] To a solution of 5-(2,2,2-trifluoroethoxy)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (78.00 g, 198.79 mmol, 1.0 equiv) in DMF (780 mL) was added TEA (20.12 g, 198.79 mmol, 1.0 equiv) and L-alaninol (29.86 g, 397.58 mmol, 2.0 equiv). The mixture was stirred at 60 °C for 3 h. The mixture was cooled to room temperature and quenched with water (1 L). The mixture was extracted with EtOAc (3 × 800 mL). The organic layers were combined, washed with brine (2 × 1.5 L), dried over anhydrous NaSO, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc = 2 / 1, V / V) to give (S)-5-((1-hydroxypropan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (72.08 g, 98.7%) as a white solid.

[0613]

number

[0614] Step E: Synthesis of (S)-2-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)isoindoline-1,3-dione

[0615] [ka] To a solution of (S)-5-((1-hydroxypropan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (57.00 g, 155.25 mmol, 1.0 equiv.) in THF (400 mL) was added N-hydroxyphthalimide (25.33 g, 155.25 mmol, 1.0 equiv.), PPh3 (44.79 g, 170.78 mmol, 1.1 equiv.), followed by the dropwise addition of DIAD (34.53 g, 170.78 mmol, 1.1 equiv.). The mixture was stirred at 25 °C for 16 h. The mixture was quenched with water (800 mL) and extracted with EtOAc (3 × 600 mL). The combined organic layers were washed with brine (1000 mL), dried over anhydrous NaSO, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc = 3 / 1, v / v) to give (S)-2-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)isoindoline-1,3-dione (79.02 g, 99.3%) as a colorless oil.

[0616]

number

[0617] Step F: Synthesis of (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (Intermediate J)

[0618] [ka] To a solution of (S)-2-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)isoindoline-1,3-dione (40.00 g, 78.04 mmol, 1.0 equiv) in a mixed solvent of DCM (120 mL) and MeOH (60 mL) was added hydrazine hydrate (7.40 g, 116.96 mmol, 1.5 equiv). The mixture was stirred at 25° C. for 1 hour. The mixture was concentrated under reduced pressure. The residue was suspended in EtOH (100 mL). The mixture was filtered, and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc = 2 / 1, V / V) to give (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (27.8 g, 93.1%) as a yellow oil.

[0619]

number

[0620] Step G: Synthesis of (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetamide

[0621] [ka] To a solution of 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetic acid (9.53 g, 33.18 mmol, 1.1 equiv) and (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (11.53 g, 30.16 mmol, 1.0 equiv) in DMF (300 mL) was added DIPEA (11.69 g, 90.48 mmol, 3.0 equiv) and HATU (13.76 g, 36.19 mmol, 1.2 equiv). The mixture was stirred at 25° C. for 1 h. The mixture was quenched with water (800 mL) and extracted with EtOAc (3×500 mL). The organic layers were combined, washed with brine (2 × 1000 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (Et0Ac / petroleum ether = 2 / 1; V / V) to give (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetamide (4.40 g, 22.4%) as a yellow oil.

[0622]

number

[0623] Step H: Synthesis of (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetamide

[0624] [ka] To a solution of (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetamide (300 mg, 0.46 mmol, 1.0 equiv) in DCM (18 mL) was added TFA (3 mL). The resulting solution was stirred at 25° C. for 0.5 h. The mixture was concentrated in vacuo. MeOH (3 mL) and KCO (100 mg, 0.72 mmol) were added to the resulting mixture. The mixture was stirred at 25° C. for an additional 0.5 h. The mixture was filtered and the filtrate was purified by preparative HPLC (FA) to give (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetamide (41.89 mg, 17.5%) as a white solid.

[0625]

number

[0626] Example 21 (S)-2-Fluoro-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetamide

[0627] [ka]

[0628] 21.1) Synthesis of intermediate L Step A: Synthesis of tert-butyl 4-(2-ethoxy-1-fluoro-2-oxoethylidene)piperidine-1-carboxylate

[0629] [ka] To a solution of ethyl 2-(dimethoxyphosphoryl)-2-fluoroacetate (1.34 g, 5.52 mmol, 1.1 equiv) in THF (20 mL) was added NaH (240 mg, 6.02 mmol, 1.2 equiv) at 0° C. The resulting mixture was stirred at 0° C. for 20 min. tert-Butyl 4-oxopiperidine-1-carboxylate (1 g, 5.02 mmol, 1.0 equiv) was added at 0° C., and the resulting mixture was stirred at 25° C. for an additional 40 min. The mixture was quenched with water (30 mL) and extracted with EtOAc (3×20 mL). The organic layers were combined, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=9 / 1, V / V) to obtain tert-butyl 4-(2-ethoxy-1-fluoro-2-oxoethylidene)piperidine-1-carboxylate (900 mg, 64.2%) as a colorless oil.

[0630]

number

[0631] Step B: Synthesis of ethyl 2-fluoro-2-(piperidin-4-ylidene)acetate hydrochloride

[0632] [ka] To a solution of tert-butyl 4-(2-ethoxy-1-fluoro-2-oxoethylidene)piperidine-1-carboxylate (900 mg) in MeOH (5 mL) was added HCl / dioxane (5 mL). The mixture was stirred at 25° C. for 30 minutes. The mixture was concentrated in vacuo to give ethyl 2-fluoro-2-(piperidin-4-ylidene)acetate hydrochloride (70 mg, 100% yield).

[0633]

number

[0634] Step C: Synthesis of ethyl 2-fluoro-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetate (Intermediate L)

[0635] [ka] To a solution of ethyl 2-fluoro-2-(piperidin-4-ylidene)acetate hydrochloride (700 mg, 4.06 mmol, 1.1 equiv.) in NMP (15 mL) was added DIPEA (1.4 g, 11.04 mmol, 3.0 equiv.) and 2-chloro-5-(trifluoromethyl)pyrimidine (670 mg, 3.68 mmol, 1 equiv.). The resulting mixture was stirred at 80° C. for 1 hour. The mixture was cooled to room temperature and diluted with water (40 mL). The mixture was extracted with EtOAc (2×35 mL). The organic layers were combined, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=9 / 1, V / V) to obtain ethyl 2-fluoro-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetate (1 g, 86.9%) as a white solid.

[0636]

number

[0637] 21.2) Synthesis of Compound 21 Step A: Synthesis of 2-fluoro-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetic acid

[0638] [ka] To a solution of ethyl 2-fluoro-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetate (1 g, 3.01 mmol, 1.0 equiv.) in a mixed solvent of THF (8 mL) and water (8 mL) was added LiOH (289 mg, 12.04 mmol, 4.0 equiv.). The mixture was stirred at 40° C. for 1 h. The mixture was diluted with water (30 mL) and extracted with EtOAc (3×25 mL). The aqueous layer was adjusted to pH 6 with 1 M aqueous HCl. The resulting mixture was extracted with EtOAc (3×25 mL), dried over NaSO, and concentrated in vacuo to give 2-fluoro-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetic acid (720 mg, 91.3% yield) as a white solid.

[0639]

number

[0640] Step B: Synthesis of (S)-2-fluoro-N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetamide

[0641] [ka] To a solution of 2-fluoro-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetic acid (200 mg, 0.66 mmol, 1.1 equiv) in THF (5 mL) was added DIPEA (153 mg, 1.18 mmol, 2.0 equiv) and HATU (337 mg, 0.89 mmol, 1.5 equiv), followed by the dropwise addition of (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (230 mg, 0.59 mmol, 1.0 equiv). The resulting mixture was stirred at 25° C. for 1 h. The reaction mixture was quenched with water (35 mL) and extracted with EtOAc (3×30 mL). The organic layers were combined, washed with brine (10 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 7 / 3, V / V) to give (S)-2-fluoro-N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetamide (290 mg, yield 66.9%) as a colorless oil.

[0642]

number

[0643] Step C: Synthesis of (S)-2-fluoro-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetamide

[0644] [ka] To a solution of (S)-2-fluoro-N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetamide (290 mg, 0.434 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (0.3 mL). The resulting mixture was stirred at 25 °C for 20 min. The mixture was neutralized with saturated aqueous NaHCO (5 mL) and extracted with DCM (3 × 10 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (3 mL) and KCO (230 mg, 1.67 mmol, 3.0 equiv) was added. The mixture was stirred for another 1 hour at 25° C. The reaction mixture was filtered, and the filtrate was purified by silica gel chromatography (petroleum ether / EtOAc=1 / 100, V / V) to give (S)-2-fluoro-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetamide (5.7 mg, yield 4.1%) as a white solid.

[0645]

number

[0646] Example 22 2-Fluoro-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetamide

[0647] [ka]

[0648] Step A: Synthesis of ethyl 2-fluoro-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate

[0649] [ka] To a solution of ethyl 2-fluoro-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetate (930 mg, 2.8 mmol, 1 equivalent) in THF (15 mL) was added DBU (2.1 g, 13.9 mmol, 5.0 equivalents). The resulting mixture was stirred at 70° C. for 3 hours. The mixture was concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc = 95 / 5, V / V) to give ethyl 2-fluoro-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate (210 mg, 22.8%) as a colorless oil.

[0650]

number

[0651] Step B: Synthesis of 2-fluoro-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid

[0652] [ka] To a solution of ethyl 2-fluoro-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate (210 mg, 0.64 mmol, 1.0 equiv) in a mixed solvent of THF (3 mL) and water (3 mL) was added LiOH (46 mg, 1.9 mmol, 3.0 equiv). The mixture was stirred at 40 °C for 1 h. The mixture was diluted with water (30 mL) and extracted with EtOAc (3 × 25 mL). The aqueous layer was adjusted to pH 6. The resulting mixture was extracted with EtOAc (3 × 25 mL), dried over Na SO , and concentrated in vacuo to give 2-fluoro-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid (210 mg, 100% yield) as a white solid.

[0653]

number

[0654] Step C: Synthesis of 2-fluoro-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetamide

[0655] [ka] To a solution of 2-fluoro-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid (170 mg, 0.56 mmol, 1 equiv.) in THF (5 mL) was added DIPEA (145 mg, 1.12 mmol, 2.0 equiv.) and HATU (320 mg, 0.84 mmol, 1.5 equiv.), followed by the dropwise addition of (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (230 mg, 0.59 mmol, 1.05 equiv.). The resulting mixture was stirred at 40° C. for 1 h. The reaction mixture was quenched with water (35 mL) and extracted with EtOAc (3×30 mL). The organic layers were combined, washed with brine (10 mL), dried over NaSO, and concentrated under vacuum. The residue was purified by silica gel chromatography (DCM / MeOH=98 / 2, V / V) to give 2-fluoro-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetamide (450 mg, 100% yield) as a colorless oil.

[0656]

number

[0657] Step D: Synthesis of 2-fluoro-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetamide

[0658] [ka] To a solution of 2-fluoro-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetamide (450 mg, 0.672 mmol, 1.0 equiv) in DCM (5 mL) was added TFA (1 mL). The resulting mixture was stirred at 25 °C for 20 min. The mixture was neutralized with saturated aqueous NaHCO (5 mL) and extracted with DCM (3 × 10 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (3 mL), and KCO (230 mg, 1.67 mmol, 3.0 equiv.) was added. The mixture was stirred at 25 °C for an additional 1 h. The reaction mixture was filtered, and the filtrate was purified by preparative HPLC to give 2-fluoro-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetamide (1.5 mg, 0.4% yield) as a white solid.

[0659]

number

[0660] Example 23 (E)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0661] [ka]

[0662] 23.1) Synthesis of Intermediate M Step A: Synthesis of (E)-tert-butyl 3-fluoro-4-(2-methoxy-2-oxoethylidene)piperidine-1-carboxylate and (Z)-tert-butyl 3-fluoro-4-(2-methoxy-2-oxoethylidene)piperidine-1-carboxylate (Intermediate M)

[0663] [ka] To a solution of trimethyl phosphonoacetate (3.35 g, 18.41 mmol, 1.0 equiv) in THF (45 mL) was added NaH (60%, 0.77 g, 19.33 mmol, 1.05 equiv) in an ice-water bath under a N atmosphere at 0 °C in small portions. The mixture was stirred at 0 °C for 0.5 h. tert-Butyl 3-fluoro-4-oxopiperidine-1-carboxylate (4.00 g, 18.41 mmol, 1.0 equiv) dissolved in THF (45 mL) was added dropwise to the mixture. The mixture was stirred at 25 °C for an additional 2.5 h. The mixture was quenched with cold saturated aqueous NH Cl (100 mL) and extracted with EtOAc (2 × 100 mL). The organic layers were combined, washed with brine (100 mL), dried over Na SO , and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=10 / 1; V / V) to give (E)-tert-butyl 3-fluoro-4-(2-methoxy-2-oxoethylidene)piperidine-1-carboxylate (940 mg, 18.7%) as a pale yellow oil and (Z)-tert-butyl 3-fluoro-4-(2-methoxy-2-oxoethylidene)piperidine-1-carboxylate (1.30 g, 25.8%) as a pale yellow oil. (E)-tert-butyl 3-fluoro-4-(2-methoxy-2-oxoethylidene)piperidine-1-carboxylate:

[0664]

number

[0665]

number

[0666] 23.2) Synthesis of Compound 23 Step A: Synthesis of (E)-methyl 2-(3-fluoropiperidin-4-ylidene)acetate hydrochloride

[0667] [ka] To a mixture of (E)-tert-butyl 3-fluoro-4-(2-methoxy-2-oxoethylidene)piperidine-1-carboxylate (250 mg, 0.92 mmol, 1.0 equiv) in DCM (5 mL) was added HCl / dioxane (4 M, 3 mL). The mixture was stirred at 25° C. for 1 hour. The mixture was concentrated in vacuo to give (E)-methyl 2-(3-fluoropiperidin-4-ylidene)acetate hydrochloride (200 mg, crude) as a white solid.

[0668]

number

[0669] Step B: Synthesis of (E)-methyl 2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetate

[0670] [ka] To a mixture of (E)-methyl 2-(3-fluoropiperidin-4-ylidene)acetate hydrochloride (170 mg, 0.76 mmol, 1.2 equiv.) in NMP (2 mL) was added DIPEA (263.2 mg, 2.04 mmol, 3.0 equiv.) and 2-chloro-5-(trifluoromethyl)pyrimidine (124 mg, 0.68 mmol, 1.0 equiv.). The mixture was stirred at 80° C. for 2 h. The mixture was cooled to room temperature and diluted with saturated aqueous NH4Cl (60 mL). The mixture was extracted with EtOAc (2×40 mL). The organic layers were combined, washed with saturated aqueous NH4Cl (2×60 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=6 / 1; V / V) to obtain (E)-methyl 2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetate (207 mg, 95.6%) as a white solid.

[0671]

number

[0672] Step C: Synthesis of (E)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetic acid

[0673] [ka] To a mixture of (E)-methyl 2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetate (100 mg, 0.31 mmol, 1.0 equiv) in THF (3 mL) and HO (1.5 mL) was added LiOH (53 mg, 1.25 mmol, 4.0 equiv). The mixture was stirred at 50 °C for 2 h. The mixture was cooled to room temperature and diluted with water (20 mL). The mixture was adjusted to pH 6 with 1 M HCl and extracted with EtOAc (2 × 50 mL). The organic layers were combined, washed with brine (100 mL), dried over NaSO, and concentrated in vacuo to give (E)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetic acid (93 mg, 97.3%) as a white solid.

[0674]

number

[0675] Step D: Synthesis of (E)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0676] [ka] To a mixture of (E)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetic acid (90 mg, 0.30 mmol, 1.0 equiv) in DMF (3 mL) was added (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (124 mg, 0.32 mmol, 1.1 equiv), DIPEA (0.15 mL, 0.89 mmol, 3.0 equiv), and HATU (135 mg, 0.35 mmol, 1.2 equiv). The mixture was stirred at 25° C. for 1 h. The reaction mixture was quenched with water (100 mL) and extracted with EtOAc (2×100 mL). The organic layers were combined, washed with brine (2 × 100 mL), dried over Na SO , and concentrated in vacuo. The residue was purified by chromatography (petroleum ether / Et0Ac=3 / 2; V / V) to give (E)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (90 mg, 46.6%) as a yellow solid.

[0677]

number

[0678] Step E: Synthesis of (E)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0679] [ka] To a mixture of (E)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (80 mg, 0.12 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (1 mL). The mixture was stirred at 25 °C for 1 h. The mixture was quenched with saturated aqueous NaHCO (50 mL) and extracted with DCM (3 × 80 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (2 mL) and KCO (76 mg, 0.55 mmol) was added. The mixture was stirred for an additional 1 hour at 25° C. The mixture was filtered, and the filtrate was purified by preparative HPLC (FA) to give (E)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (8.66 mg, 13.4%) as a white solid.

[0680]

number

[0681] Example 24 (Z)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0682] [ka]

[0683] Step A: Synthesis of (Z)-methyl 2-(3-fluoropiperidin-4-ylidene)acetate hydrochloride

[0684] [ka] To a solution of (Z)-tert-butyl 3-fluoro-4-(2-methoxy-2-oxoethylidene)piperidine-1-carboxylate (400 mg, 1.46 mmol, 1.0 equiv) in DCM (4 mL) was added HCl / dioxane (4 M, 2 mL). The mixture was stirred at 25° C. for 1 hour. The mixture was concentrated in vacuo to give (Z)-methyl 2-(3-fluoropiperidin-4-ylidene)acetate hydrochloride (310 mg, 100%) as a white solid.

[0685]

number

[0686] Step B: Synthesis of (Z)-methyl 2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetate

[0687] [ka] To a solution of (Z)-methyl 2-(3-fluoropiperidin-4-ylidene)acetate hydrochloride (310 mg, 1.48 mmol, 1.1 equiv) in NMP (5 mL) was added DIPEA (520 mg, 4.03 mmol, 3.0 equiv) and 2-chloro-5-(trifluoromethyl)pyrimidine (245 mg, 1.34 mmol, 1.0 equiv). The mixture was stirred at 60° C. for 2 hours. The mixture was cooled to room temperature, diluted with water (50 mL), and extracted with EtOAc (2×50 mL). The organic layers were combined, washed with brine (2×50 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc / petroleum ether=1 / 5; V / V) to give (Z)-methyl 2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetate (360 mg, 84.0%) as a pale yellow solid.

[0688]

number

[0689] Step C: Synthesis of (Z)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetic acid

[0690] [ka] To a solution of (Z)-methyl 2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetate (200 mg, 0.63 mmol, 1.0 equiv) in THF (4 mL) and HO (2 mL) was added LiOH (79 mg, 1.88 mmol, 3.0 equiv). The mixture was heated to 60 °C and stirred for 2 h. The mixture was diluted with water (20 mL) and acidified to pH 5 with 1 M HCl. The mixture was extracted with EtOAc (3 × 40 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo to give (Z)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetic acid (190 mg, 99.4%) as a pale yellow solid.

[0691]

number

[0692] Step D: Synthesis of (Z)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0693] [ka] To a solution of (Z)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetic acid (182 mg, 0.60 mmol, 1.2 equiv) in DMF (5 mL) was added DIPEA (193 mg, 1.49 mmol, 3.0 equiv), HATU (283 mg, 0.75 mmol, 1.5 equiv), followed by (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (190 mg, 0.50 mmol, 1.0 equiv). The mixture was stirred at 25° C. for 2 h. The mixture was quenched with water (30 mL) and extracted with EtOAc (2×50 mL). The organic layers were combined, washed with brine (2 × 40 mL), dried over Na SO , and concentrated under vacuum. The residue was purified by silica gel chromatography (petroleum ether / Et0Ac=4 / 6; V / V) to give (Z)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (120 mg, 36.1%) as a pale yellow oil.

[0694]

number

[0695] Step E: Synthesis of (Z)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0696] [ka] To a solution of (Z)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (100 mg, 0.15 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (1 mL). The mixture was stirred at 25° C. for 0.5 h. The mixture was concentrated in vacuo. The residue was dissolved in MeOH (2 mL) and KCO (40 mg, 0.29 mmol) was added. The mixture was stirred at 25° C. for an additional 0.5 h. The mixture was filtered and the filtrate was purified by preparative HPLC to afford (Z)-2-(3-fluoro-1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (3.47 mg, 4.31%) as a white solid.

[0697]

number

[0698] Example 25 (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetamide

[0699] [ka]

[0700] 25.1) Synthesis of Intermediate X Step A: Synthesis of methyl 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate

[0701] [ka] To a mixture of methyl 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-ylidene)acetate (10.00 g, 33.19 mmol, 1.0 equiv) in THF (100 mL) was added DBU (40.43 g, 265.54 mmol, 8.0 equiv). The mixture was stirred at 70° C. for 18 h. The reaction mixture was cooled to room temperature, quenched with water (300 mL), and extracted with EtOAc (3×200 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc=10 / 1; V / V) to give methyl 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate (7.45 g, 74.5%) as a colorless oil.

[0702]

number

[0703] Step B: Synthesis of 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid

[0704] [ka] To a mixture of methyl 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate (6.93 g, 23.00 mmol, 1.0 equiv) in THF (34 mL) and HO (17 mL) was added NaOH (2.76 g, 69.00 mmol, 3.0 equiv). The mixture was stirred at 50 °C for 2 h. The mixture was cooled to room temperature and adjusted to pH 6 with 1 M HCl. The mixture was extracted with EtOAc (2 × 100 mL). The organic layers were combined, washed with brine (300 mL), dried over NaSO, and concentrated in vacuo to give 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid (6.18 g, 93.5%) as a yellow solid.

[0705]

number

[0706] 25.2) Synthesis of Compound 25 Step A: Synthesis of (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetamide

[0707] [ka] To a solution of 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid (6.10 g, 21.23 mmol, 1.1 equiv.) and (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (7.38 g, 19.30 mmol, 1.0 equiv.) in DMF (200 mL) was added DIPEA (7.48 g, 57.90 mmol, 3.0 equiv.) and HATU (8.81 g, 23.16 mmol, 1.2 equiv.). The mixture was stirred at 25° C. for 1 hour. The mixture was quenched with water (600 mL) and extracted with EtOAc (3 × 500 mL). The organic layers were combined, washed with brine (2 × 1000 mL), dried over NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (EtOAc / petroleum ether = 2 / 1; V / V) to give (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetamide (10.69 g, 84.9%) as a yellow oil.

[0708]

number

[0709] Step B: Synthesis of (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetamide

[0710] [ka] To a solution of (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetamide (5.74 g, 8.81 mmol, 1.0 equiv) in DCM (60 mL) was added TFA (20 mL). The resulting solution was stirred at 25° C. for 0.5 h. The mixture was concentrated in vacuo. The residue was dissolved in a mixture of MeOH (100 mL) and HO (100 mL). K2CO3 (4.87 g, 35.24 mmol, 4.0 equiv) and ethylenediamine (3.92 g, 65.19 mmol, 7.4 equiv) were added to the reaction mixture. The mixture was stirred at 25 °C for an additional 1 h. The mixture was quenched with water (300 mL) and extracted with DCM (3 × 200 mL). The organic layers were combined, washed with brine (300 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by preparative HPLC to give (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetamide (1.54 g, 33.6%) as a white solid.

[0711]

number

[0712] Example 26 (S)-2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0713] [ka]

[0714] Step A: Synthesis of methyl 2-(1-(5-iodopyrimidin-2-yl)piperidin-4-ylidene)acetate

[0715] [ka] To a solution of methyl 2-(piperidin-4-ylidene)acetate hydrochloride (7.51 g, 39.18 mmol, 1.0 equiv) in DCM (80 mL) was added TEA (11.90 g, 117.55 mmol, 3.0 equiv) and 2-chloro-5-iodopyrimidine (9.61 g, 39.97 mmol, 1.02 equiv). The mixture was stirred at 25 °C for 16 h. The mixture was diluted with water (100 mL) and extracted with EtOAc (2 × 150 mL). The organic layers were combined, washed with saturated aqueous NH4Cl (2 × 120 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel column chromatography (EtOAc / petroleum ether=5 / 1; V / V) to obtain methyl 2-(1-(5-iodopyrimidin-2-yl)piperidin-4-ylidene)acetate (8.20 g, 58.3%) as a white solid.

[0716]

number

[0717] Step B: Synthesis of methyl 2-(1-(5-iodopyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate

[0718] [ka] To a solution of methyl 2-(1-(5-iodopyrimidin-2-yl)piperidin-4-ylidene)acetate (2.5 g, 6.94 mmol, 1.0 equivalent) in THF (30 mL) was added DBU (5.3 g, 34.72 mmol, 5.0 equivalent). The resulting mixture was stirred at 70° C. for 3 hours. The mixture was concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc = 8 / 1, V / V) to give methyl 2-(1-(5-iodopyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate (1.7 g, 68%) as a colorless oil.

[0719]

number

[0720] Step C: Synthesis of methyl 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate

[0721] [ka] To a solution of methyl 2-(1-(5-iodopyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate (700 mg, 1.949 mmol, 1.0 equiv), (2-fluorophenyl)boronic acid (542 mg, 3.899 mmol, 2.0 equiv), water (1 mL), and NaCO (515 mg, 4.861 mmol, 2.5 equiv) in dioxane (6 mL) was added Pd(dppf)Cl (114 mg, 0.155 mmol, 0.08 equiv) under a N atmosphere at 0 °C. The mixture was stirred at 90 °C under a N atmosphere for 3 h. The mixture was concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc=10 / 1, V / V) to give methyl 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate (600 mg, yield 94%) as a white solid.

[0722]

number

[0723] Step D: Synthesis of 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid

[0724] [ka] To a solution of methyl 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate (600 mg, 1.834 mmol, 1.0 equiv) in a mixed solvent of THF (6 mL) and water (4 mL) was added LiOH (45 mg, 3.669 mmol, 2.0 equiv). The mixture was stirred at 40 °C for 1 h. The mixture was diluted with water (5 mL) and extracted with EtOAc (2 × 10 mL). The aqueous layer was adjusted to pH 6 with 1 M HCl. The mixture was extracted with EtOAc (3 × 15 mL), dried over Na SO , and concentrated in vacuo to give 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid (500 mg, 87% yield) as a white solid.

[0725]

number

[0726] Step E: Synthesis of (S)-2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0727] [ka] To a solution of 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid (300 mg, 0.958 mmol, 1.0 equiv) in THF (5 mL) was added DIPEA (371 mg, 2.875 mmol, 3.0 equiv) and HATU (437 mg, 1.150 mmol, 1.2 equiv), followed by the dropwise addition of (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (402 mg, 1.054 mmol, 1.1 equiv). The resulting mixture was stirred at 25° C. for 2 h. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3×10 mL). The organic layers were combined, washed with brine (10 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc = 1 / 3, V / V) to give (S)-2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (500 mg, yield 77%) as a yellow solid.

[0728]

number

[0729] Step F: Synthesis of (S)-2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0730] [ka] To a solution of (S)-2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (350 mg, 0.516 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (0.5 mL). The resulting mixture was stirred at 25 °C for 0.5 h. The mixture was neutralized with saturated NaHCO (5 mL) and extracted with DCM (3 × 10 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (5 mL), and KCO (178 mg, 1.292 mmol, 2.5 equiv) was added. The mixture was stirred at 25 °C for an additional 1 h. The mixture was filtered, and the filtrate was purified by preparative HPLC to give (S)-2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (122 mg, 43% yield) as a white solid.

[0731]

number

[0732] Example 27 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0733] [ka]

[0734] 27.1) Synthesis of Intermediate P Step A: Synthesis of tert-butyl (E)-4-(2-methoxy-2-oxoethylidene)-3-methylpiperidine-1-carboxylate

[0735] [ka] To a solution of methyl 2-(dimethoxyphosphoryl)acetate (95 mg, 0.517 mmol, 1.1 equiv) in THF (2 mL) was added NaH (21 mg, 0.517 mmol, 1.1 equiv) at 0° C. The resulting mixture was stirred at 0° C. for 20 minutes. Then, tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate (100 mg, 0.47 mmol, 1.0 equiv) was added to the mixture at 0° C. The resulting mixture was stirred at 25° C. for 40 minutes. The mixture was quenched with water (15 mL) and extracted with EtOAc (3×20 mL). The organic layers were combined, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=4 / 1, V / V) to obtain tert-butyl (E)-4-(2-methoxy-2-oxoethylidene)-3-methylpiperidine-1-carboxylate (120 mg, 95.2%) as a colorless oil.

[0736]

number

[0737] Step B: Synthesis of methyl (E)-2-(3-methylpiperidin-4-ylidene)acetate hydrochloride

[0738] [ka] To a solution of tert-butyl (E)-4-(2-methoxy-2-oxoethylidene)-3-methylpiperidine-1-carboxylate (3.8 g, 14.13 mmol, 1.0 equiv) in MeOH (30 mL) was added HCl / dioxane (4 M, 15 mL). The mixture was stirred at 25° C. for 3 h. The mixture was concentrated in vacuo to give methyl (E)-2-(3-methylpiperidin-4-ylidene)acetate (3.18 g, 100% yield) as a colorless oil.

[0739]

number

[0740] Step C: Synthesis of methyl (E)-2-(1-(5-bromopyrimidin-2-yl)-3-methylpiperidin-4-ylidene)acetate

[0741] [ka] To a solution of methyl (E)-2-(3-methylpiperidin-4-ylidene)acetate hydrochloride (2.7 g, 15.98 mmol, 1 equiv.) in NMP (30 mL) was added DIPEA (6.1 g, 47.94 mmol, 3.0 equiv.) and 5-bromo-2-chloropyrimidine (3 g, 15.98 mmol, 1 equiv.). The resulting mixture was stirred at 80° C. for 1 h. The mixture was cooled to room temperature and diluted with water (25 mL). The mixture was extracted with EtOAc (2×20 mL). The organic layers were combined, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=96 / 4, V / V) to obtain methyl (E)-2-(1-(5-bromopyrimidin-2-yl)-3-methylpiperidin-4-ylidene)acetate (3.5 g, 68.8%) as a pale yellow oil.

[0742]

number

[0743] Step D: Synthesis of methyl 2-(1-(5-bromopyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetate (Intermediate P)

[0744] [ka] To a solution of methyl (E)-2-(1-(5-bromopyrimidin-2-yl)-3-methylpiperidin-4-ylidene)acetate (1.78 g, 5.48 mmol, 1 equivalent) in THF (18 mL) was added DBU (4.2 g, 27.3 mmol, 5.0 equivalents). The resulting mixture was stirred at 70° C. for 3 hours. The mixture was concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc = 96 / 4, V / V) to give methyl 2-(1-(5-bromopyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetate (1 g, 56.8%) as a colorless oil.

[0745]

number

[0746] 27.2) Synthesis of Compound 27 Step A: Synthesis of methyl 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetate

[0747] [ka] To a solution of methyl 2-(1-(5-bromopyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetate (450 mg, 1.39 mmol, 1 equiv.) in a mixed solvent of dioxane (7 mL) and HO (1 mL), (2-fluorophenyl)boronic acid (388 mg, 2.77 mmol, 2.0 equiv.), Pd(dppf)Cl (102 mg, 0.19 mmol, 0.14 equiv.), and NaCO (294 mg, 2.77 mmol, 2.0 equiv.) were added. The resulting mixture was stirred at 90 °C under a N atmosphere for 16 h. The reaction mixture was extracted with EtOAc (3 × 20 mL) and washed with water (20 mL). The organic layers were combined, washed with brine (10 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 97 / 3, V / V) to give methyl 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetate (590 mg, yield 100%) as a yellow oil.

[0748]

number

[0749] Step B: Synthesis of 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetic acid

[0750] [ka] To a solution of methyl 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetate (590 mg, 1.74 mmol, 1.0 equiv) in a mixed solvent of THF (4 mL) and water (2 mL) was added LiOH (125 mg, 5.2 mmol, 3.0 equiv). The mixture was stirred at 40° C. for 1 h. The mixture was diluted with water (25 mL) and extracted with EtOAc (3×10 mL). The aqueous layer was adjusted to pH 6 with 1 M HCl. The mixture was extracted with EtOAc (3×15 mL), dried over Na2SO4, and concentrated in vacuo to give 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetic acid (470 mg, 84.3% yield) as a yellow oil.

[0751]

number

[0752] Step C: Synthesis of 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0753] [ka] To a solution of 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetic acid (470 mg, 1.44 mmol, 1 equiv.) in DMF (8 mL) was added DIPEA (372 mg, 2.88 mmol, 2.0 equiv.) and HATU (820 mg, 2.16 mmol, 1.5 equiv.), followed by the dropwise addition of (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (570 mg, 1.51 mmol, 1.05 equiv.). The resulting mixture was stirred at 25° C. for 2 h. The reaction mixture was quenched with water (30 mL) and extracted with EtOAc (3×20 mL). The organic layers were combined, washed with brine (10 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 3 / 7, V / V) to give 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (540 mg, 54.3% yield) as a yellow solid.

[0754]

number

[0755] Step D: Synthesis of 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0756] [ka] To a solution of 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (540 mg, 0.78 mmol, 1.0 equiv) in DCM (5 mL) was added TFA (0.5 mL). The resulting mixture was stirred at 25 °C for 0.5 h. The mixture was neutralized with saturated aqueous NaHCO (5 mL) and extracted with DCM (3 × 10 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (5 mL), and KCO (337 mg, 2.44 mmol, 3.0 equiv.) was added. The mixture was stirred at 25 °C for an additional 1 h. The reaction mixture was filtered, and the filtrate was purified by preparative HPLC to give 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (46.9 mg, 10.7% yield) as a white solid.

[0757]

number

[0758] Example 28 (S)-2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-5-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0759] [ka]

[0760] Step A: Synthesis of (S)-2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-5-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0761] [ka] To a solution of 2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (540 mg, 0.78 mmol, 1.0 equiv) in DCM (5 mL) was added TFA (0.5 mL). The resulting mixture was stirred at 25 °C for 0.5 h. The mixture was neutralized with saturated aqueous NaHCO (5 mL) and extracted with DCM (3 × 10 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (5 mL), and KCO (337 mg, 2.44 mmol, 3.0 equiv.) was added. The mixture was stirred at 25 °C for an additional 1 h. The reaction mixture was filtered, and the filtrate was purified by preparative HPLC to give (S)-2-(1-(5-(2-fluorophenyl)pyrimidin-2-yl)-5-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (33 mg, 15.1% yield) as a white solid.

[0762]

number

[0763] Example 29 (S)-2-(1-(5-cyclopropylpyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0764] [ka]

[0765] Step A: Synthesis of methyl 2-(1-(5-bromopyrimidin-2-yl)piperidin-4-ylidene)acetate

[0766] [ka] To a solution of methyl 2-(piperidin-4-ylidene)acetate (707 mg, 4.559 mmol, 1.1 equiv) in NMP (10 mL) were added DIPEA (1.6 g, 12.53 mmol, 3.0 equiv) and 5-bromo-2-chloropyrimidine (800 mg, 4.145 mmol, 1.0 equiv). The resulting mixture was stirred at 70° C. for 2 hours. The mixture was concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc = 10 / 1, V / V) to give methyl 2-(1-(5-bromopyrimidin-2-yl)piperidin-4-ylidene)acetate (870 mg, 67%) as a colorless oil.

[0767]

number

[0768] Step B: Synthesis of methyl 2-(1-(5-bromopyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate

[0769] [ka] To a solution of methyl 2-(1-(5-bromopyrimidin-2-yl)piperidin-4-ylidene)acetate (870 mg, 2.797 mmol, 1.0 equiv) in THF (10 mL) was added DBU (2.12 g, 13.98 mmol, 5.0 equiv). The resulting mixture was stirred at 70° C. for 3 hours. The mixture was concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc = 10 / 1, V / V) to give methyl 2-(1-(5-bromopyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate (570 mg, 65%) as a white solid.

[0770]

number

[0771] Step C: Synthesis of methyl 2-(1-(5-cyclopropylpyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate

[0772] [ka] To a solution of methyl 2-(1-(5-bromopyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate (530 mg, 1.704 mmol, 1.0 equiv) in dioxane (6 mL) was added cyclopropylboronic acid (293 mg, 3.408 mmol, 2.0 equiv), NaCO (542 mg, 5.112 mmol, 3.0 equiv), water (1 mL), and Pd(dppf)Cl (124 mg, 0.170 mmol, 0.1 equiv) under a N atmosphere. The resulting mixture was stirred at 90 °C under a N atmosphere for 3 h. The mixture was concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc=10 / 1, V / V) to obtain methyl 2-(1-(5-cyclopropylpyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate (260 mg, yield 55%) as a yellow oil.

[0773]

number

[0774] Step D: Synthesis of 2-(1-(5-cyclopropylpyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid

[0775] [ka] To a solution of methyl 2-(1-(5-cyclopropylpyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetate (260 mg, 0.952 mmol, 1.0 equiv) in a mixed solvent of THF (3 mL) and water (2 mL) was added LiOH (45 mg, 1.904 mmol, 2.0 equiv). The mixture was stirred at 25 °C for 1 h. The mixture was diluted with water (5 mL) and extracted with EtOAc (2 × 10 mL). The aqueous layer was adjusted to pH 6 with 1 M HCl. The mixture was extracted with EtOAc (3 × 15 mL), dried over NaSO, and concentrated in vacuo to give 2-(1-(5-cyclopropylpyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid (230 mg, 93% yield) as a white solid.

[0776]

number

[0777] Step E: Synthesis of (S)-2-(1-(5-cyclopropylpyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0778] [ka] To a solution of 2-(1-(5-cyclopropylpyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)acetic acid (240 mg, 0.926 mmol, 1.0 equiv.) in THF (4 mL) was added DIPEA (358 mg, 2.779 mmol, 3.0 equiv.) and HATU (422 mg, 1.111 mmol, 1.2 equiv.), followed by the dropwise addition of (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (389 mg, 1.019 mmol, 1.1 equiv.). The resulting mixture was stirred at 25° C. for 2 hours. The mixture was concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 1 / 3, V / V) to give (S)-2-(1-(5-cyclopropylpyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (300 mg, yield 52%) as a white solid.

[0779]

number

[0780] Step F: Synthesis of (S)-2-(1-(5-cyclopropylpyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0781] [ka] To a solution of (S)-2-(1-(5-cyclopropylpyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (300 mg, 0.481 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (0.5 mL). The resulting mixture was stirred at 25 °C for 0.5 h. The mixture was neutralized with saturated aqueous NaHCO (5 mL) and extracted with DCM (3 × 10 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (5 mL) and KCO (166 mg, 1.203 mmol, 2.5 equiv) was added. The mixture was stirred for an additional 1 hour at 25° C. The mixture was filtered, and the filtrate was purified by preparative HPLC to give (S)-2-(1-(5-cyclopropylpyrimidin-2-yl)-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (100 mg, 42% yield) as a white solid.

[0782]

number

[0783] Example 30 2-(1-(5-cyclopropylpyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0784] [ka]

[0785] Step A: Synthesis of methyl 2-(1-(5-cyclopropylpyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetate

[0786] [ka] To a solution of methyl 2-(1-(5-bromopyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetate (450 mg, 1.39 mmol, 1 equiv.) in a mixed solvent of dioxane (7 mL) and HO (1 mL), cyclopropylboronic acid (239 mg, 2.77 mmol, 2.0 equiv.), Pd(dppf)Cl (102 mg, 0.19 mmol, 0.14 equiv.), and NaCO (294 mg, 2.77 mmol, 2.0 equiv.) were added. The resulting mixture was stirred at 90 °C for 16 h. The reaction mixture was extracted with EtOAc (3 × 20 mL) and washed with water (20 mL). The organic layers were combined, washed with brine (10 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=9 / 1, V / V) to obtain methyl 2-(1-(5-cyclopropylpyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetate (170 mg, yield 42.8%) as a colorless oil.

[0787]

number

[0788] Step B: Synthesis of 2-(1-(5-cyclopropylpyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetic acid

[0789] [ka] To a solution of methyl 2-(1-(5-cyclopropylpyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetate (170 mg, 0.593 mmol, 1.0 equiv) in a mixed solvent of THF (4 mL) and water (2 mL) was added LiOH (43 mg, 1.78 mmol, 3.0 equiv). The mixture was stirred at 40 °C for 1 h. The mixture was diluted with water (25 mL) and extracted with EtOAc (3 × 10 mL). The aqueous layer was adjusted to pH 6 with 1 M HCl. The mixture was extracted with EtOAc (3 × 15 mL), dried over NaSO, and concentrated in vacuo to give 2-(1-(5-cyclopropylpyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetic acid (140 mg, 86.9% yield) as a colorless oil.

[0790]

number

[0791] Step C: Synthesis of 2-(1-(5-cyclopropylpyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0792] [ka] To a solution of 2-(1-(5-cyclopropylpyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetic acid (140 mg, 0.52 mmol, 1 equiv.) in DMF (5 mL) was added DIPEA (135 mg, 1.04 mmol, 2.0 equiv.) and HATU (296 mg, 0.78 mmol, 1.5 equiv.), followed by the dropwise addition of (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (140 mg, 0.52 mmol, 1 equiv.). The resulting mixture was stirred at 25° C. for 2 h. The reaction mixture was quenched with water (30 mL) and extracted with EtOAc (3×20 mL). The organic layers were combined, washed with brine (10 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 35 / 65, V / V) to give 2-(1-(5-cyclopropylpyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (340 mg, 100% yield) as a white solid.

[0793]

number

[0794] Step D: Synthesis of 2-(1-(5-cyclopropylpyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0795] [ka] To a solution of 2-(1-(5-cyclopropylpyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (340 mg, 0.54 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (0.5 mL). The resulting mixture was stirred at 25 °C for 0.5 h. The mixture was neutralized with saturated aqueous NaHCO (5 mL) and extracted with DCM (3 × 10 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (3 mL), and KCO (186 mg, 1.35 mmol, 3.0 equiv) was added. The mixture was stirred at 25 °C for an additional 1 h. The reaction mixture was filtered, and the filtrate was purified by preparative HPLC to give 2-(1-(5-cyclopropylpyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (15.7 mg, 5.7% yield) as a white solid.

[0796]

number

[0797] Example 31 (S)-2-(1-(5-cyclopropylpyrimidin-2-yl)-5-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0798] [ka]

[0799] Step A: Synthesis of (S)-2-(1-(5-cyclopropylpyrimidin-2-yl)-5-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0800] [ka] To a solution of 2-(1-(5-cyclopropylpyrimidin-2-yl)-3-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-((S)-2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (340 mg, 0.54 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (0.5 mL). The resulting mixture was stirred at 25 °C for 0.5 h. The mixture was neutralized with saturated aqueous NaHCO (5 mL) and extracted with DCM (3 × 10 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (3 mL), and KCO (186 mg, 1.35 mmol, 3.0 equiv.) was added. The mixture was stirred at 25 °C for an additional 1 h. The reaction mixture was filtered, and the filtrate was purified by preparative HPLC to give (S)-2-(1-(5-cyclopropylpyrimidin-2-yl)-5-methyl-1,2,3,6-tetrahydropyridin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (17 mg, 12.6% yield) as a white solid.

[0801]

number

[0802] Example 32 (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetamide

[0803] [ka]

[0804] 32.1) Synthesis of Intermediate Q Step A: Synthesis of 4,5-dibromo-2-(4-methoxybenzyl)pyridazin-3(2H)-one

[0805] [ka] To a mixture of 4,5-dibromopyridazin-3(2H)-one (10.16 g, 40.00 mmol, 1.0 equiv) in DMF (100 mL) was added NaH (60%, 2.40 g, 60.00 mmol, 1.5 equiv) under a N atmosphere in an ice-water bath at 0 °C. The mixture was stirred at 0 °C for 0.5 h. 4-Methoxybenzyl chloride (6.26 g, 40.00 mmol, 1.0 equiv) was added to the mixture. The mixture was stirred at 10 °C for an additional 3 h. The mixture was quenched with cold water (500 mL) and extracted with EtOAc (3 × 400 mL). The organic layers were combined, washed with brine (2 × 400 mL), dried over NaSO, and concentrated in vacuo. The crude solid was washed with MeOH (2×20 mL) to give 4,5-dibromo-2-(4-methoxybenzyl)pyridazin-3(2H)-one (11.27 g, 75.3%) as a light brown solid.

[0806]

number

[0807] Step B: Synthesis of 4-bromo-5-methoxy-2-(4-methoxybenzyl)pyridazin-3(2H)-one

[0808] [ka] To a mixture of 4,5-dibromo-2-(4-methoxybenzyl)pyridazin-3(2H)-one (6.18 g, 16.52 mmol, 1.0 equiv) in MeOH (52 mL) was added KOH (2.78 g, 49.57 mmol, 3.0 equiv). The mixture was stirred at 10 °C for 3 h. The mixture was concentrated and diluted with water (80 mL). The mixture was extracted with DCM (3 × 100 mL). The organic layers were combined, washed with brine (80 mL), dried over NaSO, and concentrated in vacuo. The crude solid was washed with MeOH (10 mL) to give 4-bromo-5-methoxy-2-(4-methoxybenzyl)pyridazin-3(2H)-one (4.44 g, 82.6%) as a yellow solid.

[0809]

number

[0810] Step C: Synthesis of 5-methoxy-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one

[0811] [ka] To a mixture of 4-bromo-5-methoxy-2-(4-methoxybenzyl)pyridazin-3(2H)-one (8.08 g, 24.85 mmol, 1.0 equiv) and CuI (2.37 g, 12.43 mmol, 0.5 equiv) in DMF (42 mL) was added methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (19.10 g, 99.40 mmol, 4.0 equiv) dropwise under a N atmosphere. The mixture was stirred at 100 °C for 3 h. The mixture was cooled to room temperature and quenched with water (150 mL). The mixture was extracted with DCM (3 × 150 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc / petroleum ether=2 / 3; V / V) to give 5-methoxy-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one (5.30 g, 67.9%) as a pale yellow solid.

[0812]

number

[0813] Step D: Synthesis of 5-hydroxy-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one

[0814] [ka] To a solution of 5-methoxy-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one (3.14 g, 10.00 mmol, 1.0 equiv.) in DMF (16 mL) was added iodotrimethylsilane (2.60 g, 13.00 mmol, 1.3 equiv.) dropwise. The mixture was stirred at 90 °C for 20 h. The mixture was cooled to room temperature, quenched with water (70 mL), and extracted with DCM (2 × 80 mL). The organic layers were combined, dried over Na SO , and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc / petroleum ether = 3 / 2; V / V) to give 5-hydroxy-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one (2.82 g, 93.9%) as a light brown solid.

[0815]

number

[0816] Step E: Synthesis of 5-chloro-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one

[0817] [ka] To a solution of 5-hydroxy-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one (2.49 g, 8.29 mmol, 1.0 equiv.) in DMF (13 mL) was added oxalyl chloride (2.11 g, 16.59 mmol, 2.0 equiv.) dropwise in an ice-water bath at 0 °C. The mixture was stirred at 10 °C for 8 hours. The mixture was quenched with water (80 mL) and extracted with EtOAc (2 × 80 mL). The organic layers were combined, washed with brine (2 × 80 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc / petroleum ether = 1 / 5; V / V) to give 5-chloro-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one (2.51 g, 95.0%) as a pale yellow solid.

[0818]

number

[0819] Step F: Synthesis of 5-chloro-4-(trifluoromethyl)pyridazin-3(2H)-one (Intermediate Q)

[0820] [ka] To a solution of 5-chloro-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one (2.00 g, 6.28 mmol, 1.0 equiv) in TFA (32 mL) was added HSO (5.3 mL). The mixture was stirred at 120 °C for 3 h. The mixture was cooled to room temperature and quenched with water (100 mL). The mixture was neutralized to pH 7 with saturated aqueous NaHCO and extracted with EtOAc (3 × 70 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo to give 5-chloro-4-(trifluoromethyl)pyridazin-3(2H)-one (1.05 g, 84.3%) as a white solid.

[0821]

number

[0822] 32.2) Synthesis of Intermediate R Step A: Synthesis of (S)-tert-butyl (1-((1,3-dioxoisoindolin-2-yl)oxy)propan-2-yl)carbamate

[0823] [ka] To a mixture of 2-hydroxyisoindole-1,3-dione (4.90 g, 30.04 mmol, 1.0 equiv), N-Boc-L-alaninol (5.32 g, 30.34 mmol, 1.01 equiv), and PPh (8.82 g, 33.64 mmol, 1.12 equiv) in THF (100 mL) was added dropwise DIAD (6.68 g, 33.04 mmol, 1.1 equiv) at 0 °C under a N atmosphere. The reaction mixture was stirred at 15 °C for 3 h. The reaction mixture was quenched with water (50 mL) and extracted with EtOAc (3 × 100 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was purified by reverse phase chromatography (CHCN / H0=2 / 3; V / V) to give (S)-tert-butyl (1-((1,3-dioxoisoindolin-2-yl)oxy)propan-2-yl)carbamate (7.80 g, 81.1%) as a white solid.

[0824]

number

[0825] Step B: Synthesis of (S)-tert-butyl (1-(aminooxy)propan-2-yl)carbamate (Intermediate R)

[0826] [ka] To a mixture of (S)-tert-butyl (1-((1,3-dioxoisoindolin-2-yl)oxy)propan-2-yl)carbamate (1.00 g, 3.12 mmol) in DCM (20 mL) and MeOH (6 mL) was added hydrazine hydrate (0.16 g, 3.12 mmol). The mixture was stirred at 15° C. for 3 hours. The mixture was concentrated in vacuo. The residue was treated with DCM (40 mL). The mixture was filtered, and the filtrate was concentrated to give (S)-tert-butyl (1-(aminooxy)propan-2-yl)carbamate (650 mg, 96.3%) as a white solid.

[0827] 32.3) Synthesis of Compound 32 Step A: Synthesis of methyl 2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetate

[0828] [ka] To a mixture of methyl 4-piperidine acetate hydrochloride (1.00 g, 5.16 mmol, 1.0 equiv.) and K2CO3 (2.14 g, 15.49 mmol, 3.0 equiv.) in DMF (20 mL) was added 2-chloro-5-(trifluoromethyl)pyridine (1.03 g, 5.68 mmol, 1.1 equiv.). The mixture was stirred at 80 °C for 3 h. The mixture was cooled to room temperature and then poured into water (70 mL) and extracted with EtOAc (3 × 50 mL). The organic layers were combined, washed with water (2 × 50 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (petroleum ether / EtOAc=5 / 1; V / V) to give methyl 2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetate (0.55 g, 35.2%) as a yellow solid.

[0829]

number

[0830] Step B: Synthesis of 2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetic acid

[0831] [ka] To a solution of methyl 2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetate (300 mg, 0.99 mmol, 1.0 equiv.) in a mixed solvent of THF (3 mL), MeOH (1 mL), and HO (1 mL) was added LiOH (48 mg, 1.99 mmol, 2.0 equiv.). The mixture was stirred at 15° C. for 4 hours. The mixture was neutralized to pH 7 with 2 M HCl and concentrated in vacuo. The crude product was purified by flash column chromatography (DCM / MeOH=9 / 1; V / V) to give 2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetic acid (200 mg, 69.9%) as a white solid.

[0832]

number

[0833] Step C: Synthesis of (S)-tert-butyl (1-((2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetamido)oxy)propan-2-yl)carbamate

[0834] [ka] To a solution of 2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetic acid (150 mg, 0.52 mmol, 1.0 equiv) and (S)-tert-butyl(1-(aminooxy)propan-2-yl)carbamate (109 mg, 0.57 mmol, 1.1 equiv) in DMF (10 mL) was added DIPEA (168 mg, 1.30 mmol, 2.5 equiv) and HATU (297 mg, 0.78 mmol, 1.5 equiv). The mixture was stirred at 10° C. for 2 h. The mixture was quenched with water (50 mL) and extracted with EtOAc (2×60 mL). The organic layers were combined, washed with brine (2×50 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 3 / 7; V / V) to give (S)-tert-butyl (1-((2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetamido)oxy)propan-2-yl)carbamate (220 mg, 91.8%) as a white solid.

[0835]

number

[0836] Step D: Synthesis of (S)—N-(2-aminopropoxy)-2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetamide

[0837] [ka] To a solution of (S)-tert-butyl (1-((2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetamido)oxy)propan-2-yl)carbamate (100 mg, 0.22 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (1 mL). The mixture was stirred at 15 °C for 1 h. Excess TFA was neutralized with saturated aqueous NaHCO (20 mL), and the mixture was extracted with a mixed solution of DCM and MeOH (10 / 1; V / V, 6 × 40 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo to give (S)—N-(2-aminopropoxy)-2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetamide (75 mg, 95.8%) as a yellow solid.

[0838]

number

[0839] Step E: Synthesis of (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetamide

[0840] [ka] To a mixture of (S)—N-(2-aminopropoxy)-2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetamide (75 mg, 0.21 mmol, 1.0 equiv) in EtOH (2 mL) was added 5-chloro-4-(trifluoromethyl)pyridazin-3(2H)-one (41 mg, 0.21 mmol, 1.0 equiv). The mixture was stirred at 60° C. for 3 h. The mixture was cooled to room temperature and diluted with water (20 mL). The mixture was extracted with DCM (2×20 mL). The organic layers were combined, dried over Na2SO4, and concentrated in vacuo. The residue was purified by preparative HPLC to afford (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetamide (10.57 mg, 9.7%) as a white solid.

[0841]

number

[0842] Example 33 (S)-2-(1-(5-cyanopyrimidin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0843] [ka]

[0844] Step A: Synthesis of methyl 2-(1-(5-cyanopyrimidin-2-yl)piperidin-4-yl)acetate

[0845] [ka] To a solution of 2-chloropyrimidine-5-carbonitrile (698 mg, 5.00 mmol, 1.0 equiv) and methyl 2-(piperidin-4-yl)acetate hydrochloride (1.02 g, 5.25 mmol, 1.05 equiv) in NMP (10 mL) was added K2CO3 (2.07 g, 15.00 mmol, 3.0 equiv). The mixture was stirred at 80 °C for 16 h. The mixture was cooled to room temperature and diluted with water (100 mL). The mixture was extracted with EtOAc (2 × 80 mL). The organic layers were combined, washed with brine (2 × 100 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=3 / 1; V / V) to obtain methyl 2-(1-(5-cyanopyrimidin-2-yl)piperidin-4-yl)acetate (1.04 g, 79.9%) as a pale yellow solid.

[0846]

number

[0847] Step B: Synthesis of 2-(1-(5-cyanopyrimidin-2-yl)piperidin-4-yl)acetic acid

[0848] [ka] To a mixture of methyl 2-(1-(5-cyanopyrimidin-2-yl)piperidin-4-yl)acetate (390 mg, 1.50 mmol, 1.0 equiv) in THF (6 mL) and HO (3 mL) was added LiOH (126 mg, 3.00 mmol, 2.0 equiv). The mixture was stirred at 10° C. for 16 h. The mixture was diluted with water (10 mL) and neutralized to pH 7 with 1 M HCl. The mixture was extracted with EtOAc (2×60 mL). The organic layers were combined, washed with brine (40 mL), dried over NaSO, and concentrated in vacuo to give 2-(1-(5-cyanopyrimidin-2-yl)piperidin-4-yl)acetic acid (365 mg, 98.8%) as a white solid.

[0849]

number

[0850] Step C: Synthesis of (S)-tert-butyl (1-((2-(1-(5-cyanopyrimidin-2-yl)piperidin-4-yl)acetamido)oxy)propan-2-yl)carbamate

[0851] [ka] To a solution of 2-(1-(5-cyanopyrimidin-2-yl)piperidin-4-yl)acetic acid (246 mg, 1.00 mmol, 1.0 equiv) in DMF (5 mL) was added DIPEA (388 mg, 3.00 mmol, 3.0 equiv), HATU (456 mg, 1.20 mmol, 1.2 equiv), followed by (S)-tert-butyl (1-(aminooxy)propan-2-yl)carbamate (190 mg, 1.00 mmol, 1.0 equiv). The mixture was stirred at 10° C. for 2 hours. The mixture was quenched with water (80 mL) and extracted with EtOAc (2×80 mL). The organic layers were combined, washed with brine (2×80 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 3 / 7; V / V) to give (S)-tert-butyl (1-((2-(1-(5-cyanopyrimidin-2-yl)piperidin-4-yl)acetamido)oxy)propan-2-yl)carbamate (295 mg, 70.5%) as a white solid.

[0852]

number

[0853] Step D: Synthesis of (S)—N-(2-aminopropoxy)-2-(1-(5-cyanopyrimidin-2-yl)piperidin-4-yl)acetamide

[0854] [ka] To a solution of (S)-tert-butyl (1-((2-(1-(5-cyanopyrimidin-2-yl)piperidin-4-yl)acetamido)oxy)propan-2-yl)carbamate (126 mg, 0.30 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (1 mL). The mixture was stirred at 10 °C for 1 h. Excess TFA was neutralized with saturated aqueous NaHCO (20 mL), and the mixture was extracted with a mixed solution of DCM and MeOH (10 / 1; V / V, 6 × 60 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo to give (S)—N-(2-aminopropoxy)-2-(1-(5-cyanopyrimidin-2-yl)piperidin-4-yl)acetamide (96 mg, 99.5%) as a pale yellow oil.

[0855]

number

[0856] Step E: Synthesis of (S)-2-(1-(5-cyanopyrimidin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0857] [ka] To a solution of (S)—N-(2-aminopropoxy)-2-(1-(5-cyanopyrimidin-2-yl)piperidin-4-yl)acetamide (96 mg, 0.30 mmol, 1.0 equiv) in EtOH (3 mL) was added 5-chloro-4-(trifluoromethyl)pyridazin-3(2H)-one (60 mg, 0.30 mmol, 1.0 equiv). The mixture was heated to 60° C. and stirred for 3 h. The mixture was cooled to room temperature and diluted with water (20 mL). The mixture was extracted with DCM (2×20 mL). The organic layers were combined, dried over Na2SO4, and concentrated in vacuo. The residue was purified by preparative HPLC to afford (S)-2-(1-(5-cyanopyrimidin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (12.22 mg, 8.46%) as a white solid.

[0858]

number

[0859] Example 34 (S)-2-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0860] [ka]

[0861] Step A: Synthesis of methyl 2-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)acetate

[0862] [ka] To a solution of 6-chloropyridine-3-carbonitrile (831 mg, 6.00 mmol, 1.0 equiv) and methyl 2-(piperidin-4-yl)acetate hydrochloride (1.16 g, 6.00 mmol, 1.0 equiv) in NMP (11 mL) was added K2CO3 (2.49 g, 18.00 mmol, 3.0 equiv). The mixture was stirred at 80 °C for 16 h. The mixture was cooled to room temperature and diluted with water (100 mL). The mixture was extracted with EtOAc (2 × 80 mL). The organic layers were combined, washed with brine (2 × 100 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=3 / 1; V / V) to obtain methyl 2-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)acetate (1.35 g, 86.8%) as a yellow solid.

[0863]

number

[0864] Step B: Synthesis of 2-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)acetic acid

[0865] [ka] To a mixture of methyl 2-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)acetate (389 mg, 1.50 mmol, 1.0 equiv) in THF (6 mL) and HO (3 mL) was added LiOH (126 mg, 3.00 mmol, 2.0 equiv). The mixture was stirred at 10° C. for 16 h. The mixture was diluted with water (10 mL) and neutralized to pH 7 with 1 M HCl. The mixture was extracted with EtOAc (2×60 mL). The organic layers were combined, washed with brine (40 mL), dried over NaSO, and concentrated in vacuo to give 2-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)acetic acid (365 mg, 99.2%) as a pale yellow solid.

[0866]

number

[0867] Step C: (S)-tert-butyl (1-((2-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)acetamido)oxy)propan-2-yl)carbamate

[0868] [ka] To a solution of 2-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)acetic acid (245 mg, 1.00 mmol, 1.0 equiv) in DMF (5 mL) was added DIPEA (388 mg, 3.00 mmol, 3.0 equiv) and HATU (456 mg, 1.20 mmol, 1.2 equiv), followed by (S)-tert-butyl(1-(aminooxy)propan-2-yl)carbamate (190 mg, 1.00 mmol, 1.0 equiv). The mixture was stirred at 10° C. for 2 h. The mixture was quenched with water (80 mL) and extracted with EtOAc (2×80 mL). The organic layers were combined, washed with brine (2×80 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 3 / 7; V / V) to give (S)-tert-butyl (1-((2-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)acetamido)oxy)propan-2-yl)carbamate (300 mg, 71.9%) as a white solid.

[0869]

number

[0870] Step D: Synthesis of (S)—N-(2-aminopropoxy)-2-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)acetamide

[0871] [ka] To a solution of (S)-tert-butyl (1-((2-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)acetamido)oxy)propan-2-yl)carbamate (50 mg, 0.12 mmol, 1.0 equiv) in DCM (4 mL) was added TFA (1 mL). The mixture was stirred at 15 °C for 0.5 h. Excess TFA was neutralized with saturated aqueous NaHCO (20 mL), and the mixture was extracted with DCM (4 × 60 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo to give (S)—N-(2-aminopropoxy)-2-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)acetamide (32 mg, 84.2%) as a white solid.

[0872]

number

[0873] Step E: Synthesis of (S)-2-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0874] [ka] To a solution of (S)—N-(2-aminopropoxy)-2-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)acetamide (16 mg, 0.05 mmol, 1.0 equiv) in EtOH (1 mL) was added 5-chloro-4-(trifluoromethyl)pyridazin-3(2H)-one (10 mg, 0.05 mmol, 1.0 equiv). The mixture was heated to 60° C. and stirred for 2 hours. The mixture was cooled to room temperature and diluted with water (10 mL). The mixture was extracted with EtOAc (3×15 mL). The organic layers were combined, dried over Na2SO4, and concentrated in vacuo. The residue was purified by preparative HPLC (FA) to give (S)-2-(1-(5-cyanopyridin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (3.12 mg, 12.9%) as a white solid.

[0875]

number

[0876] Example 35 (S)—N-(2-((5-bromo-6-oxo-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide

[0877] [ka]

[0878] 35.1) Synthesis of Intermediate T Step A: (S)-4-Bromo-5-((1-hydroxypropan-2-yl)amino)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one

[0879] [ka] To a solution of 4,5-dibromo-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (2.60 g, 6.79 mmol, 1.0 equiv) in i-PrOH (40 mL) was added DIPEA (2.63 g, 20.37 mmol, 3.0 equiv) and L-alaninol (510 mg, 6.79 mmol, 1.0 equiv). The mixture was stirred at 100° C. for 16 h. The mixture was cooled to room temperature, quenched with water (200 mL), and extracted with EtOAc (3×150 mL). The organic layers were combined, washed with brine (500 mL), dried over anhydrous NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / EtOAc=4 / 1; V / V) to give (S)-4-bromo-5-((1-hydroxypropan-2-yl)amino)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (1.32 g, 51.6%) as a white solid.

[0880]

number

[0881] Step B: Synthesis of (S)-2-(2-((5-bromo-6-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)isoindoline-1,3-dione (Intermediate T)

[0882] [ka] To a solution of (S)-4-bromo-5-((1-hydroxypropan-2-yl)amino)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (1.32 g, 3.49 mmol, 1.0 equiv) in THF (15 mL) was added N-hydroxyphthalimide (569 mg, 3.49 mmol, 1.0 equiv), PPh3 (1.01 g, 3.84 mmol, 1.1 equiv), followed by the dropwise addition of DIAD (776 mg, 3.84 mmol, 1.1 equiv). The mixture was stirred at 25 °C for 1 h. The mixture was quenched with water (100 mL) and extracted with EtOAc (3 × 80 mL). The organic layers were combined, washed with brine (300 mL), dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc=3 / 1; V / V) to give (S)-2-(2-((5-bromo-6-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)isoindoline-1,3-dione (1.44 g, 78.9%) as a colorless oil.

[0883]

number

[0884] 35.2) Synthesis of Compound 35 Step A: (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-bromo-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one

[0885] [ka] To a solution of (S)-2-(2-((5-bromo-6-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)isoindoline-1,3-dione (410 mg, 0.784 mmol, 1.0 equiv) in EtOH (5 mL) was added hydrazine hydrate (58 mg, 1.16 mmol, 1.5 equiv) at 0° C. The resulting mixture was stirred at room temperature for 30 minutes. The mixture was concentrated in vacuo. The residue was triturated with MTBE (10 mL). The insoluble precipitate was filtered off and washed with MTBE (10 mL). The filtrate was concentrated in vacuo to give (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-bromo-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (170 mg, 55% yield) as a white solid.

[0886]

number

[0887] Step B: Synthesis of (S)—N-(2-((5-bromo-6-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide

[0888] [ka] To a solution of 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetic acid (89 mg, 0.308 mmol, 1.1 equiv) in DMF (2 mL) was added DIPEA (108 mg, 0.842 mmol, 3.0 equiv) and HATU (128 mg, 0.336 mmol, 1.2 equiv), followed by the dropwise addition of (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-bromo-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (110 mg, 0.280 mmol, 1.0 equiv). The resulting mixture was stirred at 25° C. for 1 h. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3×10 mL). The organic layers were combined, washed with brine (10 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 1 / 2, V / V) to give (S)—N-(2-((5-bromo-6-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide (100 mg, 53% yield) as a colorless oil.

[0889]

number

[0890] Step C: Synthesis of (S)—N-(2-((5-bromo-6-oxo-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide

[0891] [ka] To a solution of (S)—N-(2-((5-bromo-6-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide (90 mg, 0.135 mmol, 1.0 equiv) in DCM (2 mL) was added TFA (0.3 mL). The resulting mixture was stirred at 25° C. for 1 h. The mixture was neutralized with saturated aqueous NaHCO (5 mL) and extracted with DCM (3×10 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (5 mL) and KCO (46 mg, 0.339 mmol, 2.5 equiv) was added. The mixture was stirred at 25° C. for an additional 1 h. The reaction mixture was filtered, and the filtrate was purified by reverse-phase silica gel chromatography (CHCN / HO=10 / 1, V / V) to give (S)—N-(2-((5-bromo-6-oxo-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide (49 mg, yield 68%) as a white solid.

[0892]

number

[0893] Example 36 (S)—N-(2-((5-acetyl-6-oxo-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide

[0894] [ka]

[0895] 36.1) Synthesis of Intermediate W Step A: Synthesis of (S)-2-(2-((5-acetyl-6-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)isoindoline-1,3-dione

[0896] [ka] To a solution of (S)-2-(2-((5-bromo-6-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)isoindoline-1,3-dione (733 mg, 1.40 mmol, 1.0 equiv) and tributyl(1-ethoxyvinyl)stannane (607 mg, 1.68 mmol, 1.2 equiv) in toluene (28 mL) was added Pd(PPh3)4 (323 mg, 0.28 mmol, 0.2 equiv). The mixture was stirred at 100 °C for 16 h. The reaction was cooled to room temperature, quenched with water (50 mL), and extracted with EtOAc (3 × 40 mL). The organic layers were combined, washed with brine (150 mL), dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc=1 / 1; V / V) to give (S)-2-(2-((5-acetyl-6-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)isoindoline-1,3-dione (446 mg, 61.9%) as a white solid.

[0897]

number

[0898] Step B: Synthesis of (S)-4-acetyl-5-((1-(aminooxy)propan-2-yl)amino)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one

[0899] [ka] To a solution of (S)-2-(2-((5-acetyl-6-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)isoindoline-1,3-dione (390 mg, 0.80 mmol, 1.0 equiv) in DCM (10 mL) and MeOH (5 mL) was added hydrazine hydrate (76 mg, 1.52 mmol, 1.9 equiv). The mixture was stirred at 25° C. for 1 h. The mixture was concentrated in vacuo. The residue was triturated with EtOH (20 mL), filtered, and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc=2 / 1; V / V) to give (S)-4-acetyl-5-((1-(aminooxy)propan-2-yl)amino)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (230 mg, 80.5%) as a yellow oil.

[0900]

number

[0901] 36.2) Synthesis of Compound 36 Step A: Synthesis of (S)—N-(2-((5-acetyl-6-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide

[0902] [ka] To a solution of ((S)-4-acetyl-5-((1-(aminooxy)propan-2-yl)amino)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (230 mg, 0.65 mmol, 1.0 equiv) and 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetic acid (208 mg, 0.72 mmol, 1.1 equiv) in DMF (15 mL) was added DIPEA (252 mg, 1.95 mmol, 3.0 equiv) and HATU (297 mg, 0.78 mmol, 1.2 equiv). The mixture was stirred at 25° C. for 1 h. The mixture was stirred with water (50 ml). The mixture was quenched with 2 mL of ethyl acetate and extracted with EtOAc (3 × 40 mL). The organic layers were combined, washed with brine (200 mL), dried over anhydrous NaSO, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc = 1 / 1; V / V) to give (S)—N-(2-((5-acetyl-6-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide (360 mg, 88.9%) as a white solid.

[0903]

number

[0904] Step B: Synthesis of (S)—N-(2-((5-acetyl-6-oxo-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide

[0905] [ka] To a solution of (S)—N-(2-((5-acetyl-6-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide (180 mg, 0.28 mmol, 1.0 equiv) in DCM (6 mL) was added TFA (2 mL). The resulting solution was stirred at 25° C. for 0.5 h. The mixture was concentrated in vacuo. To the residue was added MeOH (6 mL), water (6 mL), KCO (174 mg, 1.26 mmol, 4.5 equiv), and ethylenediamine (124 mg, 2.07 mmol, 7.4 equiv). The mixture was stirred at 25° C. for an additional 1 h. The mixture was quenched with water (50 mL) and extracted with EtOAc (3 × 40 mL). The organic layers were combined, washed with brine (200 mL), dried over anhydrous NaSO, and concentrated under reduced pressure. The residue was purified by preparative HPLC to give (S)—N-(2-((5-acetyl-6-oxo-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide (30.83 mg, 21.6%) as a white solid.

[0906]

number

[0907] Example 37 N-(2-(5-oxo-3,4,5,6-tetrahydropyrido(2,3-d)pyridazin-1(2H)-yl)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide

[0908] [ka]

[0909] Step A: Synthesis of 6-((2-(trimethylsilyl)ethoxy)methyl)pyrido(2,3-d)pyridazin-5(6H)-one

[0910] [ka] To a mixture of pyrido(2,3-d)pyridazin-5(6H)-one (1.03 g, 7.00 mmol, 1.0 equiv) in DMF (35 mL) was added NaH (60%, 0.70 g, 17.50 mmol, 2.5 equiv) in portions at 0 °C in an ice-water bath under a N atmosphere. The mixture was stirred at 0 °C for 30 min. 2-(Trimethylsilyl)ethoxymethyl chloride (1.75 g, 10.50 mmol, 1.5 equiv) was added to the reaction mixture. The mixture was stirred at 10 °C for 2 h. The mixture was quenched with saturated aqueous NH Cl (120 mL) and extracted with EtOAc (2 × 100 mL). The organic layers were combined, washed with brine (2 × 100 mL), dried over Na SO , and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc / petroleum ether=1 / 3; V / V) to give 6-((2-(trimethylsilyl)ethoxy)methyl)pyrido(2,3-d)pyridazin-5(6H)-one (1.26 g, 64.9%) as a yellow oil.

[0911]

number

[0912] Step B: Synthesis of 6-((2-(trimethylsilyl)ethoxy)methyl)-1,2,3,4-tetrahydropyrido(2,3-d)pyridazin-5(6H)-one

[0913] [ka] To a solution of 6-((2-(trimethylsilyl)ethoxy)methyl)pyrido(2,3-d)pyridazin-5(6H)-one (1.38 g, 4.98 mmol, 1.0 equiv) in EtOH (50 mL) was added Pd / C (10%, 0.20 g) under a N atmosphere. The mixture was degassed and purged with hydrogen several times. The mixture was stirred under a hydrogen atmosphere at 10 °C for 16 h. The mixture was filtered, and the filtrate was concentrated in vacuo to give 6-((2-(trimethylsilyl)ethoxy)methyl)-1,2,3,4-tetrahydropyrido(2,3-d)pyridazin-5(6H)-one (1.38 g, 98.6% yield) as an off-white solid.

[0914]

number

[0915] Step C: Synthesis of methyl 2-(5-oxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3,4,5,6-tetrahydropyrido(2,3-d)pyridazin-1(2H)-yl)propanoate

[0916] [ka] To a mixture of 6-((2-(trimethylsilyl)ethoxy)methyl)-1,2,3,4-tetrahydropyrido(2,3-d)pyridazin-5(6H)-one (790 mg, 2.81 mmol, 1.0 equiv) in DMF (12 mL) was added NaH (60%, 898 mg, 22.46 mmol, 8.0 equiv) at 0° C. in an ice-water bath under a N atmosphere. The mixture was stirred at 0° C. for 30 minutes. To the mixture was added methyl 2-bromopropanoate (2.11 g, 12.63 mmol, 4.5 equiv). The mixture was stirred at 40° C. for 0.5 hours. The mixture was quenched with cold water (60 mL) and extracted with EtOAc (2×120 mL). The organic layers were combined, washed with brine (60 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc / petroleum ether=6 / 10; V / V) to give methyl 2-(5-oxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3,4,5,6-tetrahydropyrido(2,3-d)pyridazin-1(2H)-yl)propanoate (660 mg, yield 64.0%) as a yellow oil.

[0917]

number

[0918] Step D: Synthesis of 1-(1-hydroxypropan-2-yl)-6-((2-(trimethylsilyl)ethoxy)methyl)-1,2,3,4-tetrahydropyrido(2,3-d)pyridazin-5(6H)-one

[0919] [ka] To a solution of methyl 2-(5-oxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3,4,5,6-tetrahydropyrido(2,3-d)pyridazin-1(2H)-yl)propanoate (890 mg, 2.42 mmol, 1.0 equiv.) in THF (10 mL) was added DIBAL-H (1 M, 12.1 mL, 12.10 mmol, 5.0 equiv.) at 0° C. in an ice-water bath under a N atmosphere. The mixture was stirred at 10° C. for 1 h. The mixture was quenched with saturated aqueous NH4Cl (100 mL) and extracted with DCM (4×180 mL). The organic layers were combined, dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel chromatography (MeOH / DCM=6 / 100, V / V) to give 1-(1-hydroxypropan-2-yl)-6-((2-(trimethylsilyl)ethoxy)methyl)-1,2,3,4-tetrahydropyrido(2,3-d)pyridazin-5(6H)-one (426 mg, yield 51.8%) as a yellow oil.

[0920]

number

[0921] Step E: Synthesis of 2-(5-oxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3,4,5,6-tetrahydropyrido(2,3-d)pyridazin-1(2H)-yl)propyl 4-methylbenzenesulfonate

[0922] [ka] To a solution of 1-(1-hydroxypropan-2-yl)-6-((2-(trimethylsilyl)ethoxy)methyl)-1,2,3,4-tetrahydropyrido(2,3-d)pyridazin-5(6H)-one (100 mg, 0.29 mmol, 1.0 equiv) in DCM (10 mL) was added TEA (59 mg, 0.58 mmol, 2.0 equiv), DMAP (18 mg, 0.15 mmol, 0.5 equiv), and tosyl chloride (55 mg, 0.29 mmol, 1.0 equiv). The mixture was stirred at 35 °C for 16 h. The mixture was quenched with water (30 mL) and extracted with EtOAc (3 × 40 mL). The organic layers were combined, washed with brine (100 mL), dried over anhydrous NaSO, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc = 1 / 1, V / V) to give 2-(5-oxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3,4,5,6-tetrahydropyrido(2,3-d)pyridazin-1(2H)-yl)propyl 4-methylbenzenesulfonate (120 mg, 83.9%) as a yellow oil.

[0923]

number

[0924] Step F: Synthesis of 2-(2-(5-oxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3,4,5,6-tetrahydropyrido(2,3-d)pyridazin-1(2H)-yl)propoxy)isoindoline-1,3-dione

[0925] [ka] To a solution of 2-(5-oxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3,4,5,6-tetrahydropyrido(2,3-d)pyridazin-1(2H)-yl)propyl 4-methylbenzenesulfonate (150 mg, 0.30 mmol, 1.0 equiv) in DMF (10 mL) was added N-hydroxyphthalimide (49 mg, 0.30 mmol, 1.0 equiv) and K2CO3 (124 mg, 0.90 mmol, 3.0 equiv). The mixture was stirred at 60 °C for 16 h. The mixture was cooled to room temperature, diluted with water (50 mL), and extracted with EtOAc (3 × 50 mL). The organic layers were combined, washed with brine (2 × 60 mL), dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc = 2 / 1, V / V) to give 2-(2-(5-oxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3,4,5,6-tetrahydropyrido(2,3-d)pyridazin-1(2H)-yl)propoxy)isoindoline-1,3-dione (108 mg, 74.5%) as a colorless oil.

[0926]

number

[0927] Step G: Synthesis of 1-(1-(aminooxy)propan-2-yl)-6-((2-(trimethylsilyl)ethoxy)methyl)-1,2,3,4-tetrahydropyrido(2,3-d)pyridazin-5(6H)-one

[0928] [ka] To a solution of 2-(2-(5-oxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3,4,5,6-tetrahydropyrido(2,3-d)pyridazin-1(2H)-yl)propoxy)isoindoline-1,3-dione (90 mg, 0.18 mmol, 1.0 equiv) in DCM (4 mL) and MeOH (2 mL) was added hydrazine hydrate (14 mg, 0.27 mmol, 1.5 equiv). The mixture was stirred at 35° C. for 1 h. The reaction mixture was concentrated in vacuo. The residue was triturated with EtOH (20 mL), filtered, and the filtrate was concentrated in vacuo to give 1-(1-(aminooxy)propan-2-yl)-6-((2-(trimethylsilyl)ethoxy)methyl)-1,2,3,4-tetrahydropyrido(2,3-d)pyridazin-5(6H)-one (70 mg, 100%) as a yellow oil.

[0929]

number

[0930] Step H: Synthesis of N-(2-(5-oxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3,4,5,6-tetrahydropyrido(2,3-d)pyridazin-1(2H)-yl)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide

[0931] [ka] To a solution of 1-(1-(aminooxy)propan-2-yl)-6-((2-(trimethylsilyl)ethoxy)methyl)-1,2,3,4-tetrahydropyrido(2,3-d)pyridazin-5(6H)-one (64 mg, 0.18 mmol, 1.0 equiv) and 2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetic acid (57 mg, 0.20 mmol, 1.1 equiv) in DMF (5 mL) was added DIPEA (70 mg, 0.54 mmol, 3.0 equiv) and HATU (82 mg, 0.21 mmol, 1.2 equiv). The mixture was stirred at 35° C. for 1 h. The reaction was quenched with water (50 mL) and extracted with EtOAc (3×40 mL). The organic layers were combined, washed with brine (2 × 60 mL), dried over anhydrous NaSO, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc = 1 / 1, V / V) to give N-(2-(5-oxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3,4,5,6-tetrahydropyrido(2,3-d)pyridazin-1(2H)-yl)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide (60 mg, 53.5%) as a white solid.

[0932]

number

[0933] Step I: Synthesis of N-(2-(5-oxo-3,4,5,6-tetrahydropyrido(2,3-d)pyridazin-1(2H)-yl)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide

[0934] [ka] To a solution of N-(2-(5-oxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3,4,5,6-tetrahydropyrido(2,3-d)pyridazin-1(2H)-yl)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide (60 mg, 0.09 mmol, 1.0 equiv) in DCM (3 mL) was added TFA (1 mL). The resulting solution was stirred at 35° C. for 0.5 h. The mixture was concentrated in vacuo, and to the residue was added MeOH (2 mL) and KCO (20 mg, 0.14 mmol, 1.5 equiv). The mixture was stirred at 35° C. for an additional 0.5 h. The mixture was filtered, and the filtrate was purified by preparative HPLC to give N-(2-(5-oxo-3,4,5,6-tetrahydropyrido(2,3-d)pyridazin-1(2H)-yl)propoxy)-2-(1-(5-(trifluoromethyl)pyrimidin-2-yl)piperidin-4-yl)acetamide (15.16 mg, 33.6%) as a white solid.

[0935]

number

[0936] Example 38 (S)-2-(1-(7H-pyrrolo(2,3-d)pyrimidin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0937] [ka]

[0938] Step A: Synthesis of 2-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo(2,3-d)pyrimidine

[0939] [ka] To a mixture of 2-chloro-7H-pyrrolo(2,3-d)pyrimidine (150 mg, 0.98 mmol, 1.0 equiv) in DMF (5 mL) was added NaH (60%, 47 mg, 1.18 mmol, 1.2 equiv) under a N2 atmosphere at 0 °C. The mixture was stirred at 25 °C for 1 h. 2-(Trimethylsilyl)ethoxymethyl chloride (179 mg, 1.08 mmol, 1.1 equiv) was added dropwise to the mixture at 0 °C. The mixture was stirred at 25 °C for an additional 2 h. The mixture was quenched with water (150 mL) and extracted with EtOAc (2 × 100 mL). The organic layers were combined, washed with brine (2 × 80 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc=9 / 1; V / V) to give 2-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo(2,3-d)pyrimidine (160 mg, 57.7%) as a yellow solid.

[0940]

number

[0941] Step B: Synthesis of methyl 2-(1-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo(2,3-d)pyrimidin-2-yl)piperidin-4-yl)acetate

[0942] [ka] To a mixture of 2-chloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo(2,3-d)pyrimidine (160 mg, 0.59 mmol, 1.0 equiv) in DMF (5 mL) was added KCO (246 mg, 1.78 mmol, 3.0 equiv) and methyl 2-(piperidin-4-yl)acetate hydrochloride (114 mg, 0.59 mmol, 1.0 equiv). The mixture was stirred at 100 °C for 1 h. The reaction mixture was cooled to room temperature, diluted with water (100 mL), and extracted with EtOAc (2 × 100 mL). The organic layers were combined, washed with brine (2 × 80 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by preparative TLC (petroleum ether / EtOAc=10 / 1; V / V) to give methyl 2-(1-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo(2,3-d)pyrimidin-2-yl)piperidin-4-yl)acetate (140 mg, 60.5%) as a colorless oil.

[0943]

number

[0944] Step C: Synthesis of 2-(1-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo(2,3-d)pyrimidin-2-yl)piperidin-4-yl)acetic acid

[0945] [ka] To a mixture of methyl 2-(1-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo(2,3-d)pyrimidin-2-yl)piperidin-4-yl)acetate (130 mg, 0.32 mmol, 1.0 equiv) in THF (4 mL) and HO (4 mL) was added LiOH (54 mg, 1.29 mmol, 4.0 equiv). The mixture was stirred at 25 °C for 2 h. The mixture was diluted with water (20 mL) and adjusted to pH 6 with 1 M HCl. The mixture was extracted with EtOAc (2 × 100 mL). The organic layers were combined, washed with brine (100 mL), dried over Na2SO4, and concentrated in vacuo to give 2-(1-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo(2,3-d)pyrimidin-2-yl)piperidin-4-yl)acetic acid (110 mg, 87.7%) as a yellow solid.

[0946]

number

[0947] Step D: Synthesis of (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo(2,3-d)pyrimidin-2-yl)piperidin-4-yl)acetamide

[0948] [ka] To a mixture of 2-(1-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo(2,3-d)pyrimidin-2-yl)piperidin-4-yl)acetic acid (110 mg, 0.28 mmol, 1.0 equiv.) in DMF (5 mL) was added (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (119 mg, 0.31 mmol, 1.1 equiv.), DIPEA (0.14 mL, 0.85 mmol, 3.0 equiv.), and HATU (129 mg, 0.34 mmol, 1.2 equiv.). The mixture was stirred at 25° C. for 1 hour. The reaction mixture was quenched with water (100 mL) and extracted with EtOAc (2 × 150 mL). The combined organic layers were washed with brine (2 × 80 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 1 / 1; V / V) to give (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo(2,3-d)pyrimidin-2-yl)piperidin-4-yl)acetamide (110 mg, 51.7%) as a pale yellow oil.

[0949]

number

[0950] Step E: Synthesis of (S)-2-(1-(7H-pyrrolo(2,3-d)pyrimidin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0951] [ka] To a mixture of (S)—N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)-2-(1-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo(2,3-d)pyrimidin-2-yl)piperidin-4-yl)acetamide (95 mg, 0.13 mmol, 1.0 equiv) in DCM (6 mL) was added TFA (2 mL). The mixture was stirred at 25° C. for 1 h. The mixture was quenched with saturated aqueous NaHCO (50 mL) and extracted with DCM (3×100 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (3 mL), and KCO (81 mg, 0.45 mmol) was added. The mixture was stirred at 25 °C for an additional 1 h. The mixture was filtered, and the filtrate was purified by preparative HPLC to give (S)-2-(1-(7H-pyrrolo(2,3-d)pyrimidin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (8.03 mg, 12.9%) as a white solid.

[0952]

number

[0953] Example 39 (S)-2-(1-(6-fluoroquinazolin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0954] [ka]

[0955] Step A: Synthesis of 2-chloro-6-fluoroquinazoline

[0956] [ka] To a solution of 2,4-dichloro-6-fluoroquinazoline (350 mg, 1.61 mmol, 1.0 equiv) in DCM (7 mL) was added NH3·HO (1 mL) and saturated aqueous NaCl (7 mL). Zn powder (316 mg, 4.84 mmol, 3.0 equiv) was then added to the mixture. The mixture was stirred at 40 °C under a N2 atmosphere for 3 h. The mixture was cooled to room temperature and diluted with DCM (15 mL). The organics were washed with saturated aqueous NH4Cl (2 × 10 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc = 2 / 1; V / V) to give 2-chloro-6-fluoroquinazoline (150 mg, 50.9%) as a yellow solid.

[0957]

number

[0958] Step B: Synthesis of methyl 2-(1-(6-fluoroquinazolin-2-yl)piperidin-4-yl)acetate

[0959] [ka] To a mixture of methyl 2-(piperidin-4-yl)acetate hydrochloride (145 mg, 0.75 mmol, 1.05 equiv.) and DIPEA (276 mg, 2.13 mmol, 3.0 equiv.) in NMP (8 mL) was added 2-chloro-6-fluoroquinazoline (130 mg, 0.71 mmol, 1.0 equiv.). The mixture was stirred at 70° C. for 2 hours. The mixture was cooled to room temperature, quenched with water (30 mL), and extracted with EtOAc (3×30 mL). The organic layers were combined, washed with brine (2×30 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether / EtOAc = 2 / 1; V / V) to give methyl 2-(1-(6-fluoroquinazolin-2-yl)piperidin-4-yl)acetate (150 mg, 69.4%) as a white solid.

[0960]

number

[0961] Step C: Synthesis of 2-(1-(6-fluoroquinazolin-2-yl)piperidin-4-yl)acetic acid

[0962] [ka] To a mixture of methyl 2-(1-(6-fluoroquinazolin-2-yl)piperidin-4-yl)acetate (145 mg, 0.48 mmol, 1.0 equiv) in a mixture of THF (2 mL), MeOH (2 mL), and HO (1 mL) was added lithium hydroxide (80 mg, 1.92 mmol, 4.0 equiv). The mixture was stirred at 50° C. for 12 hours. The mixture was cooled to room temperature and diluted with water (6 mL). The mixture was adjusted to pH 6 with 1 M HCl. The mixture was extracted with EtOAc (3×10 mL). The organic layers were combined, washed with brine (10 mL), dried over NaSO, and concentrated in vacuo to give 2-(1-(6-fluoroquinazolin-2-yl)piperidin-4-yl)acetic acid (110 mg, 79.5%) as a white solid.

[0963]

number

[0964] Step D: Synthesis of (S)-2-(1-(6-fluoroquinazolin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0965] [ka] To a mixture of 2-(1-(6-fluoroquinazolin-2-yl)piperidin-4-yl)acetic acid (100 mg, 0.35 mmol, 1.0 equiv) and (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (159 mg, 0.42 mmol, 1.2 equiv) in DMF (5 mL) was added DIPEA (134 mg, 1.05 mmol, 3.0 equiv) and HATU (158 mg, 0.42 mmol, 1.2 equiv). The mixture was stirred at 25° C. for 2 hours. The mixture was diluted with water (10 mL) and extracted with EtOAc (3×15 mL). The combined organic layer was washed with saturated aqueous NH4Cl (2 x 20 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel chromatography (EtOAc / petroleum ether = 1 / 1; V / V) to give (S)-2-(1-(6-fluoroquinazolin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (195 mg, 86.3%) as a yellow solid.

[0966]

number

[0967] Step E: Synthesis of (S)-2-(1-(6-fluoroquinazolin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0968] [ka] To a mixture of (S)-2-(1-(6-fluoroquinazolin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (140 mg, 0.21 mmol, 1.0 equiv) in DCM (4.5 mL) was added TFA (1.5 mL). The mixture was stirred at 25° C. for 0.5 h. The mixture was concentrated in vacuo. MeOH (4 mL) and KCO (176 mg, 1.26 mmol, 6.0 equiv) were added to the resulting mixture. The mixture was stirred at 25° C. for an additional 0.5 h. The mixture was filtered and the filtrate was purified by preparative HPLC to give (S)-2-(1-(6-fluoroquinazolin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (14.73 mg, 13.1%) as a white solid.

[0969]

number

[0970] Example 40 (S)-2-(1-(4-(hydroxymethyl)-5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0971] [ka]

[0972] Step A: Synthesis of 2-(4-(2-methoxy-2-oxoethyl)piperidin-1-yl)-5-(trifluoromethyl)isonicotinic acid

[0973] [ka] To a solution of methyl 2-(piperidin-4-yl)acetate (380 mg, 1.97 mmol, 1.5 equiv.) in NMP (8 mL) were added DIPEA (1 g, 7.92 mmol, 6.0 equiv.) and 2-chloro-5-(trifluoromethyl)isonicotinic acid (300 mg, 1.32 mmol, 1 equiv.), and the resulting mixture was stirred in a sealed tube at 120° C. for 16 h. The mixture was cooled to room temperature and diluted with water (80 mL). The mixture was extracted with EtOAc (3×50 mL). The aqueous phase was adjusted to pH 6 with 2 M HCl and extracted with EtOAc (3×50 mL). The organic layers were combined, dried over NaSO, and concentrated under reduced pressure. The residue was purified by column chromatography (DCM / MeOH=95 / 5, V / V) to give 2-(4-(2-methoxy-2-oxoethyl)piperidin-1-yl)-5-(trifluoromethyl)isonicotinic acid (340 mg, 51.8%) as a colorless oil.

[0974]

number

[0975] Step B: Synthesis of methyl 2-(1-(4-(hydroxymethyl)-5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetate

[0976] [ka] To a solution of 2-(4-(2-methoxy-2-oxoethyl)piperidin-1-yl)-5-(trifluoromethyl)isonicotinic acid (280 mg, 0.81 mmol, 1.0 equiv.) in THF (3 mL) was added BH3 (1.62 mL, 1.62 mmol, 2.0 equiv.). The mixture was stirred at 25° C. for 16 hours. The mixture was quenched with MeOH. The mixture was concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 2 / 1, V / V) to give methyl 2-(1-(4-(hydroxymethyl)-5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetate (130 mg, 48.6% yield) as a colorless oil.

[0977]

number

[0978] Step C: Synthesis of 2-(1-(4-(hydroxymethyl)-5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetic acid

[0979] [ka] To a solution of methyl 2-(1-(4-(hydroxymethyl)-5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetate (130 mg, 0.392 mmol, 1.0 equiv) in THF (3 mL) and water (3 mL) was added LiOH (38 mg, 1.568 mmol, 4.0 equiv). The mixture was stirred at 40° C. for 1 h. The mixture was diluted with water (15 mL) and extracted with EtOAc (3×10 mL). The aqueous layer was adjusted to pH 6 with 2 M HCl. The mixture was extracted with EtOAc (3×15 mL), dried over NaSO, and concentrated in vacuo to give 2-(1-(4-(hydroxymethyl)-5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetic acid (90 mg, 72.5% yield) as a colorless oil.

[0980]

number

[0981] Step D: Synthesis of (S)-2-(1-(4-(hydroxymethyl)-5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0982] [ka] To a solution of 2-(1-(4-(hydroxymethyl)-5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)acetic acid (92 mg, 0.24 mmol, 1 equiv.) in THF (3.6 mL) was added DIPEA (62 mg, 0.48 mmol, 2.0 equiv.) and HATU (137 mg, 0.36 mmol, 1.5 equiv.), followed by the dropwise addition of (S)-5-((1-(aminooxy)propan-2-yl)amino)-4-(trifluoromethyl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyridazin-3(2H)-one (80 mg, 0.252 mmol, 1.05 equiv.). The resulting mixture was stirred at 25° C. for 1 h. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3×10 mL). The organic layers were combined, washed with brine (10 mL), dried over NaSO, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether / EtOAc = 3 / 7, V / V) to give (S)-2-(1-(4-(hydroxymethyl)-5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (120 mg, yield 62.1%) as a colorless oil.

[0983]

number

[0984] Step E: Synthesis of (S)-2-(1-(4-(hydroxymethyl)-5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide

[0985] [ka] To a solution of (S)-2-(1-(4-(hydroxymethyl)-5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)-N-(2-((6-oxo-5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1,6-dihydropyridazin-4-yl)amino)propoxy)acetamide (120 mg, 0.176 mmol, 1.0 equiv) in DCM (2 mL) was added TFA (0.2 mL). The resulting mixture was stirred at 25 °C for 20 min. The mixture was neutralized with saturated aqueous NaHCO (5 mL) and extracted with DCM (3 × 10 mL). The organic layers were combined, dried over NaSO, and concentrated in vacuo. The residue was redissolved in MeOH (2 mL) and KCO (83 mg, 0.6 mmol, 3.0 equiv) was added. The mixture was stirred for another 1 hour at 25° C. The reaction...

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt, deuterated compound, or solvate thereof 【Chemistry 1】 (In the formula, 【Chemistry 2】 represents a double bond or a single bond, provided that at most one double bond is attached to any atom; X is C １～６ Haloalkyl and C ２～６ alkanoyl, or together with Y and the carbon atom to which they are attached form a fused benzene ring; Y is either NH or, together with X and the carbon atom to which they are attached, forms a fused benzene ring; A is a nitrogen-oxo group selected from the group consisting of -N-O-, =N-O-, -O-N- and -O-N=, wherein the N atom, when its valence is not saturated, is hydrogen or C １～６ optionally substituted with alkyl; L is -(CH ２ ) ｎ -, 【Transformation 3】 n is 1, 2, or 3; and R ５ and R ５ ' are each independently hydrogen, C １～３ selected from the group consisting of alkyl, halogen and deuterium, or R ５ and R ５ ' together with the carbon atom to which they are attached form C ３～６ Forming a cycloalkyl; R １ and R ２ are each independently hydrogen, C １～６ Alkyl and C ３～６ cycloalkyl, or R １ and R ２ together with the carbon atoms to which they are attached form C ５～８ Forming a cycloalkyl; M is a group represented by the formulas (M-1), (M-4) and (M-5): 【Chemistry 4】 (In the formula, D １ , D ２ , D ３ , D8, D ９ and D １０ are each independently selected from the group consisting of N and CH, provided that at least one N is included as a ring atom of the M moiety; R ３ are each independently hydrogen, halogen, hydroxyl, and C １～４ is selected from the group consisting of alkyl, m is independently selected from the group consisting of 0, 1, or 2. is a moiety selected from the group consisting of: G is one or two R ４ is a 6-membered aromatic heterocyclic group optionally substituted with a group, R ４ are each independently cyano, C １～６ Haloalkyl, C ３～６ cycloalkyl and phenyl optionally substituted with halogen, or two R ４ groups, together with the carbon atoms to which they are attached, optionally substituted with hydroxyl, methyl, halogen, or oxo; ５～８ forming a cycloalkyl, phenyl or heteroaryl) A poly(adenosine diphosphate-ribose) polymerase-7 inhibitor comprising:

2. M is a compound represented by the formula (M-1a) and (M-5a): 【Transformation 5】 (In the formula, D １ is selected from the group consisting of N or CH, m is 1, and R ３ are each independently hydrogen, hydroxyl, halogen or C １～４ alkyl) 2. The inhibitor of claim 1, wherein the moiety is selected from the group consisting of:

3. G is represented by the formula (G-1), (G-2) and (G-6): 【Transformation 6】 wherein each Q is independently selected from the group consisting of N or CH; R ４ groups are optional substituents, each independently selected from cyano, C １～４ Haloalkyl, C ３～６ cycloalkyl, and phenyl optionally substituted with halogen.

2. The inhibitor of claim 1, wherein the moiety is selected from the group consisting of:

4. X is selected from the group consisting of trifluoromethyl and acetyl, or X together with Y and the carbon atom to which they are attached form a fused benzene ring; 2. The inhibitor of claim 1, wherein Y is selected from NH or together with X and the carbon atom to which they are attached form a fused benzene ring.

5. D of formula (M-1) or formula (M-1a) １ is N, when L is -(CH ２ ) ｎ -, 【Transformation 7】 selected from the group consisting of: D １ is CH, when L is -(CH ２ ) ｎ -, 【Transformation 8】 The inhibitor of claim 1, selected from the group consisting of:

6. When A is -N-O-, L is 【Chemistry 9】 and when A is =N-O-, L is 【Chemistry 10】 when A is -O-N-, then L is 【Chemistry 11】 and when A is -O-N=, L is 【Chemistry 12】 The inhibitor of claim 1, wherein

7. X is trifluoromethyl; Y is NH; A is —O—N—; L 【Chemistry 13】 and R ５ and R ５ are each independently selected from the group consisting of hydrogen or halogen; M is represented by the formula (M-1a) and (M-5a) (wherein D １ is selected from the group consisting of N or CH, m is independently 1, and R ３ are each independently hydrogen, halogen or C １～３ alkyl); G is a group represented by formula (G-1) (wherein Q is N and R ４ is C １～６ haloalkyl); R １ and R ２ are each independently hydrogen and C １～６ 2. The inhibitor of claim 1, wherein the inhibitor is selected from the group consisting of alkyl. 【Request Item 8】 【Chemistry 14】 represents a double bond or a single bond, provided that at most one double bond is attached to any atom; X is C １～６ haloalkyl, or together with Y and the carbon atom to which they are attached form a fused benzene ring; Y is NH or together with X and the carbon atom to which they are attached form a fused benzene ring; A is a nitrogen-oxo group selected from the group consisting of -N-O-, =N-O-, -O-N- and -O-N=, and the N atom is hydrogen or C when its valence is not saturated. １～６ optionally substituted with alkyl; L is -(CH ２ ) ｎ -, 【Chemistry 15】 wherein n is 1, 2, or 3; and R ５ and R ５ ' are each independently hydrogen or C １～３ alkyl, or R ５ and R ５ ', together with the carbon atoms to which they are attached, form C ３～６ Forming a cycloalkyl; R １ and R ２ are each independently hydrogen, C １～６ Alkyl, C ３～６ cycloalkyl, or R １ and R ２ These, together with the carbon atoms to which they are attached, form C ５～８ Forming a cycloalkyl; M is a compound represented by the formula (M-1) and (M-4): 【Chemistry 16】 (In the formula, D １ , D ２ , D ３ , D8 and D ９ are each independently selected from the group consisting of N and CH, provided that at least one N is included as a ring atom of the M moiety; R ３ are each independently a halogen, a hydroxyl, or C １～４ is selected from the group consisting of alkyl, m is independently selected from the group consisting of 0, 1, or 2. is a moiety selected from the group consisting of: G is one or two R ４ is a 6-membered aromatic heterocyclic group optionally substituted with a group, R ４ are each independently cyano and C １～６ haloalkyl, or two R ４ groups, together with the carbon atoms to which they are attached, optionally substituted with hydroxyl or methyl ５～８ The inhibitor of claim 1 which forms a cycloalkyl.

9. M is a compound represented by the formula (M-1a) and (M-4a): 【Chemistry 17】 (In the formula, D １ is selected from the group consisting of N or CH, each m is independently 0 or 1, and R ３ are each independently hydroxyl, halogen or C １～４ alkyl) 9. The inhibitor of claim 8, wherein the moiety is selected from the group consisting of:

10. G is a group represented by the formula (G-1) and (G-2): [Chemistry 18] wherein Q is selected from the group consisting of N or CH.

9. The inhibitor of claim 8, wherein the moiety is selected from the group consisting of:

11. D of formula (M-1) or formula (M-1a) １ is N, when L is -(CH ２ ) ｎ -, 【Chemistry 19】 selected from the group consisting of: D １ is CH, when L is -(CH ２ ) ｎ -, 【Chemistry 20】 9. The inhibitor of claim 8, selected from the group consisting of:

12. When A is -N-O-, L is 【Chemistry 21】 and when A is =N-O-, L is 【Chemistry 22】 when A is -O-N-, then L is 【Chemistry 23】 and when A is -O-N=, L is 【Chemistry 24】 The inhibitor of claim 8, wherein

13. A compound of formula (II) or a pharmaceutically acceptable salt, deuterated compound, solvate, ester, acid, metabolite or prodrug thereof 【Chemistry 25】 (In the formula, 【Chemistry 26】 represents a double bond or a single bond, provided that at most one double bond is attached to any atom; X is C １～６ haloalkyl, or together with Y and the carbon atom to which they are attached form a fused benzene or piperidine ring; Y is selected from NH or together with X and the carbon atom to which it is attached form a fused benzene or piperidine ring; A is a nitrogen-oxo group selected from the group consisting of -N-O-, =N-O-, -O-N- and -O-N=, wherein the N atom, when its valence is not saturated, is hydrogen or C １～６ optionally substituted with alkyl; L is -(CH ２ ) ｎ -, 【Chemistry 27】 n is 1, 2, or 3; and R ５ and R ５ ' are each independently hydrogen or C １～３ alkyl, or R ５ and R ５ ' together with the carbon atom to which they are attached form C ３～６ Forming a cycloalkyl; D is selected from the group consisting of N or CH; Q is selected from the group consisting of N or CH; R １ and R ２ are each independently hydrogen, C １～６ Alkyl, C ３～６ cycloalkyl, or R １ and R ２ together with the carbon atoms to which they are attached form C ５～８ Forming a cycloalkyl; R ３ is hydrogen or C １～３ selected from the group consisting of alkyl; R ４ is cyano and C １～６ haloalkyl) The inhibitor of claim 8, comprising:

14. The compound of formula (I) Table 1 Table 2 Table 3 Table 4 The inhibitor of claim 1, selected from the group consisting of:

15. A pharmaceutical composition for cancer treatment comprising an inhibitor according to any one of claims 1 to 14, a pharmaceutically acceptable carrier or excipient, and optionally other therapeutic agents.

16. 15. An inhibitor according to any one of claims 1 to 14 for use in the treatment or prevention of a disease, disorder or condition controlled or affected by PARP7 activity or associated with PARP7 activity or overexpression.

17. 17. The inhibitor for use according to claim 16, wherein the disease, disorder or condition is a hyperproliferative disease, an autoimmune disease or an inflammatory disease.

18. The disease, disorder, or condition is cancer selected from the group consisting of squamous cell lung cancer, lung adenocarcinoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, breast cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, colorectal cancer, melanoma, ovarian cancer, esophageal squamous cell carcinoma, gastric cancer, liver cancer, oral cancer, urothelial cancer, prostate cancer, bladder cancer, renal cell carcinoma, gastrointestinal stromal tumor, cervical cancer, endometrial cancer, rhabdomyosarcoma, fibrosarcoma, neuroendocrine tumor, mesothelioma, brain cancer, or malignant glioma.

17. An inhibitor for use according to claim 16.

Images